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Lymph nodes (LNs) are highly organized structures containing adaptive and innate 
immune cells supported by a network of specialized stromal cells. These stromal cells 
provide the structural basis for immune cell migration, localization and specialized 
microenvironments for effector function through the production of specific chemokines. 
Crosstalk between stroma and haematopoietic cells is important in regulating the 
efficacy of the immune response in part through their plastic response to inflammation 
and capacity to generate specialized structures, including germinal centres (GCs). The 
mechanisms driving tissue remodelling and GC formation in LNs are unclear. 
Understanding the timing and molecular mechanisms leading to stromal cell 
reorganization will help generate novel vaccination strategies that can control and 
regulate immune responses. An adjuvant is a non-antigenic substance that when added 
to vaccines, enhances the immune response to inoculated antigens. TLR agonists have 
been shown to be potent second-generation adjuvants. TLR4 agonist adjuvants induce 
rapid LN remodelling through the loss of B cell follicles and the formation of a ring-like 
structure in the cortex; surprisingly this was not due to a loss of CXCL13 production by 
the stromal cells. After forming this ring, large numbers of new B cell follicles appear in 
the LN paracortex. The molecular mechanisms leading to this reorganization was 
investigated. TLR4 activation and signalling has to be tightly controlled to avoid 
uncontrolled inflammation and enable tissue repair. miRNAs constitute a key 
component in a negative feedback loop in innate immune responses. Deficiency in a 
TLR4-induced miRNA leads to an altered immune response and changes to adjuvant 
induced tissue remodelling. By using a simple antigen challenge model, it was possible 
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Chapter 1:   Introduction 
1.1.   Structure of adult murine lymph nodes 
Secondary Lymphoid Organs (SLOs) such as the spleen or lymph nodes (LNs) are 
specialized immunological tissues that facilitate efficient high affinity immune 
responses. LNs are located throughout the body in strategic lymphatic drainage points 
and contain an abundance of haematopoietic cells. LNs are found at the interface 
between the blood and lymphatic systems and enable the initiation of the immune 
response as they bring Antigen-Presenting Cells (APCs) presenting antigen in contact 
with circulating lymphocytes. The main entry points for lymphocytes into the LNs is 
through High Endothelial Venules (HEVs) formed from blood vessels [1]. 
Lymphocytes circulate through the LNs and exit through the HEVs after surveying the 
LNs and then enter the blood. LNs permit the efficient detection of infection or tissue 
damage by bringing lymphocytes and antigen together. LNs are composed of the cortex, 
the paracortex and the medulla [2]. B cell follicles, which are the sites of high affinity 
antibody production, are found in the cortex [3]. The paracortex is composed of the T 
cell zone, where interactions between Dendritic Cells (DCs) and T cells happen [4]. The 
medullary sinus makes up the medulla where cells exit the LN, antigen is cleared from 
the LN and plasma cells reside. LNs are highly organized structures; stromal cells create 
the scaffold within the LN on which immune cells migrate, and provide 
compartmentalized architecture that is required for protective immunity [5]. 
The localization of immune cells within these structures results from chemokine 
expression by different stromal cell populations. Fibroblastic Reticular Cells (FRCs), or 
T cell zone stroma, express CCL19 and CCL21 that bind to the common receptor CCR7 
which is highly expressed on T cells and on activated DCs forming the paracortex of the 
LN [6, 7]. FRCs secrete extracellular matrix that provides the network for cellular 
interactions, form conduit structures and surround the blood vascular network. In 
contrast, B cells reside in follicular structures in the outer cortex with a stromal network 
that matures into Follicular Dendritic Cells (FDCs) that express high levels of CXCL13 
[8]. In the subcapsular zone, closely associated with the lymphatic endothelial vessels, 
Marginal Reticular Cells (MRCs) support macrophages, Lymphoid Tissue inducer cells 
(LTi), Natural Killer cells (NK), NKT cells and γδT cells, which are primed to respond 
to infection [9-11]. These different stromal cell networks can be visualized through the 
expression of Reticular Fibroblasts and Reticular Fibres (ER-TR7), smooth muscle actin 
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and desmin on FRCs, Complement Receptor 1 and 2 (CR1/CR2 or CD21/35) on FDCs 
and Receptor Activator of Nuclear Factor kappa-B ligand (Rank-L) or Mucosal 
Vascular Addressin Cell Adhesion Molecule-1 (MAdCAM-1) on MRCs [9-11]. These 
populations and their localization are shown in Figure 1.1 [6]. 
1.2.   Function of adult murine LNs 
LNs are important organs required for the proper development of an immune response 
leading to pathogen clearance. By bringing the different factors required in close 
contact, LNs increase the chances of specific immune cells recognizing the antigen [1]. 
Efficient immune responses are facilitated by LN architecture, characterized by the T 
cell and DC domain and the B cell domain. Until recently, the mechanisms that control 
the efficacy of the immune response were thought to be mediated by the interactions 
between leukocytes. In the past couple of years, it has been shown that non-
haematopoietic cells such as lymphoid stroma and the lymphatic and blood vasculatures 









Figure 1.1: Lymph node structure and organization.  
LNs are divided into three distinct regions, the cortex, the paracortex and the 
medulla. FRCs express CCL19 and CCL21 that bind to CCR7, which is expressed by 
T cells and activated DCs that accumulate in this region to form the paracortex. 
FDCs express CXCL13 that binds to CXCR5, which is found on B cells to form the 




1.2.1.   Lymph node entry and exit 
Cells traffic into LNs through the blood, through HEVs, or through afferent lymphatic 
vessels. Naïve lymphocytes enter through HEVs into the LNs. HEVs are composed of 
Blood Endothelial Cells (BECs). In order to cross the HEV endothelium, lymphocytes 
bind L-selectin (CD26L) on their surface to HEV glycoproteins, also called Peripheral 
Node Addressins (PNAd) that enables lymphocytes to roll on the endothelium surface 
[13]. Lymphocytes then bind CCL21, CXCL12 and CXCL13, which enables 
extravasation and entry into the parenchyma [1, 5]. HEVs produce CCL21, whereas 
FRCs and FDCs produce CXCL12 and CXCL13 respectively. These chemokines are 
then transported to the endothelial surface by transcytosis [14]. Lymphocytes bind these 
chemokines causing receptor signalling. This leads to integrin activation and extension 
of Lymphocyte Function-associated Antigen-1   (LFA-1) on lymphocytes and binding 
to Intercellular Adhesion Molecule (ICAM)-1 or 2 on HEVs causing cell arrest [1]. 
Lymphocytes then migrate along the HEV lumen until a suitable point of entry is found 
for cells to transmigrate through the endothelium and enter the LN. HEVs are important 
in the regulation of lymphocyte entry into the LNs. Pockets holding lymphocytes have 
been found to form between endothelial cells. More cells are held in these pockets 
during an immune response when lymphocyte egress is blocked. It is thought that when 
lymphocytes exit the LN through the lymphatic sinuses, cells are released from these 
pockets in order to maintain homeostasis [15]. 
Cells migrating from tissues in the periphery enter through the afferent lymphatic 
vessels. During inflammation, lymphatic vessels increase expression of cell-adhesion 
molecules promoting cell entry. DCs enter lymphatic vessels through a chemokine 
dependent manner; CCL21 produced by Lymphatic Endothelial Cells (LECs) binds to 
CCR7 expressed by DCs. CCL21 forms a gradient for the DCs to migrate along to reach 
the vessels from which they enter the LN into the sub-capsular sinus [16, 17]. DCs then 
follow CCL19 and CCL21 gradients through the LN into the T-cell zone. The atypical 
chemokine receptor CCRL1 binds CCL21, leading to cells internalizing and degrading 
this chemokine, thereby maintaining low quantities of CCL21 in the cortex helping 
maintain the gradient. Mice lacking CCRL1 lose this gradient; therefore DCs can’t 
migrate into the paracortex [18]. 
Cells exit the LNs through the medullary sinus into efferent lymphatic vessels where 
they regain circulation. This process of egress from the LN is dependent on 
Sphingosine-1-Phosphate (S1P). Lymphocytes express S1P Receptor 1 (S1PR1), which 
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probes for S1P that is released into the lymph by LECs, thus stimulating entry into the 
sinus [19, 20]. In the absence of S1PR1 expression, lymphocytes are unable to exit the 
LN through the cortical sinus causing blood lymphopenia [21]. 
1.2.2.   Immune response within LNs 
The immune system is composed of two major types, the innate immune system and the 
adaptive immune system. The innate immune response is an evolutionary older defence 
strategy that provides immediate defence against infection but no long-lasting protective 
memory. The adaptive immune response creates immunological memory after the 
immune reaction to a specific antigen. This acquired immune response is specific for a 
particular antigen and requires highly specialized cells [22, 23].  
Once pathogens have penetrated tissues, there is an acute local inflammatory response 
with recruitment of innate cells such as neutrophils, monocytes and macrophages. In 
most cases, these cells then surround the pathogen in a phagosome and kill the ingested 
pathogen with mechanisms involving oxidants such as nitric oxide. After this event of 
phagocytosis, macrophages and DCs internally process the digested pathogen then 
display fragments of it to their surface, which participates in antigen presentation [24]. 
These APCs are important for the innate immune response but also for the adaptive 
immune system as they contribute to T-cell activation within the LNs. Antigen is 
transported to the draining LNs either through the lymph or within activated APCs. DCs 
are guided to the paracortex by the chemokines CCL19 and CCL21, which bind to the 
receptor CCR7. It has been shown that CCR7 expression is critical for DCs to migrate 
in response to inflammation [6].  
DCs exposed to antigen change into mature APCs. During an immune response, DCs 
migrate and remain near HEVs, increasing the probability of naïve T cells recognizing 
the antigen on their surface. Maturation of DCs involves up-regulation of Major 
Histocompatibility Complex II (MHCII), CD80/86 and chemokine receptors such as 
CCR7, enabling them to migrate from peripheral tissues into the draining LNs [25]. 
DCs in the LN present MHCII restricted antigens to T cells, which recognize these with 
their T Cell Receptor (TCR). This interaction is the first signal required for T cell 
activation. CD80/86 molecules then bind to CD28 on T cells, further stimulating T 
cells. These signals trigger the expression of CD40L on T cells that binds CD40 on 
DCs, in turn stimulating cytokine release by DCs, further activating T cells. Depending 
on the cytokine produced by DCs, determined by the type of antigen, the naïve T cells 
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differentiate into different T Helper (TH) subsets: TH1, TH2, TH17, Regulatory T cells 
(Treg), Follicular Helper T cells (TFH) or Follicular Regulatory T cells (TFR) [26]. Upon 
activation T cells undergo clonal expansion during which they differentiate into either 
effector cells migrating to the site of infection or into memory cells for protective 
immunity [27]. There are two types of memory T cells, Central Memory (TCM) or 
Effector Memory (TEM). TCM cells enter and patrol LNs through CD62L and CCR7 
expression, whereas TEM cells lack these molecules and instead produce effector 
cytokines [28]. TFH cells are defined by high CXCR5 expression. These cells migrate to 
B cell follicles where they are essential for B cell activation and for the formation of 
Germinal Centres (GCs) [29]. Activation of CD8 T cells requires interaction with 
mature DCs. CD4 helper T cells license the DCs to give activating signal to naïve CD8 
T cells. Licensing involves CD40-CD40L signalling. CD8 T cells differentiate into 
Cytotoxic T Lymphocytes (CTL) through IL-2, IL-12 and IFNγ production by CD4 T 
cells. After being activated, CD8 T cells go through clonal expansion and differentiate 
into either memory CD8 T cells or CTLs [30]. CTLs are specialized in killing cells, 
which is important for fighting intracellular pathogens and tumours [31].  
Naïve B cells reside in follicles in the cortex of the LN. Once their B Cell Receptor 
(BCR) binds a specific antigen, B cells migrate to the interface between B cell follicle 
and T cell zone where they present antigen to CD4 T cells. T cells that recognize the 
antigen through the TCR provide survival and proliferation signal for B cells through 
CD40-CD40L interactions. The type of immunoglobin produced by B cells is dictated 
by the different cytokines secreted by TH1 and TH2 cells. TH1 cells stimulate IgG2a 
production, whereas TH2 cells stimulate IgG1 production. After encountering antigen, B 
cells differentiate into GC B cells, memory cells or plasma cells [32]. GC B cells 
proliferate and undergo somatic hypermutation of the variable region of their BCR and 
Ig class switch recombination, increasing the affinity of the immunoglobulin-antigen 
binding. TFH cells are essential for the survival and proliferation of GC B cells. 
Antibodies that are self-reactive are eliminated in a FAS dependent process by negative 






1.3.  Development of stromal networks 
There are various mesenchymal-derived stromal cell subsets that are indispensable for 
immune homeostasis and LN function [5]. Mesenchymal cells require interaction with 
haematopoietic cells in order to differentiate into the different stromal subsets found in 
the LN [34]. 
1.3.1.   Lymphoid stromal organizer cells 
LNs start to develop at embryonic days 11 and 16. At these early stages of development 
stromal cells can already be found and they are required for the formation of LNs [34, 
35]. Evidence indicates that retinoic acid produced by neurons can act on mesenchymal 
stromal cells stimulating the production of the chemokine CXCL13. However, CXCL13 
is not required for LN development nor is retinoic acid likely to be the only mechanism 
inducing CXCL13 production [36]. CXCR5+ haematopoietic cells are attracted to the 
developing CXCL13 gradient in the LN anlagen. These cells originate from foetal liver 
progenitor cells and are called LTis. [37] LTis were thought to have the capacity of 
differentiating into B cells, T cells, NK cells or DCs, although it is now thought that 
true LTis are terminally differentiated effector cells rather than being common 
lymphoid progenitor cells [38]. LTis express lymphotoxin α1β2 (LTα1β2), which binds 
to the LTβ Receptor (LTβR) expressed by mesenchymal stromal cells. The initiation of 
lymphotoxin expression is believed to be dependent on RANK/RANKL signalling. The 
LTα1β2/LTβR signalling promotes the differentiation of mesenchymal stromal cells 
into Lymphoid Tissue organizer cells (LTos) [39, 40]. LTo cells then up-regulate the 
chemokines CXCL13, CCL19 and CCL21, Interleukin-7 (IL-7), as well as adhesion 
molecules (Vascular Cell Adhesion Molecule-1 (VCAM-1), ICAM-1 and MAdCAM-1) 
[41], leading to an increased recruitment of cells as well as promoting their survival 
[42]. LTos differentiate into different stromal cell populations through LTβR signalling.  
A few days after birth, LNs are colonized by lymphocytes that interact with the stromal 
cells and drive their survival and functional maturation [43]. Stromal cells differentiate 
into different subsets depending on the cell types they interact with. The accumulation 
of lymphocytes leads to a rapid increase in LN size and to the formation of distinct T 




Figure 1.2: Different stages of LN formation.  
At embryonic day 12, retinoic acid stimulates mesenchymal cells to produce 
CXCL13. This chemokine then attracts LTi precursor cells, which start to form 
clusters. These events facilitate signalling through RANK/RANL-L. This leads to 
LTα1β2 expression by LTi cells leading to their maturation. LTα1β2 interacts with 
the LTR found on stromal cells leading to their activation where they produce 
chemokines and adhesion molecules. These molecules attract more haematopoietic 
cells to the cluster leading to LN formation. Adapted from Mebius, RE et al., Nature 





1.3.2.   FDC differentiation and role 
The interaction between LTis and stromal cells triggers the formation of follicles. After 
birth, B cells colonize the LN and form clusters in the cortex of the LN. This entry of B 
cells is essential for the expression of FDC markers that can be found seven days after 
birth [45]. Differentiation into FDCs requires LTα1β2 and Tumor Necrosis Factor α 
(TNFα) production by B cells; these chemokines activate the NKκB pathway [46, 47]. 
The B cell area contains a conduit system ensheathed by FDCs. This happens after 
alteration of the network whereby FDCs replace FRCs around the conduit network [48]. 
Maturation of stromal cells into FDCs expressing CXCL13 is dependent on B cells. 
FDCs require TNFα and lymphotoxin produced by B cells [49]. Lymphotoxin is 
essential for the survival of FDCs [46]. FDCs in turn produce B cell Activating Factor 
(BAFF), which is required for B cell survival and CXCL13 which attract B cells into 
the follicle [50]. FDCs express CD21/35, enabling the capture and display of antigen on 
their surface to B cells [51]. FDCs also have an essential role in the formation of GCs 
[3]. GCs possess a light zone composed of FDCs that is located in the Subcapsular 
Sinus (SCS), and a dark zone where B cells go through rapid proliferation. The dark 
zone extends towards the T cell zone and contains CXCL12-producing stromal cells. 
FDCs maintain GC by promoting B cell survival [52].  
1.3.3.   FRC development and role 
FRCs ensheathe the conduit system and form the framework within the paracortex. ER-
TR7 production is stimulated by interaction between stromal cells and T cells [11]. 
FRCs express the chemokines CCL19 and CCL21, which are chemoattractants for T 
cells and DCs. Heparin sulphate residues bind CCL21 to FRCs thus guiding DCs and T 
cells by haptotaxis along the network [5]. DC migration on FRCs is also mediated by 
the expression of C-type Lectin receptor (CLEC-2) on DCs, which binds to podoplanin 
(gp38) on FRCs. Absence of CLEC-2/gp38 interactions leads to a defect in developing 
T-cell responses as well as in DC migration [53]. FRCs guide both T cells and DCs 
facilitating an efficient immune response. IL-7 expressed by FRCs is critical for the 
survival of naïve T cells [54]. Lymphocytic Choriomeningitis Virus (LCMV) has been 
shown to lead to a reduction in FRC numbers and in IL-7 expression causing the host to 
be unable to respond to secondary infections [55]. In LNs lacking FRCs, after infection 
with inactivated influenza virus, there is a defect in T cell activation and disorganized 
GCs. Studies in which FRCs were ablated showed LNs with a loss of rigid B and T cell 
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compartments, abnormal T cell numbers, and there was a loss of specific CD4 and CD8 
responses to viral infections [56]. However, FRCs are only required for naïve 
lymphocytes, as when FRCs were depleted during an immune response, there was no 
loss of activated cells or a failure to clear viral infections [57]. FRCs localized in B cell 
follicles have been found to produce BAFF helping maintain B cells homeostasis. This 
illustrates the key role for FRCs in promoting immune cell survival and activation while 
also establishing the important architecture required for the function of the LN. FRCs 
ensheathe the conduits that connect the lymphatic vessels with the HEVs. This network 
permits the entry of molecules such as chemokines, cytokines and soluble antigen into 
the LN [58, 59].  
1.3.4.   MRC development 
MRC differentiation is dependent on LTβR and TNFR1 signalling [60]. MRCs are 
found in the SCS region of the LN, on the outer margin at the edge of B cell follicles. 
These cells resemble FRCs but express RANK-L and MAdCAM-1, and not CCL21. 
The FDC marker CD21/35 is also absent from these cells and they express CXCL13 at 
lower levels than mature FDCs. MRCs are important in B cell migration and entry of 
DCs and memory lymphocytes into the LN. [61]. During an immune response, MRCs 
act as precursor cells that have the potential to differentiate into FDCs [62].  






Figure 1.3: LN stromal cells and their interactions with immune cells.  
Lymphocytes enter LNs through HEVs where they encounter FRCs. B cells migrate 
along the FRC network following the CXCL13 gradient towards the B cell follicles. 
T cells and DCs migrate along the FRC network within the T cell zone. B cells 
migrate in the B cell follicles in response to CXCL13 produced by FDCs and MRCs 
in search of antigen. T cells meanwhile traffic around the T cell zone following 
CCL19 and CCL21 gradients and interact with DCs. DCs present antigen to T cells. 





1.4.  Role of stroma in immune responses 
The crosstalk between stroma and haematopoietic cells is important in regulating the 
immune response within the LNs. Stromal cells regulate immune responses in many 
different ways controlling cell positioning, motility and survival, but are also plastic in 
responding to localised inflammation. Stromal cells are able to change their chemokine 
expression patterns during inflammation leading to changes in cell trafficking and 
lymphocyte entry into the LN [64]. Self-reactive T cells are eliminated in the thymus; 
however, a small percentage escape central tolerance. A number of mechanisms 
regulate pathological T cell activation including regulatory T cells, regulatory DCs and 
stromal cell presentation of self-antigens, in the absence of co-stimulation, helping to 
enforce peripheral tolerance [65]. Under inflammatory conditions, LECs express cell 
adhesion molecules, which promote the entry of DCs into the LNs [66]. FRCs promote 
T cell survival by producing IL-7 [4], contribute to peripheral T cell tolerance by 
presenting self-Ag [67], and secrete Vascular Endothelial Growth Factors (VEGFs) 
which stimulates HEV growth [68]. FDCs control B cell homeostasis and survival by 
secreting BAFF [3]. FRCs, LECs and BECs are able to up-regulate MHCII on their 
surface in an inflammatory context [69]. During an immune response, there is a down-
regulation of CCL19, CCL21 and CXCL13 by stromal cells resulting in a change in 
trafficking of lymphocytes and APCs. This reduction occurs at the peak of the immune 
response and aids the accumulation of specific cells. However, this event leads to a 
lessened reaction to a secondary antigen when the primary response has started [64]. 
The chemokines CCL19 and CCL21 promote T-cell activation and enhance T-cell 
interactions with APCs. CCL19 and CCL21 are also important in the stimulation of DC 
maturation, antigen presentation, endocytosis and promoting the extension and probing 
of dendrites [70-72]. DCs associated with FRCs have the capacity of taking up antigens 
found in conduits and presenting it to T cells [59]. FDCs promote GC formation. Light 
zone FDCs express CXCL13 and dark zone FDCs express CXCL12; these chemokines 
are critical for the different stages of B cell maturation. B cells migrate rapidly between 
the light and dark zones of GCs following the chemokine patterns. Thus, FDCs are 
critical in the control of B cell response and memory [3, 73]. It has recently been 
discovered that there is a dormant population of stromal cells that helps regulate B cell 
follicles during the immune response [74]. LECs and FRCs have also been shown to 
suppress inflammation. DC maturation and function is suppressed by LECs [75] and 
FRCs produce nitric oxide which blocks the proliferation of activated T cells [76, 77]. 
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Suppression of T cell proliferation by FRCs requires Interferon-γ (IFN-γ) produced by 
activated T cells and is also dependent on direct contact between activated FRCs and T 
cells. This regulation is crucial, as it is a way to avoid tissue destruction and undesirable 
stimulatory effects [76]. Certain pathogens such as LCMV directly target and infect 
FRCs in the LNs [78]. Leishmania major infects ER-TR7 fibroblasts in LNs [79]. 
Ebola, Marburg and Lassa viruses infection of FRCs and endothelial cells leads to LN 
cell apoptosis [80, 81]. The contraction phase of the immune response is when a large 
percentage of effector cells die. This Antigen Induced Cell Death (AICD) returns the 
LN to its original state ready for future responses. CCL19 and CCL21 promote AICD in 
effector T cells [77]. 
1.5.  LN changes during inflammation  
1.5.1.   LN hypertrophy 
During an immune response there is an increase in lymphocytes entering and a 
reduction of lymphocyte exiting the LN leading to LN hypertrophy. In order to 
accommodate the increase in cells into the LN, there is vasculature remodelling and 
growth. The expansion of these capillaries enables the increased entry of nutrients and 
oxygen into the LN. The first two days correspond to the initiation phase, where 
proliferation of BECs leads to an increase in the HEV network. This proliferation is 
dependent on VEGF produced by FRCs [68]. There is also rapid proliferation and 
growth of HEVs due to increased VEGF expression by FRCs upon LTβR stimulation 
by CD11c expressing cells [82]. Pro-inflammatory cytokines promote the up-regulation 
of cell adhesion molecules expression on HEVs [83]. Inflammation leads to an increase 
in CCL21 expression by HEVs leading to an increase in blood flow through the LN 
[84]. The reticular network expands in response to inflammation as well and follows the 
same kinetics as HEVs [68]. LN remodelling and hypertrophy occur differently 
according to the type of infection.  
Inflammation leads to the growth of lymphatic vessels through the LN leading to 
changes in its structure. Lymphangiogenesis permits an expansion in DCs and activated 
myeloid cells in LNs [85]. Growth of lymphatic vessels leads to an increase in the size 
of the medulla to accommodate the augmented number of cells. In some inflammation 
models, lymphangiogenesis was shown to be dependent on B cells. In mice lacking T 
cells or myeloid cells, the process of lymphangiogenesis is intact; however, this process 
does not occur in mice lacking B cells. Blockade of VEGF-2 or VEGF-3 as well as 
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LTβR leads to a decrease in lymphatic growth and remodelling [85, 86].  
After infection of LNs, cell egress is blocked due to a down-regulation of S1PR1 
expression on lymphocytes. The increase in cells entering the LN and the block of the 
exit causes a rapid accumulation of cells in the LN. This block in T cell egress is critical 
as it permits T-cell activation and effector T-cell expansion. When T cells are activated, 
CD69 is expressed at high levels and binds to S1PR1 on the surface of T cells leading to 
its internalization. When the immune response is in its contraction phase, CD69 
expression is lost and S1PR1 is re-expressed which allows T cells to exit the LN 
following the S1P gradients on the lymphatic vessels [87, 88].  
1.5.2.   LN remodelling 
During an immune response, LNs go through structural changes that differ according to 
the antigen. LN remodelling involves an increase in B cell follicles that can be found in 
the paracortex of the LN. Remodelling of inflamed LNs that increase in size is closely 
linked to stromal cell expansion and namely proliferation of FRCs [89]. Structural 
changes and growth of the reticular network occurs in response to lymphocyte 
accumulation. Appropriate immune response requires the stromal network to remodel 
and proliferate following an increased influx of cells. The homeostatic situation 
involving FRCs, DCs and T cells is disrupted once an antigen is detected in the LN. 
Depending on the model studied, FRCs either proliferate or stretch [89, 90]. 
Unpublished work from the Coles’ lab showed that during S. pneumonia infection, 
FRCs stretch. LN architecture is critical to have an efficient immune response. This 
structure-function link of LNs was determined in mice that conditionally lack LTβ, as 
this deficiency leads to a reduced LN structure integrity [91, 92]. These studies illustrate 
a dependent relationship between LN organization and the immune response towards 
viruses. Mice that lack CCL21 and CCL19 (plt/plt), and CCR7-/- mice were found to 
have malformed T cells zones but are still able to mount potent T cell responses to 
LCMV [93, 94] but possess weaker responses to Listeria monocytogenes [95, 96]. 
Cytomegalovirus infection leads to a decrease in CCL19 expression and infection with 
the vaccinia virus leads to a decrease in CCL21 [64]. These chemokines are critical in 
LN structure so a decrease leads to a disorganization of LN structure. This mechanism 
of loss of structure is necessary in excluding naïve T cells from the inflamed LN [88] 
and also the decrease in these chemokines prevents AICD in T cells [97]. Changes in 
LN structure reduce lymphocyte compartmentalisation and enhances interactions that 
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are needed for an appropriate immune response. Impaired stromal networks cause an 
altered LN architecture leading to lymphocytes being in the wrong area. Responses to a 
secondary infection are not altered during an infection that does not affect stromal cells 
[55]. Changes to the homeostatic LN architecture occurs in response to 
lipopolysaccharide (LPS) [64] or of specific adjuvants, e.g. Complete Freund’s 
Adjuvant (CFA) [10]. This change in LN architecture during an immune response in 
most cases does not alter the adaptive immune response. The virulence of Salmonella 
typhimuirum is linked to LPS induced down-regulation of CCL21 and CXCL13 leading 
to changes in LN architecture and cell trafficking [98].  
1.6.  TLR signalling pathways 
Toll-Like Receptors (TLRs) are part of the Pattern Recognition Receptor (PRR) family. 
TLRs are evolutionarily conserved and are members of the type-1 transmembrane 
receptor family. They are part of the innate immune system and are able to bind 
specifically to highly preserved molecules from pathogens. Ten TLRs have been 
identified in humans and twelve in mice. TLRs can be found expressed on diverse cell 
types including innate immune cells such as macrophages and DCs but also epithelial 
and endothelial cells. Bacterial LPS is specifically recognized by TLR4 and its 
activation promotes pro-inflammatory cytokines production. LPS was discovered as a 
ligand for TLR4 through the LPS-induced endotoxin shock in mice resulting from loss 
of function mutations of TLR4 [99]. TLRs have an extracellular Leucine-Rich Repeat 
(LRR) domain important for ligand recognition, a single transmembrane helix and an 
intracellular Toll/Interleukin-1 Receptor-like (TIR) domain required for signal 
transduction [100]. LPS Binding Protein (LPB) initially binds LPS and transfers it to 
CD14, a membrane protein that lacks an intracellular domain so associates with TLR4 
to form a functional LPS complex. The MD-2 protein associated with the extracellular 
domain of TLR4 is also required for correct LPS binding. LPS is split into monomeric 
molecules by CD14 enabling recognition by TLR4/MD-2 [101]. LBP and CD14 have 
been shown to not be essential for TLR4/LPS signalling but to enhance the signalling 
[102].  
Once there is ligand binding, TLR4 receptors homodimerize through TIR domain 
interactions. Through homophilic interactions between the TIR domains, adapter 
molecules are recruited. There are different adapter molecules which are essential in 
TLR4 signalling; Myeloid Differentiation Factor 88 (MyD88), TIR-domain-containing 
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adapter protein (TIRAP), TIR-domain-containing adapter inducing interferon-β (TRIF) 
and TRIF-Related Adapter Molecule (TRAM) [100]. MyD88 is composed of an N-
terminal death domain and a C-terminal TIR domain that anchors to TLR4’s TIR 
domain. Activation of the TIRAP-MyD88 pathway initiates intracellular signalling that 
regulates NF-κB activation and inflammatory cytokine production. Intracellular 
signalling following TLR4 activation also activates the TRIF-TRAM pathway, 
activating the Interferon Regulatory Factor 3 (IRF3) transcription factor leading to the 
up-regulation of Interferons (IFNs), TNFα and stimulatory molecules. TNFα then 
activates the NF-κB pathway [103].  
1.7.  Adjuvants in biology 
1.7.1.   Principles of vaccination 
Vaccination is the most effective method of preventing infectious diseases that we 
possess. It aims to generate a de novo immune response to a pathogen in order to 
provide long-term protection against infection. Immunization aims to get the best 
protection with limited side effects due to inflammation. In most cases, vaccines are 
developed in order to protect an entire population against the infectious disease. Edward 
Jenner is the pioneer of vaccination as he showed through experiments that it was an 
effective way of protecting against the disease. In the 18th century he used cowpox 
infection to prevent smallpox. Since then, many vaccines have been developed and are 
commonly used and many more are being designed or are in trials.  
The first vaccines contained live attenuated viruses or the whole pathogen. Attenuated 
vaccines are produced by inactivation or by passaging in culture until the virulence is 
reduced but the organism is still viable. Exposure to high temperatures inactivates 
pathogens, which enables the production of whole-pathogen vaccines [104]. These two 
methods are still found in vaccines, although they are known to have some reactivity 
and can have diminished potency or efficacy. In recent years, modern vaccines contain 
purified antigen in suspension rather than the whole pathogen. This improves 
vaccination efficacy and decreases the chance of adverse reactions. However, the 
limitation to purified antigens is that there are a reduced number of epitopes, and 
therefore limits the potential immune receptor range from immune cells.  
Vaccination relies on the proper stimulation of the adaptive immune response in order 
to get long lasting immunity against the pathogen. This process is dependent on the 
maturation of APCs, which leads to adaptive cell activation. It has been determined 
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that the diminished efficacy of purified vaccines to induce immunity is due to an 
inability in promoting APC maturation [105]. The ability of B cells to mature and 
differentiate leading to immune memory is dependent on TH cells. APCs present antigen 
to CD4 TH cells. There are different types of activated TH cells, which release cytokines 
specific to their population (TH1, TH2 and TH17) leading to efficient pathogen clearance. 
A TH1 response is necessary for the clearance of intracellular pathogens, TH2 for 
extracellular parasites and TH17 for bacteria and fungi [106]. Immune response 
mechanisms vary greatly according to the pathogen. Manipulating the immune response 
and more importantly the type of response can overcome some of the obstacles facing 
designing potent vaccines.  
1.7.2.   The discovery of adjuvants 
An adjuvant is a substance that when added to vaccines, stimulates an increase in the 
immune response to inoculated antigens, while not possessing any specific antigenic 
effect [107]. For example, a tetanus vaccine contains small quantities of Clostridium 
tetani toxin adsorbed in aluminium (Alum) hydroxide [108]. The adjuvant effect was 
discovered in the 1920s as vaccines lost efficacy when produced under clean conditions. 
In the 1920s, it was discovered that horses had higher antibody titres when they 
developed an abscess at the site of injection. The generation of abscesses to unrelated 
substances along with the diphtheria toxoid increased the immune response [109]. The 
adjuvant potential of aluminium-based compounds was demonstrated in 1926 with 
diphtheria toxin [110]. In 1936, Freund developed one of the most potent adjuvants; 
CFA that is a water-and-oil emulsion containing inactivated mycobacteria. CFA causes 
severe reactions and is considered too toxic for human use, while under Home Office 
guidance can only be administered once in mice [111].  
Immunostimulatory adjuvants present conserved Pathogen-Associated Molecular 
Patterns (PAMPs) such as LPS, double-stranded RNA (dsRNA) or unmethylated CpG 
DNA, which are recognized by PRRs including TLRs. The ten functional TLRs have 
evolved to recognize specific PAMPs. This recognition can trigger and shape a response 
from the adaptive immune system [112]. Additional mechanisms of how adjuvants 
work include increasing the vaccine antigens half-life, modifying the presentation of 
antigens by the MHC on APCs, improving antigen delivery and presentation, on 
intracellular signalling within APCs, modulating co-stimulatory signal recognition by T 
cells or inducing cytokine production [113]. Though adjuvants are commonly used, 
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their mechanism and function is still incompletely understood.  
1.7.3.   Aluminium-based adjuvants 
To this day, aluminium-based adjuvants are the most commonly used in human 
vaccination; including diphtheria-tetanus-pertussis [108], human papillomavirus and 
hepatitis vaccines. The original aluminium-based adjuvant originated in the 1920s and 
was called aluminium phosphate. In the 1920s it was believed that aluminium was an 
effective adjuvant as it allowed antigen to remain in the body for longer, which was 
termed the depot effect [110]. Up to a year after vaccination, traces of Alum can be 
found at the injection site. This effect was considered dogma for 60 years and only 
recently has research into aluminium salts, referred to as Alum in this project, started 
but the mechanisms still remain unclear. Vaccines containing alum are prepared by 
having the antigen in suspension be adsorbed to aluminium hydrogel [114]. Alum also 
activates innate immune cells resulting in a TH2 immune response [115]. Aluminium 
salts support antigen uptake and presentation by macrophages [116]. Antigen uptake by 
DCs and B cells is greater in an antigen/alum mix than antigen alone, and Alum 
increases CD86 expression in DCs [117]. It was thought that Alum might function as a 
PAMP and induce signal through a particular or several TLRs; however, Myd88-/- mice 
produced normal IgG1 quantities in response to aluminium-adsorbed antigen [118]. 
Mice deficient for both Myd88 and TRIF had normal antibody responses compared to 
control mice upon vaccination with antigen/alum [119]. Alum promotes the release of 
cytokines such as IL-1β through the NLR family, Pyrin Domain containing 3 (NLRP3) 
inflammasome and adaptor protein Apoptosis-associated Speck-like protein containing 
CARD (ASC), which activates caspase 1. Inflammasomes are a pathogen recognizing 
system essential for protection. The ATP receptor P2X, that has a role in NLRP3 
inflammasome stimulation, was not linked to IL-1β production [120, 121]. Aluminium 
salts are thought to activate the NLRP3 inflammasome through two different ways. The 
first is that phagocytic cells take in aluminium salt particles, which leads to damage and 
rupture of lysosomes and antigen and enzyme release, such as cathepsin B, into the 
cytoplasm. This event causes to NLRP3 inflammasome activation [122]. The second 
way is an indirect activation linked to aluminium salt toxicity leading to Damage 
Associated Molecular Patterns (DAMPs) release, namely uric acid resulting in 
activating NLRP3 inflammasome [117]. Aluminium salts are known to induce strong 
antibody responses. Alum preferentially induces IL-4, which promotes TH2 cells that 
stimulates B cell antibody production of the IgG1 and IgE subtypes [123, 124]. IL-4 
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inhibits TH1-type responses. The increase in GR1+ IL-4 producing cells in the spleen is 
promoted by Alum six days following immunization. These cells are also found at the 
site of injection shortly after immunization and are able to stimulate B cells [125].  
Oral or intranasal immunization of Alum is not possible due to the formation of 
antigenic deposits [126] and has been found to be unusable with DNA-based vaccines 
[127]. Another limitation found with Alum is the strong TH2 bias of immune responses 
that limits the development of vaccines against certain pathogens requiring a TH1 
response.  
1.7.4.   Novel adjuvants: TLR4 agonist adjuvants 
Gram-negative bacterial components such as LPS, which binds to TLR4 and its co-
receptor CD14, are potent adjuvants but their clinical use is not possible as they induce 
a high fever. LPS stimulates a plethora of cells to produce cytokines and chemokines 
that control APC trafficking and maturation. Uncommonly, LPS can be delivered at a 
site different than the site of immunization and still retain its adjuvant properties [126]. 
 Monophosphoryl Lipid-A (MPL-A) was developed as a less toxic derivative of LPS 
and it contains only the Lipid A portion which is responsible for LPS’ adjuvant effect 
but also its toxicity. It is derived from LPS from Salmonella minnesota. Removing a 
phosphate group, a sugar moiety and an ester-linked fatty acid group diminishes the 
toxicity of Lipid A but does not affect its adjuvant function [128]. Although MPL-A 
interacts with TLR4, it has been found that the adjuvant effect can occur in cases where 
TLR4 is absent [119]. MPL-A activates TRIF rather than NFκB directly leading to 
production of pro-inflammatory cytokines, namely IL-1β, IL-12 and INFγ. MPL-A 
stimulates TH1 immune responses including CTLs and the production of antibodies 
against the complement and the IgA subtype [129]. 
Combination adjuvants that simulate different parts of an immune response may 
produce a better immune response, as a pathogen stimulates different pathways. MPL-
A’s use in combination with aluminium oxyhydroxide, called AS04 is approved in 
Europe and is found in a Hepatitis B vaccine and the human papillomavirus vaccine, 
Cervarix [113]. Formulations of Alum and MPL-A enhance memory response; studies 
have shown that Alum prolongs the cytokine production after immunization at the 
injection site [130].  
Glucopyranosyl Lipid Adjuvant-Stable oil in water Emulsion (GLA-SE) is a synthetic 
TLR4 agonist oil-in-water emulsion that was developed by the Infectious Disease 
 
35 
Research Institute (IDRI) [131]. GLA-SE is a potent adjuvant that induces a TH1 
response and activates the inflammasome with early IL-18 and IFNγ production [132]. 
Squalene oil-in-water emulsions enhance the immune response generated by TLR 
agonists [133]. Formulation is key in adjuvant development and in modulating their 
activity. An influenza vaccine H5N1 with GLA-SE as an adjuvant has passed phase I 
clinical trials [134]. Adjuvants have different effects on the immune system and should 
be chosen according to the desired immune response for the vaccine [135]. 
1.7.5.   Other adjuvants 
See Table 1.1 for a list of licenced adjuvants.  
 
Emulsions 
Water-in-oil-emulsion adjuvants such as Incomplete Freund’s Adjuvant (IFA) or CFA 
were never validated for their use in humans due to the strong toxicity. These types of 
adjuvants work through depot formation at the injection site and stimulate antibody 
production [136]. These adjuvants are mostly used for terminal conditions such as 
cancer as they are considered toxic. Since then there have been new versions of 
emulsions such as Montanide emulsions, which is in clinical trials for studies against 
prostate cancer and ovarian cancer [137, 138]. There are also oil-in-water emulsions, 
which activate innate inflammatory responses through APC recruitment and activation. 
These emulsions are less reactive than the water-in-oil emulsions and have been used 
successfully in vaccines such as the seasonal influenza vaccine FluadTM [139]. Water-
and-oil emulsions are known to stimulate a TH1 response whereas the oil-in-water 
emulsions a TH2 response [140].  
Liposomes and virosomes 
Liposomes are lipid layers in synthetic nanospheres that are capable of encapsulating 
antigen and act as presenters of antigen [141]. The efficacy of these adjuvants is 
dependent on the lipid layer number, electric charge, molecular composition and 
preparation [142]. Licenced vaccines contain virosomes, which are similar to liposomes 
but contain empty envelopes of the influenza virus. This adds envelope glycoproteins to 
the adjuvant considered to aid in the uptake of antigen by cells. Virosomes are 
composed of stable membrane lipids and viral fusion proteins [143]. This type of 
adjuvant mimics virus infectivity without the risks involved with attenuated viruses and 
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can deliver the antigen directly into the cell cytosol [127]. Virosomes stimulate both 
TH1 and TH2 responses [129]. 
Saponins 
Saponins derived from the bark of the Quillaja saponaria tree have been commonly 
used in medicine. Saponins such as QS21 promote antigen presentation by APCs, 
induce CTL production, and stimulate both a TH1 and TH2 response but are considered 
quite reactogenic [144]. The problems of QS21, most importantly the residual lytic 
activity found at the immunization site can be overcome by the addition of MPL-A, 
which has a synergic effect [139]. Saponins are also used in Immune Stimulating 
Complexes (ISCOM) formulations, which are structures containing antigen, cholesterol, 
phospholipid and saponin. Vaccines containing ISCOM stimulate both TH1 and TH2 
responses [145]. 
TLR2 ligands 
There are many derivatives of TLR2 ligands, gram-positive cell wall components that 
have been used in experimental vaccines. For example, a vaccine against Lyme disease 
was developed with OspA from Borrelia burgdorferi as an adjuvant [146]. The 
synthetic compound Pam2Cys enhances cell mediated immunity and antibody 
responses in a vaccine for Listeria monocytogenes [147].  
CpG adjuvants 
Prokaryote DNA contains unmethylated CpG dinucleotides recognized by the innate 
immune system, as they are ligands for TLR9 found in intracellular vesicles of cells. 
These sequences are specific to a type of species and in humans there are two types of 
motifs that have been described, type K and type D. The type K motifs promote B cell 
and monocyte proliferation and IgM, IL-10 and IL-6 production. Type D motifs activate 
DCs and stimulate TNFα and IL-8 secretion [148]. Vaccines containing CpG motifs 
induce a TH1 response. These motifs can induce a strong immune response to weak 
antigens such as malarial antigens [148]. Many experimental vaccines contain CpG 
motifs against pathogens such as Listeria monocytogenes [149]. 
Bacterial toxins 
Bacterial toxins have been studied as vaccine adjuvants due to their strong 
immunogenicity and specific receptors. Pertussigen derived from pertussis toxin has 
been used as an adjuvant as it augments IgE levels and increases sensitivity to antigen 
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and the immune response in the case of the trivalent childhood vaccine for diphtheria, 
pertussis and tetanus [150]. Heat-labile enterotoxin from E.coli enhances mucosal 
immunity, stimulates both TH1 and TH2, and has been shown to be safe and to enhance 
the vaccine against Campylobacter [151]. Cholera enterotoxin is similar to heat-labile 
enterotoxin but stimulates TH2 responses and elicits strong mucosal immunogenic 
responses. Cholera enterotoxin has also been linked to strong side effects and diarrhoea 
in humans [152].  
Cytokines 
Cytokines can also be found in the modern classifications of adjuvants. Their use is 
particularly studied in the formulation for DNA vaccines where the cytokines can be 
expressed in the same vector as the antigen [153]. Cytokines could provide a less toxic 
way of enhancing vaccine efficacy. For example, inclusion of either IL-2 or IL-12 in a 
DNA vaccine with the sequence of the HIV antigen produces a strong TH1 immune 
response [129].  
 
Table 1.1. List of licensed adjuvants. 
Adjuvant 
name 
Type of adjuvant Description 
Alum Mineral salts Enhances TH2 type humoral immune 
responses and antigen stability.  
MF59 
(Novartis) 
Oil-in-water emulsion Used in influenza vaccines and activates 
humoral and cell-based immunity. 
Virosomes 
(Berna Biotech) 
Liposomes Enhances humoral and cell-based 
immunity. 
AS03 (GSK) Oil-in-water emulsion Used in influenza vaccines and activates 
humoral and cell-based immunity. 
AS04 (GSK) Alum-absorbed TLR4 
agonist 
Used for HPV and hepatitis-B vaccines. 
Activates humoral and cell-mediated 
immunity.  
 
1.8.  MicroRNAs: regulators of the immune response 
MicroRNAs (miRNAs), discovered in 1993, are small highly conserved non-coding 
RNAs of about 18-25 nucleotides that function as important post-transcriptional 
regulators of gene expression [154]. They belong to the non-coding RNA family 
consisting of, transfer RNAs (tRNAs), small interfering RNAs (siRNAs), small nuclear 
RNAs (snRNAs), and ribosomal RNAs (rRNAs). Each miRNA targets several hundred 
different mRNAs and acts to regulate mRNA levels to control protein content of the 
cells. They are able to modify cellular functions such as proliferation, differentiation, 
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signalling, metabolism and apoptosis, and also functions such as inflammation [155]. 
1.8.1.   miRNAs biogenesis 
miRNA transcription is very similar to that of mRNA. Their genomic sequence can be 
found in introns or in inter-genic regions where they are transcribed by RNA 
polymerase II or RNA polymerase III into primary miRNAs measuring hundreds of 
base pairs in length. miRNAs are never located in exonic regions as this would lead to 
the loss of the mRNA transcript. Primary miRNAs possess a stem-loop secondary 
structure and the mature miRNA sequence is located within one or both stem strands 
[156]. Transcripts can go through a post-transcriptional modification by adenosine 
deaminases modifying adenosine into inosine leading to changes in the transcript’s base 
pairing and potentially to structural changes. The pri-miRNA is spliced capped and 
polyadenylated in a similar way to that of mRNAs.  
There are two endonuclease steps required for maturation of miRNAs. The RNase II 
enzyme called Drosha associates with the RNA binding protein DGCR8 making it 
capable of cleaving pri-miRNAs. Within the nucleus, Drosha processes the transcripts 
and cleaves them to 70 base pairs thus becoming precursor miRNAs. Flanking pri-
miRNA sequences are released from the stem-loop precursor by Drosha cleavage. 
Drosha cleaves the 5’ and 3’ parts of the miRNA structure, while DGCR8 interacts with 
the primary miRNA and molecularly determines the correct cleavage sites [157].  
Exportin 5 and Ran-GTP export these precursor miRNAs into the cytoplasm [158]. The 
Rnase III processing enzyme Dicer associated with a RNA-binding domain protein Tar 
RNA Binding Protein (TRBP) cleaves the loop region of the precursor miRNAs leading 
to mature miRNAs of their final length of between 18 and 25 base pairs [159]. After this 
cleavage, RNA helicases unwind the secondary hairpin structure of the precursor 
miRNAs.  
Single stranded miRNAs enter the RNA-Induced Silencing Complex (RISC) facilitating 
mRNA repression [160, 161]. One mature strand miRNA is loaded into the RISC 
complex, the other strand, called the star strand is usually degraded but in some cases is 
loaded in the RISC complex at the same frequency as the other strand. When both 
strands are capable of entering the RISC complex, the nomenclature is different, 5p is 
the miRNA from the 5’ end of the stem loop and 3p is from the 3’ end [162]. miRNAs 
can have differential strand usage depending on the cell type and state [163]. Figure 1.4 




Figure 1.4: miRNA synthesis and function within a cell.  
MicroRNAs are encoded within an intronic region of a gene or from an intergenic 
region. They are then transcribed by RNA polymerase II into primary transcripts or 
primary miRNA respectively. Primary miRNA is processed into pre-miRNA by the 
ribonuclease Drosha and DGCR8. This is the result of splicing from primary mRNA. 
Pre-miRNA is then processed by Dicer to form the functional miRNAs. The RISC 
complex forms around the miRNAs to enable the binding to the target gene leading 
to an inhibition of translation or mRNA degradation. Adapted from Miyaki et al. 





1.8.2.   miRNAs function 
Mature miRNAs are loaded into RISC. The RISC loading complex is composed of the 
RNase Dicer, TRBP, Protein Activator of PKR (PACT) and argonaute 2 (Ago2). TRBP 
and PACT aren’t essential for cleavage but act to stabilize and facilitate it [164]. 
Argonaute proteins in this RISC complex carry out endonucleic cleavage of mRNAs by 
miRNAs. The argonaute family in humans is composed of 4 members, but only Ago2 
possesses enzymatic activity [165]. Argonaute proteins possess a Piwi Argonaut and 
Zwille (PAZ) domain that enables their binding to the stem-loop structure of pri-
miRNAs and to mature miRNAs present in the RISC complex [166]. The PIWI domain 
of argonaute proteins is composed of an RNAse H domain enabling the splicing activity 
[167]. miRNA interactions with mRNAs occur at the 3’ untranslanted region (3’UTR) 
through imperfect base-pairing, this improves the chances for a miRNA to have 
multiple binding sites within a single mRNA and to many different mRNAs. The seed 
region consisting of a region of 6-8 nucleotides at the 5’ end of miRNAs is essential for 
interactions between miRNAs and mRNAs. It is thought that the 5’ end is necessary for 
target identification and that the 3’ end is necessary for modulating repression of 
mRNAs. AU rich areas close to the seed region contribute to miRNA efficacy [168].  
miRNAs’ control of mRNA levels may not be as efficient as proteosomal degradation 
but allows a strong inflammatory response that can then be slowly modulated. A perfect 
match between a miRNA and its target leads to cleavage and degradation of the mRNA. 
However, if the interaction with the target involves more mismatches, this leads to an 
inhibition of translation [169]. The mRNA fragments formed after cleavage go through 
standard degradation. 
1.8.3.   miR-132 
MicroRNAs regulate the strength and timing of TLR responses and signalling. miRNAs 
can regulate TLR expression, TLR signalling proteins, target transcription factors, target 
TLR signalling regulators, and target cytokine mRNAs. Two microRNAs, miR-132 and 
miR-212 form a miRNA cluster that has been shown to have a role in inflammation. 
miR-132 is highly expressed in the brain [170-173] and induces neuronal growth and 
dendritic plasticity [174]. miR-132 and miR-212 are encoded on chromosome 17 of the 
human genome and chromosome 11 in mice and is transcribed by cAMP-Response 
Element Binding protein (CREB) in neuronal cells [175] and by Repressor Element 1 
Silencing Transcription factor (REST) in non-neuronal cells [176]. The same primary 
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transcript gives rise to miR-132 and miR-212 and this cluster possesses similar mature 
sequences and the same seed region but miR-132 is preferentially expressed [173]. 
TLR activation and signalling must be controlled to avoid excessive and sustained 
inflammation and tissue damage. miRNAs form a key factor in a negative feedback 
loop of the innate immune system [177]. There are several miRNAs induced by TLR 
activation that target mRNAs encoding the TLR signalling system [178]. This is 
illustrated in Figure 1.5 [112]. Due to miR-132's dual role in inflammation and brain 
functions, it has been dubbed “NeurimmiR” [179]. Several targets for miR-132 are 
known, including mediators involved in neurological development, synaptic 
transmission, inflammation and angiogenesis. miR-132’s transcription is stimulated by 
TLR4 agonists and up-regulated at early stages of infection [180]. Different cell types 
including stromal fibroblasts express miR-132, and in mammary stroma this miRNA 
inhibits the Matrix Metalloproteinase 9 (MMP-9). Mice lacking miR-132 are unable to 
have proper epithelial-stroma interactions and therefore lack the ductal overgrowth that 
is required for mammary glands development [181]. miR-132 is induced in bone 
marrow (BM) and splenocytes of mice treated with LPS and represses 
acetylecholinesterase (AChE) expression. AChE is a key regulator of peripheral 
inflammation [180]. Heparin-Binding Epidermal-like Growth Factor (HB-EGF) 
involved in cell proliferation and migration as well as wound healing is repressed in 
mast cells by miR-132 [182]. In NK cells, miR-132 regulates IL-12 signalling by 
repression of Signal Transducer and Activator of Transcription 4 (STAT4) [183]. miR-
132 is up-regulated during virus infections such as with Human Cytomegalovirus 
(HCMV) which could be a way for the virus to evade the immune response. This is 
further explained by the fact that upon virus stimulation, miR-132 regulates p300 that 




Figure 1.5: miRNAs regulate TLR4 signalling.  
The TLR4 signalling pathway uses the adaptor molecule MyD88 to initiate NFκB 
dependent gene transcription. TLR activation and signalling must be tightly 
controlled to avoid extreme inflammation and enable tissue repair. Proteasome 
degradation is one such mechanism, another is mediated by miRNAs. miRNAs bind 
to the 3’ untranslated region of specific mRNA target sequences to inhibit gene 
synthesis of the signalling pathway or of cytokines. Adapted from O’Neill, L. et al., 
Nature Reviews Immunology, 2011. 
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1.9.   Summary and aims 
Stromal cells provide the structural basis for lymphocyte and DC migration and 
localization, providing specialized microenvironments for their homeostasis and 
function. Although stromal cell gene expression and function has been studied under 
homeostatic conditions, less is known about the behaviour of stroma during 
inflammation or the process leading to rapid stromal cell remodelling. During the early 
stages of a pathogen driven immune response, LNs rapidly enlarge which results from 
the vascular remodelling and increase in the rate of T and B cell influx. This can in part 
explain changes observed in the stromal network; however, adjuvant treatment has been 
shown to drive new stromal architecture for the immune response to take place. The aim 
is to determine the role of LN architecture in vaccine efficacy. 
Using adjuvants, TLR agonists and infection models the timing and molecular 
mechanisms leading to stromal cell reorganization and changes in cytokine and 
chemokine expression was addressed. Rapid changes in inflammatory gene expression 
and cytokine production by LN stroma were observed both in in vitro stromal cell 
cultures and in adjuvant administration in vivo. A schematic showing the aim of the 
work undertaken is illustrated in Figure 1.6. 
1.10.   Hypothesis 
The working hypothesis of my project is that adjuvant efficacy is not only dependent on 
DC activation and on antigen maintenance but on LN stromal cell remodelling. 
Specifically, the aim is to determine the molecular mechanisms of stromal cell 
activation and remodelling in response to TLR4 agonism. By developing a better 
understanding of these processes, we hope to create improved vaccines through the 
manipulation of stromal cell network organization leading to efficient cell interactions 
to optimally prime the immune response. 
1.11.   Specific aims 
•   Investigate stromal remodelling and LN expansion following immunization.  
•   Determine the mechanisms and cell changes behind LN remodelling. 
•   Analyse the role of miR-132 in regulating LN remodelling. 
•   Determine mechanisms by comparing miR-132 deficient mice with WT mice 





Figure 1.6: Schematic illustrating the specific aim of the project.  
LNs have been shown to remodel during an immune response to adjuvants [11]. The 
mechanisms underlying how LNs rapidly change their architecture in response to 













Chapter 2:    Materials and Methods 
2.1.  Reagents 
Table 2.2. Adjuvants 
Adjuvant name Manufacturer 
Catalogue 
number 
Imject Alum  (formulation of aluminum 
hydroxide and magnesium hydroxide) 
Thermo Scientific 77161 
Freund’s Adjuvant, Complete (CFA) Sigma Aldrich F5881 
Glucopyranosyl lipid adjuvant-stable oil in 





Freund’s Adjuvant, Incomplete (IFA) Sigma Aldrich F5506 
Sigma Adjuvant System. (Monophosphoryl 
Lipid-A (MPL-A) and Trehalose 
Dicorynomycolate (TDM)). 
Sigma Aldrich S6322 
Second generation lipid adjuvant – stable oil 
in water emulsion (SLA-SE) 
IDRI IDRI-EM030 
Formulated oil-in-water emulsion (W/OE) IDRI IDRI-EM582 
 
Table 2.3. Vaccines 
Vaccine name Manufacturer Catalogue number 
Engerix B Glaxo Smith Kline (GSK) NDC 58160-821-05  
Fendrix GSK AFENA015AR 
Inactivated Influenza 
Vaccine (TIV) 




Table 2.4. Primary antibodies 








BV421 Biolegend FC 
CD3 
eFluor 660 
17A2 Rat IgG2b 
eBioscience IHC 
PE-Cy7 Biolegend FC 
CD4 Pacific Blue RM4-5 Rat IgG2a Biolegend FC 
CD8 APC-Cy7 53-6.7 Rat IgG2a Biolegend FC 
CD11b PE-Cy7 M1.70 Rat IgG2b Biolegend FC 
CD11c 












APC-Cy7 6D5 Biolegend 










CD44 APC IM7 Rat IgG2b Biolegend FC 
















L138D7 Rat IgG2b Biolegend FC 
PE 
ER-TR7 Purified ER-TR7 Rat IgG2a Abcam IHC 
FDCM2 Purified FDC-M2 Rat IgG2a Immunokontact IHC 
Foxp3 PE-Cy7 FJK-16s Rat IgG2a eBioscience FC 
ICAM Pacific Blue 
YN1/1.7.
4 
Rat IgG2b Biolegend FC 
IgD FITC 11-26c Rat IgG2a eBioscience 
IHC, 
FC 
GL7 eFluor 660 GL7 Rat IgM eBioscience FC 
gp38 
eFluor 660 
8.1.1 Hamster IgG eBioscience FC 
AF 488 
Ly6C PE HK1.4 Rat IgG2c Biolegend FC 
Ly6G AF 647 1A8 Rat IgG2a Biolegend FC 




Rat IgG2a Biolegend FC 
Biotin 
Meca-79 AF 488 Meca-79 Rat IgM eBioscience IHC 
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MHCII eFluor 450 
M5/114.
15.2 
Rat IgG2b eBioscience FC 




Rat IgG2a Biolegend FC 
 PNA Biotin Lectin from Arachis hypogaea Sigma IHC 
RANK-L Purified IK22.5 Rat IgG2a  IHC 
SIGN-R1 APC 22D1 Hamster IgG eBioscience FC 
VCAM APC 429 Rat IgG2a Biolegend FC 
 
Table 2.5. Secondary antibodies 
 Fluorophore Host Manufacturer Use 







AF 647 IHC 
Rat IgG AF 488 Goat Invitrogen IHC 
Rabbit IgG AF 647 Goat Invitrogen IHC 
Mouse IgG Alkaline phosphatase (AP) Goat Sigma Aldrich ELISA 
Mouse IgG1 Alkaline phosphatase Goat Southern Biotech ELISA 
Mouse IgG2c Alkaline phosphatase Goat Southern Biotech ELISA 
Mouse IgA Alkaline phosphatase Goat Southern Biotech ELISA 




Table 2.6. Primers 
Gene Forward Primer Reverse Primer 
AICDA GCCACCTTCGCAACAAGTCT CCGGGCACAGTCATAGCAC 
CXCL12 CAGAGCCAACGTCAAGCA AGGTACTCTTGGATCCAC 
CXCL13 CATAGATCGGATTCAAGTTACGCC TCTTGGTCCAGATCACAACTTCA 
HPRT AGGAGTCCTGTTGATGTTGCCAGT GGGACGCAGCAACTGACATTTCTA 
HTRA1 AGTGGGTCAGGATTCATCGTA GTGACCACGTGAGCATTTGT 
IL-1β AACCTGCTGGTGTGTGACGTTC CAGCACGAGGCTTTTTTGTTGT 
IL-22BP TCACTCCATGGTGGGAAACAAA CGCAGTAGCTGGAATGAGGT 
IL-6 GGGACTGATGCTGGTGACAA CGCACTAGGTTTGCCGAGTA 
MMP-9 GTCCAGACCAAGGGTACAGC ATACAGCGGGTACATGAGCG 
TLR4 AGTGGGTCAAGGAACAGAAGCA CTTTACCAGCTATTTCTCACC 
TNFα CTGTAGCCCACGTCGTAGC TTGAGATCCATGCCGTTG 
Gene Assay name Manufacturer 
RNU6 U6 snRNA Applied Biosystems 





All mice used were maintained at the University of York Biological Services Facility 
(BSF). Mice were purchased and housed at the BSF under-pathogen free conditions. All 
mice used were between 6 to 10 weeks of age unless otherwise stated. 
B6.Rag2KO.CD45.1Cg, B6.CD11cCreTg and Rosa26iDTRfl and miR-132-/- [185] mice 
were bred at the BSF. B6CD11cCreTg mice were crossed with Rosa26iDTRfl mice to 
generate B6.CD11cCreTg.Rosa26iDTRfl mice [186]. All mice were kept in micro-
isolator cages in the vivarium under standard laboratory conditions with an artificial 
12hrs dark/light cycle, and fed on a standard irradiated rodent diet with autoclaved 
water ad libitum. Sentinel mice were housed with experimental mice and tested for 
pathogens every three months. Animal care and protocols were in accordance with the 
European Union regulations and performed under a United-Kingdom Home Office 
licence. Immunized mice were treated following a randomized block design to remove 
the nuisance factor. In this case, the cage is considered the blocking factor. Another 
person who was blind to the treatment and to the aim of the experiment treated the mice 
to remove bias.  
2.3.  Adjuvant immunizations 
Different adjuvants and vaccines (Table 2.1 and 2.2) were used and tested following 
two different immunization protocols.Mice were either immunized subcutaneously in 
the flank with 100μl or in the hock [187] with 25μl of Ovalbumin (OVA) (Sigma 
Aldrich) at 0.1mg/ml in a mixture of adjuvant diluted in Phosphate Buffered Saline 
(PBS). Different adjuvants were used following these two methods: Alum (Imject 
Alum, Pierce chemicals co.), MPL-A+TDM (Sigma), GLA-SE (IDRI), CFA or IFA 
(Sigma). Vaccines used clinically were tested, the Hepatitis B Virus (HBV) vaccines 
Fendrix (GSK) containing aluminum hydroxide and MPL-A, and Engerix B (GSK) that 
contains aluminum hydroxide only; and finally the seasonal Inactivated Influenza 
Vaccine (TIV) (Sanofi Pasteur) adsorbed in aluminum hydroxide. These vaccines were 
kindly provided by Prof. Charles Lacey and were diluted 1:2 in PBS and injected into 
mice subcutaneously in the flank.  
Two to three weeks after the first challenge, mice were immunized with the same 
emulsion. Mice immunized with CFA were boosted with IFA or not at all. Four days 
later, inguinal LNs (iLNs) or popliteal LNs (pLNs) were isolated for analysis. 
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2.4.   Sample collection 
Blood was removed by cardiac puncture while the mice were anesthetized with 
isoflurane using heparin (Sigma Aldrich) coated syringes. Mice were then cervically 
dislocated to confirm death by a second method. When serum wasn’t needed, mice were 
schedule 1 killed using increased concentrations of CO2 and then cervically dislocated. 
Popliteal and inguinal LNs were removed and placed in Fluorescence-Activated Cell 
Sorting (FACS) wash, PBS containing 0.5% Bovine Serum Albumin (BSA) (Sigma 
Aldrich) and 2mM Ethylenediaminetetraacetic Acid (EDTA) (Sigma Aldrich). 
2.5.  Enzymatic digestion of lymph nodes 
The digestion protocol was adapted from Fletcher A. et al. [188]. For flow cytometry or 
cell culture, LNs from mice were dissected and placed in RPMI-1640 media (Life 
Technologies). LNs were then pierced once with fine forceps and incubated with freshly 
made enzymatic mix containing 0.2mg/ml Collagenase P (Roche), 0.8mg/ml Dispase 
(Roche) and 0.1mg/ml DNaseI (Roche) in RPMI-1640. The tubes were then incubated 
at 37°C in a thermomixer with gentle mixing. After 20 minutes, LNs were carefully 
pipetted, releasing most leukocytes as it disrupted the capsule. Large fragments were 
then allowed to settle and the enzymatic mix was removed and added to 3 ml of cold 
FACS wash or cell culture media (αMEM (Life Technologies), 10% Foetal Calf Serum 
(FCS) and 5% L-glutamine) and centrifuged at 300g for 5 minutes at 4°C. The 
enzymatic mix was then added to the digestion tube, the contents mixed using a pipette 
and incubated for 10 minutes at 37°C in a thermomixer with gentle mixing. After the 
incubation, cells were mixed vigorously, after the fragments were again allowed to 
settle, the supernatant was removed and added to the previously spun cell pellet and 
centrifuged again. By this time, the fragments left over were fat and the LNs are 
digested. Cells were filtered through 70μm cell strainers, counted using a 
hemocytometer and plated at 500,000 cells/cm2 or used for flow cytometry/cell 
isolation. For FRC culture, αMEM medium supplemented with FCS was used and after 
24hrs post plating, cells were washed to remove non-adherent cells. Cells were 




2.6.   FRC culture and treatment of cells 
Total LN cells were cultured at 37°C with 5% CO2 until a pure population of FRCs was 
obtained. When there was a pure population of FRCs, cells were plated at appropriate 
cell concentrations and treated with TLR agonists and incubated at 37°C with 5% CO2. 
TLR agonists (Invivogen) were used at the concentration that was indicated by the 
manufacturer and adjuvants were used 1:1000. 
2.7.  Bone Marrow Dendritic Cell isolation and culture 
Bones were removed from mice and cleaned. Bones were gently flushed and the bone 
marrow was collected into a petri dish. The cell suspension was transferred to a tube 
using a narrow gauge needle and through a cell strainer to remove debris. Cells were 
diluted to 2x106 cells/ml with complete medium and 1ml of cells were distributed into 
6-well plates. Medium containing 40ng/ml of murine recombinant Granulocyte 
Macrophage Colony-Stimulating Factor (GM-CSF) (Peprotech) was prepared and 1ml 
added to each well (final concentration of GM-CSF at 20ng/ml). Thereafter, 3, 6, 8 and 
10 days later, media was removed and replenished with fresh medium containing GM-
CSF. At day 11, cells were used for experiments and treated with TLR agonists 
(Invivogen) according to manufacturer’s indication.  
2.8.   Flow cytometry procedure 
2.8.1.    Surface marker antibody staining 
The single cell suspensions from the digested LNs were transferred into V-Bottom 96-
well plates. Cells were resuspended in freshly made Fc block containing TruStain fcX a 
rat anti-mouse CD16/32 antibody (Biolegend) and rat IgG (Sigma) and incubated on ice 
for 10 minutes. The plates were then spun for 5 minutes at 4°C at 300g and the 
supernatant was discarded. The antibody staining mix containing the primary antibodies 
diluted in FACS wash was added to the cells and incubated 25-30 minutes on ice in the 
dark. Unstained controls and single stain controls prepared at the same concentration as 
in the master mix were also prepared. The antibodies used are listed in Table 2.3. Cells 
were washed three times, in cases where it was necessary the cells were incubated in the 
appropriate secondary antibody for 25-30 minutes on ice. Cells were then washed three 
times, resuspended in 150μl FACS wash and transferred to micro tubes (Titertube micro 
test tubes, Bio-Rad) containing 50μl of AccuCheck counting beads (Life Technologies). 
The samples were run on a Beckmann Coulter CyAn ADP flow cytometer machine 
 
53 
using the Summit software. Data acquired was analysed using the FlowJo software 
(Tree Star).  
Gating strategies for identifying different cell types are shown in figures 2.2, 2.3 and 
2.4. 
2.8.2.   Intracellular staining 
In cases where the marker to be analysed was intracellular and did not require 
stimulation (e.g. FOXP3), following Fc block and surface staining, the cells were 
incubated in fixation/permeabilisation solution (eBioscience) for 30 minutes. The cells 
were washed twice in 1X permeabilisation buffer (eBioscience). Cells were then stained 
with the antibody master mix diluted in the permeabilisation buffer for 30 minutes on 
ice. The cells were washed twice and transferred to micro tubes. 
2.8.3.   Viability determination 
After cell surface staining, cells were resuspended in PBS containing 4’,6’-diamidino-2-
phenylindole (DAPI) at a 1:5000 dilution and incubated 5 minutes on ice. Cells were 
then washed and transferred to micro tubes. The samples were run on a Beckmann 
Coulter CyAn ADP flow cytometer with the acquisition boost turned off. DAPI enters 
dead cells that have membrane permeability, this makes it possible to discriminate 
between live and dead cells as shown in Figure 2.1. For cells having undergone 
stimulation for intracellular staining, a viability dye eFluor 780 (eBioscience) was 
added to the master mix containing the surface marker antibodies instead of DAPI.  
2.8.4.   Quantifying cell numbers 
To accurately calculate total cellularity of samples, AccuCheck counting beads were 
used. Prior to adding the beads to the micro tubes, the counting beads were thoroughly 
mixed. The cell and bead suspension was mixed before running on the flow cytometer. 
To ensure accuracy and that the beads were mixed properly, the counting beads consist 
of two types of beads that have different fluorescent intensity in the PE channel and 
should be at a ratio of 50:50 for the cell count to be accurate, but 45:55 was considered 
acceptable. Figure 2.1 illustrates how the counting beads appear on a flow cytometer 
plot. In order to calculate cell number, the beads were gated on along with the cell 





The number of beads per microliter was provided with the counting beads and varied 






Figure 2.1: Accucheck beads were used to determine cellularity and a live-
dead marker to determine viability.  
Representative flow cytometry plots are shown here. A: Singlet discrimination was 
done by using the Pulse width. B: After staining, AccuCheck counting beads were 
added to the samples. The beads have a high side scatter (SSC) and a low forward 
scatter (FSC) that enables the easy distinction between the beads and the cells. C: 
The beads have different intensities in the FL2 channel; this helps distinguish the two 
sets of beads that need to be at a ratio near 50:50 to be deemed accurate. D: The live-
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Figure 2.2: Gating strategies for identifying stromal cell subsets.  
Representative flow cytometry plots are shown here. Singlet discrimination was done 
by using the Pulse width. Within CD45 negative cells it is possible to distinguish 
different cell types by using different markers. FRCs (CD45-gp38+CD31-), LECs 
(CD45-gp38+CD31+), BECs (CD45-gp38-CD31+), MRCs (CD45-
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Figure 2.3: Gating strategies for identifying adaptive immune cell types.  
Representative flow cytometry plots are shown here. Singlet discrimination was done 
by using the Pulse width. Different cell types can then be distinguished using 
different markers. Follicular B cells (CD19+IgD+CD95-), and Activated B cells 
(CD19+IgD-CD95+GL7+). CXCR5 is expressed in cells. T cells can be 
subcategorized as CD4+ and CD8+. Follicular Regulatory T Cells 
(CD4+PD1+CXCR5+Foxp3+CD44+), Follicular Helper T Cells 
(CD4+PD1+CXCR5+Foxp3-CD44+), T regulatory cells (CD4+PD1-CXCR5-
Foxp3+CD44int), T effector memory cells (CD4+PD1-CXCR5-Foxp3-CD44high), T 
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Figure 2.4: Gating strategies for identifying innate immune cell types.  
Representative flow cytometry plots are shown here. Singlet discrimination was done 
by using the Pulse width. Different cell types can then be distinguished using 
different markers. NK cells (NK1.1+), NKT (NK1.1+CD3+), DCs 
(CD11c+MHCIIhigh), neutrophils (CD11b+Ly6CintLy6Ghigh), monocytes 
(CD11b+,Ly6G-Ly6Chigh), Macrophages (CD169+), subcapsular sinus macrophages 



































2.9.  Cell sorting 
To isolate specific cells from the draining LN, five mice were treated and their LNs 
were pooled to ensure sufficient cell numbers would be sorted. Samples were processed 
as described in section 2.5 and stained for flow cytometry as described in section 2.8. 
The staining was undergone in 15ml falcon tubes instead of 96 well plates. Before 
sorting, the cells were passed through a 40μm cell strainer to ensure there were no cell 
clumps and resuspended at a density of 107 cells/ml in FACS buffer. Cells were sorted 
using a Beckman Coulter MoFlo Astrios machine into tubes coated with FCS. A post-
sort sample was run to check that the purity was above 95%. Cells isolated were spun 
down and used for quantitative PCR (qPCR) analysis of genes.  
2.10.   Immunohistochemistry 
2.10.1.  Sample preparation and cryosectioning 
LNs removed from mice were snap frozen in cryomoulds in Tissue-Tek™ CRYO-OCT 
Compound (Sakura) and stored at -80°C. 6µm sections were cut using a cryostat (Leica 
1850) at -15°C onto labelled poly-L-lysine coated slides. Sections were air-dried for an 
hour and then stored at -20°C.  
2.10.2.  Immunofluoresent staining 
Slides were removed from the freezer and left on the bench to reach room temperature 
for 30 minutes. Slides were then fixed with cold acetone for 10 minutes. The sections 
were circled with an Immedge pen (Vector Laboratories) and rehydrated by washing 
three times in PBS for 5 minutes. Samples were then incubated with blocking buffer 
containing 5% Goat serum and 1.5% Triton X-100 (Sigma Aldrich) for an hour. The 
serum chosen was dependent on the species the secondary antibody was raised in. 
Sections were then stained in the blocking buffer containing the diluted antibodies 
(Table 2.3) for one hour at room temperature. As a control conjugated isotype controls 
were used to check specificity of staining. Slides were then washed in PBS three times. 
When the primary antibody was purified or biotinylated, a secondary antibody (Table 
2.4) incubation step was performed at room temperature for an hour. The slides were 
then washed in PBS again and dried. Prolong gold (Life technologies) was added to 
each section and mounted in SLS Coverslips No 1.5 22x64 mm. After incubating the 
slides overnight at 4°C, nail varnish was used to seal the coverslip onto the slide. All 
stained slides were stored at 4°C. 
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2.10.3.  Confocal imaging 
Sections were then examined using a Zeiss 710 confocal microscope on a fully 
motorised invert microscope and the Zen 2009 software. The microscope has five 
independent lasers and seven laser lines (405, 458, 488, 514, 561, 594 and 633 nm). 
LNs were imaged using the 10x objective, and tile scans were performed to image the 
whole tissue. The images were taken at 1024x1024 pixels with an average of 16. Images 
obtained were analysed using the image-processing package Fiji and the images were 
further processed using Photoshop (Adobe CS4). 
2.10.4.  Image quantification 
The images obtained from stained sections (e.g. sections stained for B and T cells) were 
quantified by using Cell Profiler image analysis software (www.cellprofiler.org (Broad 
Institute)). This software works by creating a pipeline allowing sequential algorithms to 
be applied to image stacks. The “LN image analysis pipeline” first sets the specific 
channels to black and white, then it blurs the images permitting the software to 
distinguish B cell areas or T cell areas depending on which channel has been set to 





Figure 2.5: Cell profiler B cell follicle quantification pipeline. 
A: Illustrates the pipeline used on a PBS treated LN and B: An OVA/GLA-SE 
treated LN. The green fluorescence staining the B cells is changed to black and white 




2.11.   Antibody ELISA 
2.11.1.  Sample preparation 
Blood removed from mice by cardiac puncture was spun down at 300g for 10 minutes 
to isolate the serum. Immediately following centrifugation, the supernatant was 
transferred to a new tube. Samples were stored at -80°C and maintained at 4°C during 
Enzyme-Linked Immunosorbent Assay (ELISA) experiments. 
2.11.2.  Measuring serum antibody titres 
To determine serum antibody titres, direct ELISAs were performed. The OVA antigen 
is bound to the multiwell Nunc immunoplate (Thermo Scientific) at 20μg/ml in 
Carbonate/Bicarbonate buffer (Sigma Aldrich) for 2 hours at room temperature. The 
plates were washed 3 times with PBS/0,05%Tween (PBS/T) and then blocked in 
PBS/2.5%BSA for 2hrs at room temperature. After which, the plates were washed 3 
times with PBS/T. The serum was diluted at 1:300 in PBS/T, added to the plates and 
then serially diluted 1:3 and incubated overnight at 4°C. After washing the plates with 
PBS/T, secondary antibodies were added to plates (see Table 2.4) diluted in PBS/T and 
incubated for 2hrs at room temperature. The plates were washed and the BluePhos 
Microwell Substrate (Insight Bio) was added and left to react for 1hr at room 
temperature. The reaction was stopped by adding the Alkaline Phosphatase Stop 
Solution (Insight Bio). The plates were then read at 595nm in a Bio-Rad Microplate 
reader. The antibody titre was calculated as the serum dilution needed for a pre-
determined optical density.  
2.11.3.  Measuring serum antibody avidity 
To determine serum antibody avidity, direct ELISAs were performed. The plates were 
treated in the same way as described in paragraph 2.11.2 until serum was to be added. 
The serum was diluted 1:2000, added to plates and incubated overnight at 4°C. The 
plates were washed 3 times with PBS/T and prepared dilutions of sodium thiocyanate 
(NaSCN) of 3M, 2.5M, 2M, 1.5M, 1M, 0.5M, and 0.25M were added to the wells. The 
plates were washed and the secondary antibodies were added to the wells and incubated 
for 2hrs at room temperature. The plates were washed and the BluePhos Microwell 
Substrate (Insight Bio) was added and left to react for 1hr at room temperature. The 
reaction was stopped by adding the Alkaline Phosphatase Stop Solution (Insight Bio). 
The plates were then read at 595nm in a Bio-Rad Microplate reader. The avidity index 
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is the NaSCN concentration at which 50% of the bound antibodies are eluted off.  
2.12.   Quantitative PCR 
2.12.1.  RNA extraction 
Isolated cells were spun down at 300g for 5 minutes at 4°C, supernatant was removed 
and cells were lysed using QIAzol Lysis Reagent (Qiagen) and disrupted by vortexing 
the cells for one minute. The homogenate was incubated at room temperature for 5 
minutes and the lysates were stored overnight at -80°C. RNA was extracted from cells 
following the Qiagen miRNeasy mini or micro kit protocol. These kits enable the 
purification of total RNA, including RNA of 18 nucleotides and upwards. The micro kit 
was used for the sorted stromal cells that were in low quantity. The micro kit is 
designed for small numbers of cells and elutes in a final volume of 14μl. The RNA 
quantity and quality was determined by using a nanodrop spectrometer. The 260/280 
ratio of the sample had to be above 1.8 to not be considered contaminated. RNA 
samples were then stored at -80°C and kept at 4°C at all times during experiments. 
2.12.2.  Total complementary DNA synthesis 
RNA was diluted in nuclease free water to a final volume of 10μl at known quantities 
determined by the nanodrop. If samples had a yield that was too low, which was the 
case for sorted stromal cells, RNA was left undiluted and 10μl was directly used. The 
master mix was added to the diluted RNA samples and contained 4.2μl H20, 2μl 
Reverse Transcriptase (RT) buffer, 0.8μl dNTP mix, 2μl RT Random Primer, and 1μl 
MultiScribe Reverse Transcriptase from the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems). The samples were retro-transcribed in a thermo 
cycler PCR machine (SensoQuest). The conditions were 10 minutes at 25°C, two hours 
at 37°C and finally 5 minutes at 85°C. The samples were maintained at 4°C when 
handled and 80μl of nuclease free water was added to the samples before storage at -
20°C. 
2.12.3.  Specific miRNA complementary DNA synthesis 
Levels of mature miRNAs were determined using commercially available probes from 
Invitrogen. The reverse transcriptase procedure was followed as described. 
Two microliters of RNA was added to the master mix containing 8.16μl nuclease free 
water, 1.5μl RT buffer, 0.15μl dNTPs, 0.19μl RNase inhibitor, 2μl of miR-specific RT 
 
64 
probe and 1μl Multiscribe Reverse Transcriptase from the TaqMan MicroRNA Reverse 
Transcription Kit (Life Technologies). The samples were retro-transcribed in a thermo 
cycler PCR machine (SensoQuest). The conditions followed were 5 minutes at 4°C, 30 
minutes at 16°C, 30 minutes at 42°C and 5 minutes at 85°C. The samples were 
maintained at 4°C when handled and stored at -20°C. 
2.12.4.  Primer design 
Primers for SYBR green qPCR were designed using the NCBI Blast software to be 
between 18 and 24 nucleotides and ordered from Sigma. This length enables the primers 
to have adequate specificity and to bind to the template at the annealing temperature. To 
decrease the possibility of genomic DNA amplification, primers were designed to span 
an exon-to-exon junction. Primers had a melting temperature in the range of 60°C, a GC 
content of 50% and possessed no possible secondary structure as this would reduce the 
primer availability in the reaction. The amplicon product length is of 100-200 base 
pairs. Upon arrival, primers were hydrated with nuclease free water to a concentration 
of 100nM, a 10nM working stock for each primer was then made and stored at -20°C.  
Taqman probes for miR-132 and the internal control RNU6 were ordered from 
Invitrogen. 
2.12.5.  qPCR reaction 
Power SYBR Green PCR Master Mix or TaqMan Universal PCR Master Mix, no 
AmpErase UNG (Life Technologies) were used for qPCR. Each sample was run in 
duplicate and Hprt (hypoxanthine phosphoribosyltransferase) or Rnu6 (U6 small 
nuclear RNA) were used as endogenous control genes. The qPCR mix was composed of 
12.5μl of one or the other PCR Master Mix, 1μl of forward primer, 1μl of reverse 
primer, and 6.5μl H20 for total cDNA or 9.5μl H20 for specific miRNA. 4μl cDNA or 
2μl specific miRNA were added to the MicroAmp Optical 96-well reaction plate 
(Applied Biosystems) along with the prepared master mix. Control samples for the 
qPCR reaction containing no cDNA or no RT reaction were included in the plates. The 
reaction was run on an Applied Biosystems 7300 real time PCR machine. The qPCR 
reaction was composed of the activation step consisting of heating the plate to 50°C for 
two minutes, followed by 95°C for 10 minutes. The data collection step was 40 cycles 
of a step at 95°C for 15 seconds, followed by one minute at 60°C. The qPCR reaction 
was followed by a melt curve that is described below. 
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2.12.6.  Melt curve 
After the SYBR green qPCR reaction, a melt curve analysis was done to assess that the 
assay produced a single amplicon. The final product is exposed to a temperature 
gradient from 50°C to 95°C while the fluorescence is analysed. The temperature at 
which the double stranded DNA melts into single stranded DNA leads to a decrease in 
fluorescence as the dye dissociates. The peak number is a reflection of the amplicon 
number. Therefore, primers producing a single peak are considered specific. This is 
illustrated in Figure 2.6.  
2.12.7.  qPCR analysis 
After the reaction was finished, the threshold was placed automatically at 0.2Rn (which 
is the fluorescence signal normalized to a reference dye signal) in the linear part of the 
curve. This enabled the collection of Threshold cycles (Ct) that is the cycle number at 
which the fluorescence reaches threshold. The average Ct values and standard deviation 
were calculated from the duplicate raw Ct values for each sample. The values for each 
gene analysed were normalized to Ct values for Hprt or Rnu6 for each sample giving 
the ΔCt values. The ΔΔCt values were then calculated using a control sample as 
calibrator and subtracting every sample’s ΔCt from the control sample. The fold 





Figure 2.6: Melt curve analysis to confirm product specificity plots 
fluorescence vs Derivative fluorescence.  
A: A single peak illustrates the specificity of the product amplified whereas B: 







2.13.   CD11c+ cells depletion 
B6.CD11cCreTg.Rosa26iDTRfl mice express the primate Diphtheria Toxin Receptor 
(DTR) in all cells that have expressed CD11c. Diphteria toxin (DTx) is harmless to the 
mice but specifically eliminates cells that express the DTR upon DTx administration 
[186]. 100ng of DTx (Sigma) diluted in PBS was administered intraperitoneally. After 
24hrs after DTx treatment, mice were immunized with OVA/GLA-SE for 48hrs. pLNs 
were then analysed by flow cytometry. 
2.14.   TNFα inhibition 
B6CD45.1 and miR-132-/- mice were administered 2.5mg/ml InVivoMAb anti-TNFα 
(BioXCell) in 100μl intraperitoneally. 72hrs post treatment, mice were sacrificed and 
LNs were analysed by histology.  
2.15.   Statistics 
Statistical analysis was done using the software GraphPad Prism. When comparing the 
effect of one parameter, such as a treatment, a one-way ANOVA was done to check the 
variances followed by a Tukey’s or Dunnett’s multiple comparison test and when 
comparing the effect of genotype and treatment a two-way ANOVA was done followed 
by a Tukey’s or Dunnett’s multiple comparison test. When comparing two groups a 
standard unpaired t-test was done. Data was then plotted on graphs with bars illustrating 




Chapter 3:   TLR4 agonists induce LN remodelling 
3.1.   Introduction 
3.1.1.   Initiation of LN hypertrophy 
The innate immune response modulates LN microenvironments leading to changes in 
lymphocytes and DCs recruitment. This increases the chance of T cells interacting with 
APCs, thus initiating the adaptive immune response. The increase in lymphocyte and 
DC recruitment leads to an increase in LN size supported by an increase in stromal 
cells. “Inflammation induced recirculation” is the term used to refer to naïve 
lymphocytes being recruited into draining LNs from the site of infection [189]. In 
homeostatic conditions, lymphocytes regularly enter the LNs through HEVs from the 
blood. The cellular entry into LNs is dictated by chemokines produced by stromal cells, 
namely CCL19, CCL21 and CXCL13. HEVs express chemokines and adhesion 
molecules permitting the extravasation of cells into the LN [1]. Mice lacking certain 
adhesion molecules possess a deficiency in immune cell entry and in the formation of 
immune responses [190, 191].  
During an immune response, T and B cell numbers increase while cell egress is shut 
down, enabling the rapid accumulation of cells [192]. Rapid changes to the stromal 
networks have to occur during the first few days of the immune response to facilitate the 
increase in cell numbers and drive an efficient immune response. Right after an 
infection, lymphatic vessels expand leading to an increase in APC entrance into the LN 
from the periphery [85]. Early stages of expansion are associated with an increase in LN 
neo-vascularisation, leading to an increase in blood flow to and from the LN. After 
antigen stimulation the HEV network increases in length. This increase in vascularity is 
not only due to vasodilatation but to proliferation of BECs [193]. HEVs proliferation in 
draining LNs is thought to be induced by DCs facilitating immune cell interactions and 
LN hypertrophy [194]. Although there are more HEVs, the growth is proportional to the 
increase in LN size; therefore the density of HEVs remains the same. Vasculature 
expansion is initiated by DCs that produce IL-1β stimulating VEGF production by 
FRCs [68, 195]. Further expansion of the LN architecture is dependent on T and B cells 
[82]. Cell egress through S1PR signalling is blocked in a CD69 mediated process so 
that there can be rapid lymphocyte accumulation in the LN. Early presence of DCs and 
trapping of lymphocytes results in FRC expansion [89]. CLEC-2 expressed by DCs 
interacts with podoplanin on FRCs leading to a reduction in FRC contractility, thus 
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enabling FRCs to stretch to accommodate the increase in LN size [90]. Further 
expansion of the FRC network depends on interaction with T cells through lymphotoxin 
and LIGHT [89]. Changes in the LN architecture are regulated by the reticular network 
through TNFR and LTβR signalling [11]. 
3.1.2.   LN architecture changes 
Changes in LN architecture are dependent on the type of infection or immunization. 
Immune cell compartmentalization in LNs has been shown to be disrupted during an 
immune response. In some studies, this has been shown to be due to direct targeting of 
FRCs or to certain pathogens causing a down-regulation of CCL21, CCL19 and 
CXCL13 [55, 64]. Immunization with OVA/CFA or injections of DCs has been shown 
to lead to BECs proliferation illustrating the plasticity of these stromal cells and that 
BECs can be regulated by DCs [194]. It has been shown that in the case of LCMV 
infection, LN expansion is not facilitated by VEGF but by LTβ production by B cells 
[196]. Immunizations with LPS and CFA both lead to changes in LN architecture and in 
changes to T and B cell zones [11, 98]. Repeated CFA delivery has been shown to 
potently stimulate LN hypertrophy, reorganisation of B cell follicles and blood and 
lymphatic vasculature angiogenesis [11]. 
3.1.3.   Summary 
In response to an infection or immunization, LNs rapidly expand to accommodate the 
rapid influx of innate and adaptive immune cells. To understand the molecular 
mechanism controlling this process it was important to identify and validate an 
appropriate model to investigate changes in LN architecture following adjuvant 
immunization.  
3.1.4.   Aims 
•   Establish an adjuvant-based model to investigate LN remodelling, defined as 
changes in LN architecture namely B cell follicles appearing in the paracortex. 
•   Investigate the effect of long-term treatment on LN architecture and on stromal 
cells. 
•   Investigate the dynamics of LN hypertrophy. 




3.2.  Establishing a model of adjuvant mediated LN remodelling 
Many different systems have been previously used to stimulate immune responses in 
draining LNs, thus it was necessary to identify and characterise a system that potently 
and reproducibly induced LN remodelling. Previous work analysing LN stromal 
remodelling was based on repeated footpad administrations of CFA [11]. Even though 
delivery of CFA drives high affinity antibody responses and tissue remodelling, it is 
toxic in humans and repeated administration cannot be done in the UK due to ethical 
concerns resulting from uncontrolled tissue inflammation. Therefore, different 
adjuvants and routes of administration were tested, focusing initially on subcutaneous 
delivery in the mouse flank, which drains to the inguinal LNs (iLNs). This injection was 
difficult to consistently reproduce, leading to high variation and limited LN remodelling 
(Figure 3.1). To test the effect of clinically approved vaccines on LNs, the HBV 
vaccines Fendrix (GSK) that contains aluminium hydroxide and MPL-A, and Engerix B 
(GSK), which contains aluminium hydroxide only; and finally the seasonal Inactivated 
Influenza Vaccine (TIV) (MASTA) adsorbed in aluminium hydroxide were injected. 
Immunizations led to a doubling in LN volume; however, although B cell follicles did 
increase in size they remained in the cortex. 
An alternate technique to footpad administration was then used for the rest of the 
project called hock immunization [187]. Hock immunizations are done by subcutaneous 
injection with adjuvant/antigen complex in the region just above the ankle proximal to 
the Achilles tendon. The draining LN is mainly the popliteal LN (pLN) and small 
amounts of antigen/adjuvant complex drives immune response in the medial iliac LNs 
and to iLNs [197]. Injecting adjuvants in this site provides enlarged LNs with no 
impairment on the mouse’s mobility, as it is a non-weight bearing structure. Adjuvants 
were administered at day 0, mice were then boosted at day 21 for three further days 
before sampling the pLNs at day 24. Immunization led to an enlargement of pLN when 
compared to the PBS treated mice (Figure 3.2). The strongest response was observed in 
MPL-A+TDM treated mice where the pLNs were massively enlarged and B cell 
follicular remodelling was observed. The synthetic TDM contained in the Sigma 
Adjuvant System is an analogue of the TDM of the tubercle bacillus. TDM is known to 
activate the immune response through the Mincle receptor and through TLR2. Imject 
Alum is formulated as a mix of aluminium hydroxide and magnesium hydroxide and 
will be referred to as Alum. From these results, the focus of all subsequent experiments 




Figure 3.1: LN architecture when treated with antigen/adjuvant complexes 
in the flank.  
Immunizations with OVA in combination with different adjuvants induce dynamic 
change of the LN. Frozen sections of the inguinal LN from B6CD45.1 mice injected 
in the flank. PBS, TIV, Engerix, Fendrix, OVA/Alum, OVA/IFA, OVA/CFA, and 
OVA/CFA+IFA immunized mice were stained with antibodies against CD3 (T cells) 










Figure 3.2: LN architecture when treated with antigen/adjuvant complexes 
in the hock. 
Immunizations with OVA in combination with different adjuvants induce dynamic 
change of the LN. Frozen sections of the popliteal LN from B6CD45.1 mice injected 
in the hock. PBS, OVA/Alum, OVA/IFA, OVA/CFA, OVA/CFA+IFA, and 
OVA/MPL-A+TDM immunized mice were stained with antibodies against CD3 (T 









3.3.  Effect of adjuvants on LN remodelling 
3.3.1.   Treatment induces LN hypertrophy 
The mice were injected in the hock for three weeks with TLR4 agonist adjuvants, then 
boosted for three further days before sampling the pLNs (Figure 3.3). To quantify LN 
enlargement LNs were digested and absolute cell number were compared (Figure 3.3A). 
Treatment with OVA/MPL-A+TDM led to a 2-fold increase in total cellularity 
compared to a 4-fold increase in cellularity in OVA/GLA-SE injected mice. This shows 
a significant increase in total cellularity after injection of OVA/GLA-SE. To determine 
how changes in cell numbers correlated with changes in LN volume, LNs were weighed 
(Figure 3.3B) and frozen sections from LNs were cut from the centre for the LN and the 
area of each section was quantified (Figure 3.3C). The images obtained from separate 
experiments were quantified by using Cell Profiler image analysis software 
(www.cellprofiler.org). This image analysis package works by creating a pipeline 
allowing sequential algorithms to be applied to image stacks. The “LN image analysis 
pipeline” first sets the specific channels to black and white, then it blurs the images 
permitting the software to distinguish B cell areas. Using this approach, the images were 
analysed for LN area. OVA/MPL-A+TDM injected LNs had 3-fold increase in weight, 
whereas treatment with OVA/GLA-SE led to a 12-fold increase in weight. A 6-fold 
increase in total LN area was also observed upon OVA/GLA-SE stimulation. As a 
TLR4 agonist adjuvant, GLA-SE is significantly more potent in inducing LN 
hypertrophy compared to MPL-A+TDM. For all subsequent experiments we focused on 
GLA-SE as a TLR4 agonist adjuvant. 
3.3.2.   Treatment induces an increase in immune cells 
To determine if the expansion observed resulted from selective expansion of specific 
cell types during hypertrophy, LN cell populations were quantified by flow cytometry 
(Figure 3.4) after treatment with adjuvants. Alum was used here as a control as it is to 
this day the most commonly used in vaccines. Treatment led to a significant increase in 
all cell types analysed, both with OVA/Alum and with OVA/GLA-SE when compared 
to PBS. OVA/GLA-SE treatment led to a significant increase in total cellularity, B cells, 
T cells, CD4 T cells, CD8 T cells and NK cells compared to OVA/Alum. Analysis of 
macrophages (subcapsular and medullary) showed no significant difference in 
OVA/Alum and OVA/GLA-SE treated mice. There was a significant reduction in the 




Figure 3.3: Effect of different adjuvants on lymph node size.  
Mice were treated with PBS, OVA/MPL-A+TDM or OVA/GLA-SE for 3 weeks 
then boosted with the same solution for a further 3 days. LNs from mice were 
digested and stained for flow cytometry or stained for histology and LN size was 
measured using Cell Profiler. A: Weight, B: Total cells, and C: Lymph Node Area. 
AccuCheck counting beads from Invitrogen were used to get an accurate cell count. 
Data are cell number +/- SEM with A: N=10 and B: N=5 mice. One-Way ANOVA 
followed by multiple comparison Tukey’s test. C: N=16 student t-test: *P ≤ 0.05, 



























































Figure 3.4: Effect of adjuvants treatment on immune cells.  
Mice were treated with PBS, OVA/Alum, or OVA/GLA-SE for 3 weeks then 
boosted with the same solution for a further 3 days. LNs from mice were digested 
and stained for flow cytometry. A: Total cells, B: B cells (CD19+), C: T cells 
(CD3+), D: CD4 T cells (CD4+), E: CD8 T cells (CD8+), F: Macrophages 
(CD169+), G: Dendritic Cells (CD11c+MHCII+), and H: NK cells (NK1.1+). 
AccuCheck counting beads from Invitrogen were used to get an accurate cell count. 
Data are cell number +/- SEM with N=10 or 5 mice from 2 separate experiments. 
One-Way ANOVA followed by multiple comparison Tukey’s test: *P ≤ 0.05, **P ≤ 
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3.3.3.   Treatment effect on B and T cell zones 
Immunofluorescent stained tissue sections from popliteal LNs from long-term 
experiments (24 days; prime and boost) were analysed by confocal microscopy using 
antibodies specific for B cells and T cells (B220/CD3 respectively) (Figure 3.5). For the 
control PBS treated mice, the LNs were small with distinct B and T cell zones. 
Treatment with OVA/MPL-A+TDM led to an increased size but with still distinct B and 
T cell zones whereas OVA/GLA-SE led to remodelling and B cell follicles found in the 
cortex. The water-and-oil emulsion is a control for GLA-SE as it is the basis for this 
adjuvant but doesn’t contain the TLR4 agonist. Treatment with OVA/water-and-oil 
emulsion led to an enlargement of the LNs with bigger B cell follicles. Due to the effect 
of the water-and-oil emulsion on LN structure and it being the basis of GLA-SE, this 
adjuvant should have been added as an additional control. OVA/Alum and OVA/IFA 
treated mice had LNs that were bigger and had larger follicles. 
The images obtained from separate experiments were quantified by using Cell Profiler 
image analysis software. Using this approach, the images were analysed for LN area, 
follicle area and follicle number (Figure 3.6). Analysis from cell profiler correlated with 
the images obtained and with the flow results. OVA/GLA-SE leads to a 6-fold increase 
in LN area, a 1.5-fold increase in follicle area and a 3-fold increase in follicle number. 







Figure 3.5: Dynamic remodelling of the LN when treated with different 
antigen/adjuvant complexes.  
Mice were treated with PBS, OVA/Alum, or OVA/GLA-SE for 3 weeks then 
boosted with the same solution for a further 3 days. A: Frozen sections of the 
popliteal LN from PBS, OVA/MPL-A+TDM, and OVA/GLA-SE and B: Frozen 
sections of the popliteal LN from PBS, OVA/Water-and-oil emulsion, OVA/Alum, 
and OVA/IFA immunized mice were stained with antibodies against CD3 (T cells), 

















Figure 3.6: Quantification of histology results with Cell Profiler.  
Frozen sections of the popliteal LN from PBS, OVA/Alum, or OVA/GLA-SE 
immunized mice were stained with antibodies against CD3 and B220. Images 
obtained were then run through a Cell Profiler pipeline to get the A: Lymph node 
area, B: Follicle Area, and C: Follicle number. N=15 from 3 separate experiments. 
One-Way ANOVA followed by multiple comparison Tukey’s test: *P ≤ 0.05, **P ≤ 



























































3.3.4.   Stroma in lymph node remodelling 
Stromal cell networks support lymphocytes and DCs in LNs through producing 
chemokines, cytokines and an extracellular network on which lymphocyte can migrate 
and interact with APCs. Thus, stromal cell networks were characterised in sections 
using antibodies specific for LN reticular network (ER-TR7), FDC (FDCM2), and 
vascular networks (Lyve-1 (lymphatic vasculature) and Meca79 (HEVs)) (Figure 3.7). 
Immunizations with the TLR4 agonist adjuvants OVA/MPL-A+TDM and OVA/GLA-
SE leads to pLN enlargement. The stromal network, as shown with the CD21/CD35 and 
ER-TR7 staining, mirrors the B and T cell distribution (as shown in Figure 3.5) and 
illustrates the LN remodelling. Treatment induced an expansion into the cortex of the 
LNs by the lymphatic vessels and an increase in the blood vasculature.  
To quantify non-haematopoietic cells, LNs were processed using a reproducible low 
mortality enzymatic digestion protocol [188] (Figure 3.8). This method permits the 
analysis of the different major subsets of LN stroma by using the markers CD45, 
podoplanin (gp38) and CD31. Additionally, MRCs were identified and isolated by 
using MAdCAM-1 as a marker, and the FDC population using the CD21/35 marker. 
Treatment with OVA/GLA-SE leads to a significant increase in non-haematopoietic 
cells, FRCs, MRCs, LECs and BECS compared to both PBS and OVA/Alum treated 
LNs (Figure 3.9). This is consistent with the process of LN hypertrophy driving 





Figure 3.7: Architecture of the reticular network in mouse LN, and the 
dynamic remodelling when treated with antigen/adjuvant.  
Mice were treated with PBS, OVA/Alum, or OVA/GLA-SE for 3 weeks then boosted 
with the same solution for a further 3 days. Immunizations with OVA in combination 
with different adjuvants induce dynamic change of the LN. Frozen sections of the 
popliteal LN from PBS, OVA/MPL-A+TDM, or OVA/GLA-SE immunized mice were 
stained with antibodies against CD3 (T cells), B220 (B cells), CD21/35 (FDCs), ERTR7 
(Reticular network), Lyve-1 (Lymphatic vessels) and Meca-79 (HEVs). N=5 mice, 2 


















Figure 3.8: Flow cytometry profiles of lymph node stromal subsets freshly 
isolated from lymph nodes of individual mice.  
LNs from B6CD45.1 mice were digested and once a single cell population was 
obtained, stained for gp38, CD45 and CD31. It is then possible to separate the 
different subsets, FRCs, LECs, BECs and the double negative population (platelets 






















Figure 3.9: Effect of adjuvants on stromal cell and endothelial populations.  
Mice were immunized with PBS, OVA/MPL-A+TDM or OVA/GLA-SE and the 
pLNs were removed and analysed by flow cytometry. Cells were stained with CD45, 
gp38 and CD31, which is a way to distinguish between the different stromal cell 
populations. A: Non-haematopoietic cells (CD45-), B: FRCs (CD45-gp38+CD31-), 
C: MRCs (CD45-gp38+MAdCAM-1+), D: LECs (CD45-gp38+CD31+), and E: 
BECs (CD45-gp38-CD31+). AccuCheck counting beads from Invitrogen were used 
to get an accurate cell count. Data are cell number +/- SEM with N=10 from 2 
separate experiments. One-Way ANOVA followed by multiple comparison Tukey’s 


































































































3.4.  Rapid lymph node hypertrophy 
3.4.1.   Quantifying immune cell populations 
To further understand the mechanisms behind LN enlargement and the differences 
between adjuvants, a time course experiment of the first three days post stimulation 
comparing OVA/Alum and OVA/GLA-SE was done. Immune cell types were then 
analysed by flow cytometry (Figure 3.10). Lymph nodes rapidly undergo LN 
hypertrophy with significant changes to cellularity occurring in the first 24hrs post 
stimulation, this process is rapidly accelerated over the following 48hrs with increased 
numbers of T and B cells. Treatment with OVA/Alum led to no change in T cells but an 
increase in B cells at 48hrs that resorbs by 72hrs. This correlates with the fact that 
OVA/Alum stimulates antibody production. OVA/GLA-SE treatment led to an increase 
in T cells from 12hrs and of B cells from 48hrs. The change in innate immune cell 
numbers is variable when treated with OVA/GLA-SE, but very little increase is 
observed with OVA/Alum. OVA/GLA-SE treatment induces an increase in monocytes 
from 48hrs, of neutrophils and DCs from 12hrs. OVA/GLA-SE is much more potent in 
inducing immune cell increase and expansion of LNs than OVA/Alum. Although the 
mechanism of this process is unclear, this indicates that TLR4 ligands have the capacity 
to rapidly modulate the kinetics of key innate and adaptive cell entry into tissue draining 
LNs. 
3.4.2.   Early remodelling of B cell follicles 
To analyse the remodelling of LNs, the time course experiment comparing OVA/Alum 
and OVA/GLA-SE was analysed by immunohistochemistry for B and T cells (Figure 
3.11) and quantified in Cell Profiler (Figure 3.12) to understand the remodelling process 
dynamics. OVA/Alum induces an increase in LN size with no remodelling and an 
increase in distinct B cell follicle size. Quantification by Cell Profiler showed that 
OVA/GLA-SE administration leads to increased LN size, more follicles and a larger 
follicle area by 72hrs compared to OVA/Alum treatment. There is no difference in the 
increase in T cell zone area upon either treatment. By day seven, the process of nascent 
follicle formation was complete, with multiple small follicular structures. Over the first 
72hrs post OVA/GLA-SE stimulation, there was a rapid loss of B cell follicular 






Figure 3.10: Time course of OVA/GLA-SE vs. OVA/Alum and the effect on 
immune cell types.  
Mice were immunized with OVA/Alum or OVA/GLA-SE and the popliteal LNs 
were removed, stained and analysed by flow cytometry. A: Total cells, B: T cells 
(CD3+), C: B cells (CD19+), D: Monocytes (CD11b+Ly6G-Ly6Chigh), E: 
Neutrophils (CD11b+Ly6G+Ly6Cint), F: Macrophages (CD169+), and G: Dendritic 
cells (CD11c+MHCII+). AccuCheck counting beads from Invitrogen were used to 
get an accurate cell count. N=5 per time point. Data are cell number +/- SEM. Two-
Way ANOVA followed by multiple comparison Tukey’s test: *P ≤ 0.05, **P ≤ 0.01, 
*** P≤0.001, ****P ≤ 0.0001. OVA/Alum compared to OVA/GLA-SE at each time 
point. 






















































































































Figure 3.11: LN architecture at different time points.  
Frozen sections of the popliteal LN from PBS, OVA/Alum and OVA/GLA-SE 
immunized mice at different time points were stained with antibodies against CD3 (T 
cells), and B220 (B cells). N=5 mice, 2 slides/LN, representative image was chosen. 
















Figure 3.12: Quantification of histology results with Cell Profiler.  
Immunizations with OVA in combination with different adjuvants induce dynamic 
change of the LN. Frozen sections of the popliteal LN from PBS, OVA/Alum or 
OVA/GLA-SE immunized mice were stained with antibodies against CD3 and B220. 
Images obtained were then run through a Cell Profiler pipeline to get the A: Lymph 
node area, B: T cell zone area, C: Follicle number, and D: Follicle area. N=5. Two-
Way ANOVA followed by multiple comparison Tukey’s test: *P ≤ 0.05, **P ≤ 0.01, 



































































3.4.3.   Effect of treatment on stromal architecture 
FDCs produce the chemoattractant CXCL13 that has a key role in B cell recruitment 
and retention in LNs. The remodelling process might involve a loss of FDCs. To 
quantify FDC networks, LNs were stained with FDCM2 in mice administered with 
OVA/GLA-SE and OVA/Alum along with the reticular and vascular networks (Figure 
3.13 and Figure 3.14). The stromal architecture mirrors that of the B and T cell zones 
(Figure 3.11). In the GLA-SE injected mice during the first 48hrs condensed FDC 
networks dissolve, even though there was no loss of FDCM2 staining, rather by 72hrs a 
scattered population of stromal cells form a ring like structure around the LN. This 
process was not observed in the OVA/Alum injected mice. Although remodelling of 
vascular networks was observed demonstrating initiation of lymphangiogenesis 72hrs 
post stimulation, there is no evidence for a relationship between the vascular 
remodelling and B follicle remodelling. 
3.4.4.   Quantifying stromal cell populations 
Stromal cells were quantified by flow cytometry (Figure 3.15). Stromal cells increase 
very little when the mice were treated with OVA/Alum; however, from 48hrs, non-








Figure 3.13: Stromal network architecture in mouse LN when treated with 
OVA/Alum.  
Frozen sections of the popliteal LN from PBS, and OVA/Alum immunized mice at 
different time points were stained with antibodies against ERTR7 (Reticular 
network), FDCM2 (FDCs), Lyve-1 (Lymphatic vessels) and Meca-79 (HEVs). N=5 























Figure 3.14: Stromal network architecture in mouse LN when treated with 
OVA/GLA-SE.  
Frozen sections of the popliteal LN from PBS, and OVA/GLA-SE immunized mice 
at different time points were stained with antibodies against ERTR7 (Reticular 
network), FDCM2 (FDCs), Lyve-1 (Lymphatic vessels) and Meca-79 (HEVs). N=5 








Figure 3.15: Time course of OVA/GLA-SE vs. OVA/Alum and the effect on 
stromal cell types.  
Mice were immunized with OVA/Alum or OVA/GLA-SE and the popliteal LNs 
were removed, stained and analysed by flow cytometry. A: Non-haematopoietic cells 
(CD45-), B: FRCs (CD45-CD31-gp38+), C: LECs (CD45-CD31+gp38+), and D: 
BECs (CD45-CD31+gp38-). AccuCheck counting beads from Invitrogen were used 
to get an accurate cell count. N=5 per time point. Data are cell number +/- SEM. 
Two-Way ANOVA followed by multiple comparison Tukey’s test: *P ≤ 0.05, **P ≤ 
0.01, *** P≤0.001, ****P ≤ 0.0001. OVA/Alum compared to OVA/GLA-SE at each 
time point. 
  































































3.5.  Role of lymphocytes in LN expansion 
LN stroma provides signals that promote the survival, migration and organisation of 
LNs. To determine if lymphocytes are required to drive the stromal remodelling 
process, Rag-/- mice were primed with antigen/adjuvants for 48hrs. LNs were stained 
with ER-TR7, Lyve-1 and Meca-79 for the reticular network, the lymphatic vessels and 
the HEVs respectively (Figure 3.16). The LNs were larger with increased numbers of 
HEVs and migration of lymphatic vessels into the cortex. In addition, stromal 
populations were analysed by flow cytometry. Treatment led to an increase in total 
cellularity, LECs and BECs. There is no change upon treatment to FRCs. This indicates 
a requirement for lymphocytes in FRC proliferation. These results are consistent with 
previous findings [89] where, they observed that FRCs numbers closely followed the 
number of lymphocytes during LN expansion and that the initiation of LN swelling is 
lymphocyte independent.  
3.6.  Role of CD11c expressing cells in LN expansion 
DCs have an essential role in antigen presentation, adjuvants have been shown to induce 
DC activation and migration to draining LNs. Migratory DCs are also thought to initiate 
the hypertrophy process by trafficking antigen and inflammatory signals to LNs. CD11c 
is expressed at high levels by DCs and at lower levels by subcapsular macrophages. To 
analyse the effect of these CD11c expressing cells in the remodelling process, 24hrs 
post DTR injection, CD11c-iDTR mice were treated with OVA/GLA-SE for 48hrs 
(Figure 3.17). The DTR injection led to a significant reduction in DC numbers (Figure 
3.17A). It has previously been shown that macrophages are also depleted in these mice 
[198]. Treatment with OVA/GLA-SE led to a non-significant increase in total 
cellularity, non-haematopoietic cells, FRCs and LECs but no change was observed in 
the other cell types. A significant increase in BEC numbers was observed. 
To distinguish between DCs and macrophages, as both are depleted with DTR, bone 
marrow chimeras were established, as macrophages are radioresistant. This would have 
enabled the depletion of DCs but not macrophages. However, this experiment didn’t 
work as the DCs were still present in high numbers and no difference was observed 






Figure 3.16: Architecture of the reticular network in Rag-/- mouse LNs, and 
the dynamic remodelling when treated with antigen/adjuvant.  
Rag-/- mice were treated with OVA/MPL-A+TDM or OVA/GLA-SE for 48hrs. A: 
Frozen sections of the popliteal LN from PBS, OVA/MPL-A+TDM, or OVA/GLA-
SE immunized mice were stained with antibodies against ER-TR7 (reticular 
network), Lyve-1 (lymphatic vessels) and Meca-79 (HEVs). Scale bar = 200µm. B: 
Total cells, C: Non-haematopoietic cells, D: FRCs, E: BECs, and F: LECs. 
AccuCheck counting beads from Invitrogen were used to get an accurate cell count. 
Data are cell number +/- SEM with N=5 mice. One-Way ANOVA followed by 










































































































Figure 3.17: CD11c expressing cell effect on remodelling when treated with 
antigen/adjuvant.  
24hrs post DTR injection, mice were treated with OVA/GLA-SE for 48hrs. A: 
Dendritic cells in WT vs. CD11c-DTR mice, B: Total cells, C: B cells (CD19+), D: 
T cells (CD3+), E: Monocytes (CD11b+Ly6G-Ly6Chigh), F: Neutrophils 
(CD11b+Ly6G+Ly6Cint), G: Non-haematopoietic cells (CD45-), H: FRCs (CD45-
CD31-gp38+), and I: LECs (CD45-CD31+gp38+), and J: BECs (CD45-
CD31+gp38-). AccuCheck counting beads from Invitrogen were used to get an 
accurate cell count. Data are cell number +/- SEM with N=5 mice. One or Two-Way 
ANOVA followed by multiple comparison Tukey’s test: *P ≤ 0.05, **P ≤ 0.01, *** 
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3.7.   Summary of findings 
•   To investigate LN remodelling, an effective and reproducible model was 
established. 
•   Treatment with TLR4 agonist adjuvants proved to be effective in initiating LN 
remodelling and hypertrophy compared to Alum and other adjuvants. 
•   Treatment with GLA-SE leads to rapid increase in immune and stromal cells 
leading to rapid enlargement of LNs.  
•   Lymphocytes were shown to not be indispensable for the initiation of 
hypertrophy in LNs but are necessary for the expansion of FRCs. 
•   Mice depleted of CD11c expressing cells showed a diminished response to 
adjuvants. 
3.8.  Discussion 
3.8.1.   TLR4 adjuvants drive LN hypertrophy and remodelling 
The mechanisms driving tissue remodelling in secondary lymphoid tissues upon 
initiation of immune responses are unknown. Understanding the timing and molecular 
mechanisms leading to stromal cell reorganization will help generate therapeutics and 
vaccination strategies that can control and regulate immune responses. Although 
adjuvants have been used to boost immune responses for nearly 100 years, the 
mechanisms of action are still not well understood. More recently adjuvants containing 
PAMPs have been developed based on their potency in stimulating immune responses. 
After testing several different adjuvants, TLR4 agonist adjuvants were found to be the 
most effective in inducing LN remodelling with new follicular structures in the 
paracortex. TLR4 agonists were also found to be the most efficient in inducing rapid 
hypertrophy of the LN with a rapid increase in cells, both stromal and immune. The 
results obtained showed that immunization with TLR4 agonist adjuvants leads to rapid 
LN remodelling. Immunizations induce rapid hypertrophy and B cell follicle 
remodelling. The new follicle formation and changes in B and T cell zones mirrored the 
stromal networks. New vascular networks with lymphangiogenesis and HEV growth 
were observed enabling to accommodate the rapid influx and increase of cells in the 
LN. Different adjuvants were compared and TLR4 agonists appeared to drive drastic 
changes in LN architecture compared to all others investigated. It is also interesting to 
note that Alum which has been used in vaccines commonly since 1926 doesn’t lead to 
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LN remodelling or new follicular structures forming but to bigger B cell follicles. The 
difference in potency of these two adjuvants needs to be investigated. Previous studies 
using different models lead to LN hypertrophy and varying degrees of remodelling [11, 
68, 82, 98].  
3.8.2.   Immunization leads to changes to LN structure and cell numbers 
One mechanism by which adjuvants may accelerate and potentiate immune responses is 
through increasing immune cell recruitment to tissue draining LNs. This increase in the 
influx of cells into the LN is key in the initiation of the immune response, as it brings all 
cell types in close contact. Upon treatment with different TLR4 containing adjuvants it 
was possible to show a dramatic increase both in size and cellularity of the draining LN. 
Surprisingly, this involved not just an increase in lymphocyte and dendritic cells but 
also large-scale expansion in stromal cell populations, indicating that adjuvants either, 
directly through TLR expression on stromal cells, or indirectly through immune cells, 
drive this expansion process. Histological and FACS analysis of LN architecture and 
cells indicated that TLR4 stimulation leads to changes in LN structure with B cell 
follicles forming in the paracortex and an increase in all cell types. This increase in cells 
is required for an efficient immune response. Stromal cells increase in numbers to adapt 
to the large numbers of immune cells in the LN that are entering the LN and 
proliferating. Changes in LN architecture differ according to the adjuvant just as it 
would depending on the pathogen. These changes in LN architecture leads to cells being 
released from their compartments and new interactions can be formed which are critical 
for an efficient immune response. This efficient immune response is even more 
important when it comes to vaccination as an adjuvant that can drive new architecture 
efficiently could be driving a different set of immune memory than Alum. This is 
important to address as Alum has limitations such as the fact that it drives a very 
polarized TH2 response.  
3.8.3.   TLR4 adjuvants drive a dissolution of B cell follicles 
Upon treatment with TLR4 adjuvants, an increase in the number of B cell follicles was 
observed with the remodelling process leading to new follicular structures appearing in 
the paracortex. This could reflect the plethora of different cell types in a LN that TLR4 
agonists can directly stimulate. During a time course experiment, a LN expansion stage 
was observed followed by, at 72hrs post immunization, a ring-like structure forming 
with a loss of B cell follicles. Following this ring forming around the LN, by seven days 
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post-treatment, new follicular structures had formed in the paracortex of the LN 
mirroring the structure observed after a long-term treatment. The mechanisms behind 
the formation of new B cell follicles following immunization are still unknown. The 
first step of this process is the dissolution of the B cell follicle structure. A possible 
explanation is that the signals that form the B cell follicles are lost leading to this 
disintegration. FDC differentiation and maturation into cells producing CXCL13 
requires LTβR and TNFα from B cells. This dissolution could be linked to a change in 
any of these signals. Either FDCs differentially express CXCL13 leading to B cells 
being released from the B cell follicles or B cells lose expression of TNFα leading to 
loss of B cell follicles.  
3.8.4.   Initiation of LN expansion 
Treatment with OVA/GLA-SE and OVA/MPL-A+TDM of Rag deficient mice, lacking 
T and B lymphocytes, led to an increase in both the blood and lymphatic endothelial 
cell networks but not of the FRC network that supports lymphocyte homeostasis and 
migration. These results are similar to findings [89] where FRCs numbers closely 
follow lymphocyte numbers during LN swelling. Expansion of FRCs is dependent on 
the increase in lymphocytes entering the LN during an immune response. However, 
lymphocytes are not necessary for the increase in new lymphatic and vasculature 
networks. DCs are required for this rapid expansion of the vasculature network. This 
indicates that during an immune response after immunization the first step in LN 
hypertrophy is dependent on APCs, namely DCs. These innate cells are critical in the 
first steps of LN expansion. By interacting with stromal cells, DCs stimulate the growth 
and proliferation of BECs that compose HEVs [68, 82]. Lymphocytes can then be 
recruited into the LN at a higher frequency through the new lymphatic vessels and 
HEVs. This correlates with our results, where in the absence of lymphocytes in Rag-/- 
mice there is increased blood and lymphatic vasculature but no change in the reticular 
network. Therefore, the LN microenvironment and architecture is shaped by the cells it 
supports. It has previously been speculated that this process is an IL-7/IL-7-receptor 
dependent process [199] whereby IL-7 is crucial in new LN architecture forming. It 
would be interesting to investigate the outcome of mice where IL-7 is removed during 
an antigen/adjuvant-mediated immune response. 
The results obtained with depleted DCs are similar to results from other studies. In mice 
depleted of DCs, treatment with the water-and-oil emulsion OVA/Montanide reduced 
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lymphocyte trapping and lymphocyte expansion, as well as a reduction in the number 
and proliferation of FRCs [89]. They also addressed the question of whether the transfer 
of migratory DCs was sufficient to trigger FRC expansion in DTR-treated mice. FRC 
expansion and LN swelling was observed when they transferred LPS-matured Bone 
Marrow Dendritic Cells (BMDCs). It has also been shown that migratory DCs transmit 
signals to LN resident DCs, which leads to FRC expansion [82, 194]. They also showed 
that as LN expand; BECs undergo rapid growth that is dependent on DCs and VEGF, 
which is in part produced by FRCs. A model was proposed where migratory DCs 
transmit a signal to LN-resident DCs, which then triggers vasculature changes leading 
to T cell trapping, which is critical for FRC expansion [89]. This model correlates with 
the results obtained here. This illustrates that DCs and macrophages are important in the 
initiation of the immune response, but also have a key role in regulating the stromal cell 
expansion phase. The molecular basis that drives this proliferation process leading to 
LN expansion and remodelling is unknown. It is also important to note that other cell 
types such as macrophages are depleted in CD11c DTR mice [198]. DCs are critical in 
the initiation phase of LN expansion as their absence led to no increase in any cell 
types. Lymphocytes and stromal cells are required for the expansion phase following 
initiation by DCs. These results indicate that the cellular process governing LN 
expansion involves a multitude of cell types, and it is the interactions between different 
cell types in the LN microenvironment that drive this process.  
3.8.5.   Conclusion 
TLR4 adjuvants lead to LN hypertrophy and remodelling. It is necessary to investigate 
the mechanisms behind this change in architecture. Results here indicated that Alum as 
an adjuvant does not lead to new follicle formation and to very little changes in LN 
architecture and diminished hypertrophy compared to treatment with TLR4 agonists. 
Therefore, Alum was used as a comparator to investigate how GLA-SE leads to these 
changes in LN architecture. Different mechanisms and cell types were investigated to 
elucidate the phenotype observed in remodelled LNs. A microRNA, miR-132 was 




Chapter 4:   miR-132 is a regulator of the immune 
response 
4.1.   Introduction 
4.1.1.   Macrophages in LNs 
Macrophages are defined as phagocytic cells that internalize and degrade pathogens and 
then secrete factors that alert the adaptive immune cells. LN macrophages are bone 
marrow derived and their development depends on Colony Stimulating Factor-1 (CSF-
1) [200]. Resident macrophages can be found in LNs and are sub-divided into 
Subcapsular Sinus Macrophages (SSMs) and Medullary Sinus Macrophages (MSMs). 
In reactive LNs, a third population of macrophages can be found, tingible body 
macrophages that are specialized in the phagocytosis of apoptotic cells in GCs [201]. 
Just beneath the capsule, on the outer margin of LN’s cortex is an area called the 
Subcapsular Sinus. SSMs are found lining the SCS and are normally immobile and 
extend into B cell follicles through dendrite-like protrusions [52]. SSMs express CD11b 
and CD169 as well as low levels of CD11c, which is why macrophages are depleted 
from LNs in CD11c-DTR mice. They also do not express the markers SIGN-R1 and 
F4/80 [201]. These cells are capable of quickly capturing lymph-borne antigens but 
have a diminished phagocytic capacity thus they have taken on a very specialised role 
distinct from other tissue macrophage populations [51]. Upon the capture of antigen on 
their surface, SSMs transport antigen along their projections that enter the B cell 
follicles. There, cognate B cells are able to recognize the antigen through their BCR 
[202]. In the case of opsonized antigen, follicular non-cognate B cells can take up 
antigen through the complement receptors 1 and 2 and transport the complexes to FDCs 
in the light zone of GCs. This process is essential for GC formation and in driving 
development of high affinity B cells [51]. Lymphotoxin produced by B cells is essential 
for macrophage development and maintenance [203]. SSM numbers are reduced when 
B cells are absent, or in the absence of B-cell produced lymphotoxin and increased 
when lymphotoxin is overexpressed [201]. SSMs are subject to infections by various 
viruses. For example, in mice, many SSMs are infected by systemic Vesicular 
Stomatitis Virus (VSV) thereby preventing VSV spread to the periphery. Depletion of 
SSMs leads to the spread of VSV to the central nervous system. Macrophages produce 
IFN-α, which is essential in preventing the spread of VSV [204]. SSMs have also been 




In contrast, MSMs are located in the medulla that is composed of LECs and reticular 
strands. Macrophages in this area are attached to the sinus and reticular fibres in the 
lumen [207]. MSMs are characterized by their expression of CD11b, CD169, but also 
express F4/80, SIGN-R1, Macrophage Receptor with Collagenous Structure (MARCO), 
Mannose Receptor (MR) and Lyve-1 [201]. SIGN-R1 is a receptor for bacterial 
dextrans such as pneumococcal polysaccharide of Streptococcus pneumoniae. MARCO 
belongs to the scavenger receptor family and binds unopsonised bacteria. These 
receptors along with the localization in the medulla suggest that the role of medullary 
sinus macrophages is antigen clearance in the lymph, enabling the prevention of 
pathogens spreading from draining LNs and entering blood circulation. In the hours 
following subcutaneous injection of labelled antigen, label accumulation occurs in 
lymph exposed MSMs. Due to the large amount of antigen that these cells internalize 
and their large lysosomes and high vesicle numbers, these cells are described as highly 
phagocytic. Imaging studies have shown that MSMs often contain apoptotic 
polymorphonuclear cells such as eosinophils [201, 208].  
4.1.2.   Role of LN MRCs  
MRCs as novel stromal cells were first described in 2012 [61]. A layer of reticular cells 
can be found in the SCS on the outer region of B cell follicles. Phenotypically these 
cells resemble FRCs; however, they express CXCL13, RANK-L and MAdCAM-1 but 
not CCL19 and CCL21 or the FDC markers CD21/35 indicating that these cells are a 
distinct population and most closely resemble LTo mesenchymal cells that are found in 
the developing LN anlagen [60]. MRCs support the recognition of antigen entering the 
LN through the lymph. In the outer area of follicles, MRCs mediate antigen transport to 
B cells and FDCs [48, 209]. MRCs express CXCL13, ICAM-1 and VCAM-1 promoting 
interstitial migration of follicular B cells on the scaffold they create. Thus, MRCs 
promote interaction between macrophages expressing antigen on their surface and B 
cells [51, 61, 210]. During an immune response, LNs undergo rapid remodelling 
through changes in stromal cells. Fate-mapping studies have shown that MRCs serve as 
a potential precursor that can give rise to FDCs, providing a pool of cells that can 




4.1.3.   MicroRNAs effect on the immune response in LNs 
MicroRNAs are short non-coding RNA sequences. They act by binding to the 3’UTR 
region of complementary mRNAs leading to their degradation or inhibition of their 
translation. miRNAs have been shown to be important in haematopoiesis regulation. 
The tightly regulated process of haematopoiesis and the development of all blood cell 
lineages is ensured by miRNAs. miR-223 is a microRNA that has been shown to have 
an important role in B cell differentiation through the down-regulation of LMO2. In the 
different stages of peripheral B cell maturation, the miRNAs expression patterns 
changes drastically to regulate the diverse differentiation stages [211]. GC B cells 
require specific gene expression that is regulated by different miRNAs [212, 213]. 
MicroRNAs have also been shown to play a key role in T cell differentiation [214]. 
MicroRNAs are also known to be involved in different diseases. miR-15 and miR-16 
are deleted or down-regulated in patients with Chronic Lymphocytic Leukemia [215]. 
Certain microRNAs that are necessary for lymphocyte differentiation can also be 
deregulated leading to pathologies. The cluster miR-17-92 is involved in B cell 
maturation during a GC reaction but has also been shown to have a role in B cell 
lymphomas [211, 216]. As B cells are the key producers of antibodies and play an 
indispensable role in adaptive immunity it is critical that their regulation be tightly 
controlled. The balance between normal immune function and pathologies is regulated 
from B cell differentiation to the production of specific antibodies. It has been shown 
that loss of the Dicer microRNA processing protein results in a block of the transition 
between pro-B and pre-B cells as well as antibody diversity and B cell survival [217]. 
The transition between pro-B cell and pre-B cell is regulated by miR-150 and miR-34a 
that target c-Myb and Foxp1 respectively [218, 219]. miR-181 and miR-155 regulate 
class switching and somatic hypermutation by regulating Activation-Induced Cytidine 
Deaminase (AICDA) [220, 221]. 
4.1.4.   miR-132 in regulating the immune response  
The miR-132/212 cluster has been shown to be a key regulator of the immune response. 
This cluster regulates haematopoietic cell differentiation and function [222], the 
antiviral immune response [184], wound healing inflammation and proliferation [223], 
and immune cell function [180, 224, 225]. The miR-132/miR-212 cluster regulates 
haematopoietic stem cell cycling and survival through autophagy. It has been shown 
that over-expression and deletion of miR-132 can both lead to defects in haematopoiesis 
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[222]. Recent studies have shown that miR-132 has a role in pathological angiogenesis 
[226] as well as in the proliferation and invasion of tumours [227, 228]. miR-132 is 
deregulated in certain types of B cell cancers such as Chronic Lymphocytic Leukemia 
[229, 230]. miR-132 also plays a role in B cell development through the targeting of 
SOX4 and induces apoptosis in B cells [231]. SOX4 is known to have a key role in cell 
fate and has also been shown to be up-regulated in different human cancers including 
breast cancer and prostate cancer [232-234]. Down-regulation of miR-132 in breast 
cancer inhibits proliferation, invasion and metastasis through targeting HN1 [228]. By 
inhibiting its target Sox4, miR-132 inhibits invasion of lung cancer cells [235]. 
TLRs are key in recognizing pathogenic invaders such as LPS or peptidoglycan. Upon 
receptor triggering, signalling leads to cytokine and chemokine production through 
activation of the NFκ-B pathway leading to the triggering of the immune response to 
clear the infection. TLR signalling pathways have to be tightly regulated to control the 
onset and termination of the immune response in order to avoid over-inflammation 
leading to pathologies or damage. MicroRNAs have emerged as regulators of TLR 
signalling. miR-146a has been shown to have a key role in endotoxin tolerance through 
the regulation of the adaptor molecules IRAK1 and TRAF6, though this doesn’t 
completely extinguish cytokine production [236, 237]. Molecules of the pathway 
directly targeted by the miR-132/miR-212 cluster have yet to be elucidated. By 
targeting AChE, miR-132 limits inflammation in mouse brains [180]. miR-132 targets 
p300, which modulates the immune response induced by infection with Kaposi’s 
sarcoma-associated herpesvirus [184]. Stimulation of cells with TLR2 agonists leads to 
an increase in the expression of miR-132/miR-212, which have been shown to be 
critical in the modulation of TLR2-induced tolerance [224]. 
4.1.5.   Summary 
Macrophages and MRCs line the SCS and present the first line of defence as they scan 
lymph-borne antigen and present it to B cells and FDCs. Their role in the remodelling 
process of LNs during an immune response is still poorly understood. The miR-
132/miR-212 cluster has been linked to various aspects of inflammation and is known 
to regulate TLR4 signalling. TLR4 is expressed on various cell types in the LN. Thus, 
we hypothesised that miR-132 is important in the regulation of LN remodelling during a 




4.1.6.   Aims 
•   Investigate the role of TLR4 on stromal cells. 
•   Determine the effect of TLR4 stimulation of different cell types. 
•   Investigate the role of miR-132 in LN remodelling and architecture and the 
kinetics behind this. 
•   Investigate the potential mechanisms leading to the difference in remodelling. 
•   Determine what happens after a long-term treatment of 6 months. 
•   Investigate the stromal and haematopoietic contributions to LN remodelling. 
4.2.   Stroma responds to TLR stimulation 
4.2.1.   Expression of TLRs by stromal cells 
The Immunological Genome Project (Immgen) developed a gene expression microarray 
database for cells of the mouse’s immune system [69]. Preliminary analysis from the 
Data Browser indicates that some TLRs are expressed by FRCs, BECs, and LECs 
(TLR2 and TLR4), as well as key components of the TLR signalling pathways such as 
MyD88 (Figure 4.1).  
4.2.2.   Enzymatic isolation of mouse LN stromal cells 
LN stromal cells were isolated as previously described by Fletcher et al. using a 
reproducible low mortality enzymatic digestion protocol [188]. It is then possible to 
distinguish the different major subsets of LN stroma by using the markers CD45, 
podoplanin (gp38) and CD31. Additionally, MRCs can be identified and isolated by 
using MAdCAM-1 as a marker, and the FDC population using the CD21/35 marker. 
After digestion, it is possible to plate the cells and culture them and after three passages 
a pure population of FRCs that express podoplanin is obtained (Figure 4.2).  
4.2.3.   TLR4 expression in FRCs 
To validate that TLR4 expression can be found at least on an mRNA level, gene 
expression was analysed by RT-qPCR after treatment of FRCs with LPS at different 
time points (Figure 4.3). An increase in TLR4 was observed upon treatment and though 
its expression stays up-regulated at all time points, there is a slow decrease in 
expression. This indicates that these molecules are expressed and the presence of the 





Figure 4.1: Expression of Toll Like Receptors by stromal cells.  










Figure 4.2: Flow cytometry profiles of lymph node stromal subsets freshly 
isolated from lymph nodes of individual mice after culturing.  
LNs from B6CD45.1 mice were digested and once a single cell population was 
obtained, cultured in vitro and then stained for gp38, CD45 and CD31. It is then 
possible to separate the different subsets, FRCs, LECs, BECs and the double 
negative population (platelets and FDCs) by flow cytometry. Here only a pure 

















Figure 4.3: LPS treatment effect on TLR4 expression in FRCs.  
TLR4 mRNA expression was analysed from isolated FRCs treated for 1.5, 4, 8, 24, 
48 or 72 hours with 1µg/ml of LPS. Cells were lysed, total RNA was isolated, retro-
transcribed into cDNA and analysed by RT-qPCR. Expression values were then 
normalized to the HPRT internal standard values. Data is shown as relative values. 
































































4.2.4.   FRCs respond to a wide range of TLR agonists 
FRCs were isolated from WT mice and cultured, then treated for 5hrs with a panel of 
TLR agonists from Invivogen. PAM3CK4 is a synthetic lipopeptide that mimics 
bacterial lipoprotein; its recognition is mediated by TLR2 that cooperates with TLR1 to 
activate the NF-κB pathway. HKLM is a TLR2 agonist and is a heat-killed preparation 
of an intracellular Gram-positive bacterium. Poly(I:C) is a synthetic analogue of dsRNA 
and therefore is a TLR3 agonist. LPS-EK from E.coli is a TLR4 agonist. ST-FLA is 
flagellin from S.typhimurium and is a TLR5 agonist. FSL-1 is a synthetic lipoprotein 
that is recognized by TLR6 and TLR2. ssRNA40 is a protected single-stranded RNA 
oligonucleotide that is recognized by TLR8 in humans and TLR7 in mice. ODN1826 is 
a synthetic oligonucleotide containing unmethylated CpG dinucleotides that induce 
strong immunostimulatory effects through TLR9.  
Response to FRC stimulation was determined by RT-qPCR by measuring the gene 
expression of pro-inflammatory cytokines TNFα, IL-1β and IL-6. TLR1, TLR2, TLR4, 
TLR6 and TLR9 stimulation led to an increased expression of these cytokines by FRCs 
(Figure 4.4).  
4.2.5.   TLR mediated gene expression in FRCs 
LNs from WT, TLR4-/- and Myd88-/- were digested and grown as a monolayer. FRCs 
were treated with PBS, OVA/MPL-A+TDM or OVA/GLA-SE for 5hrs, the cells were 
lysed and TNFα, IL-1β and IL-6 mRNA expression levels were analysed by RT-qPCR 
(Figure 4.5). WT FRCs are able to generate a strong response to stimuli, by expressing 
abundant TNFα, IL-1β and IL-6, that is significant when treated with OVA/MPL-
A+TDM. Although GLA-SE is very potent in vivo, it doesn’t have the same efficacy in 
vitro. FRCs that are deficient for either TLR4 or MyD88 were unable to generate a 
response and no up-regulation was observed, thus inflammatory cytokine production by 
FRCs in response to adjuvants is TLR mediated. 
These results demonstrate that stromal cells can respond directly to TLR4 ligands in 







Figure 4.4: Effect of different TLR agonists on cultured FRCs’ gene 
expression.  
LNs from the mice were digested and plated. Isolated FRCs were treated with a 
panel of TLR agonists for 5hrs, cells were lysed, total RNA was isolated, 
retrotranscribed into cDNA and analysed by RT-qPCR. A: IL-6, B: IL-1β, and C: 
TNFα. Expression values were then normalized to the HPRT internal standard 
values. Data is shown as relative values. From 3 separate experiments. One-Way 
ANOVA followed by multiple comparison Dunnett’s test (compared to control): *P 






































































































































































Figure 4.5: FRC response is TLR mediated. 
LNs from WT, TLR4-/- and Myd88-/- mice were digested and plated. The cells were 
treated with TLR4 agonists, OVA/MPL-A+TDM and OVA/GLA-SE for 5 hours, 
cells were lysed, total RNA was isolated, retrotranscribed into cDNA and analysed 
by RT-qPCR. A: IL-6, B: IL-1β, and C: TNFα. Expression values were then 
normalized to the HPRT internal standard values. Data is shown as relative values. 
From 3 separate experiments. Two-Way ANOVA followed by multiple comparison 

























































































































































4.3.  TLR4 signalling regulates cytokines and miR-132 expression 
4.3.1.   Gene expression in FRCs 
Mice were treated for 12hrs with either OVA/MPL-A or OVA/GLA-SE after which 
FRCs were sorted to analyse expression changes at early time points. IL-1β, TNFα and 
miR-132 expression was analysed by RT-qPCR (Figure 4.6). Treatment with both 
OVA/MPL-A+TDM and OVA/GLA-SE leads to an expansion of FRCs, therefore this 
cell type was analysed. An increase in all of the genes analysed was observed in FRCs. 
The increase in miR-132 mirrored the increase in the different inflammatory factors. 
This led to an interest in miR-132 as a regulator of FRCs and of the enlargement and 
remodelling process LNs go through. Further analysis was done from total LNs after 24 
days of treatment and there is a significant 2.5-fold increase upon immunization. 
miR-132 became the focus of this project, as it is known to be expressed in immune and 
stromal cells alike and to be involved in inflammation. 
4.3.2.   LPS treatment of isolated B cells 
To study the changes in gene expression, B cells were isolated from WT and miR-132-/- 
mice and treated with LPS, for 3hrs, 6hrs and 24hrs. miR-132 is up-regulated in WT 
mice from 3hrs. There is no difference between WT and miR-132-/- B cells concerning 
the three genes analysed, IL-1β, IL-6 and TNFα (Figure 4.7). 
4.3.3.   Decreased response in miR-132-/- FRCs to TLR stimulation 
Cultured FRCs from WT and miR-132-/- mice were treated with TLR4 agonist 
adjuvants. A small decrease was observed in the production by miR-132-/- FRCs of 






Figure 4.6: Effect of TLR4-agonist adjuvants on isolated FRCs gene 
expression or on total LN.  
A-C: Mice were immunized with PBS, OVA/MPL-A+TDM or OVA/GLA-SE for 
12hrs and the popliteal LNs were removed and FRCs were sorted by MOFLO. A: 
TNFα, B: IL1-β, and C: miR-132 mRNA and miRNA expression were analysed 
from FRCs.  
D: Mice were immunized for 24 days and then total LN was digested. Cells were 
lysed, miR-132 was isolated, retro-transcribed into cDNA and analysed by RT-
qPCR. Expression values were then normalized to the HPRT or RNU6 internal 
standard values. Data is shown as relative values. Two-Way ANOVA followed by 











































































































Figure 4.7: Role of miR-132 in B cells response to adjuvants. 
B cells were isolated from mice using the MACS separation columns. The cells were 
treated with LPS for 3hrs, 6hrs and 24hrs. Cells were then lysed, total RNA was 
isolated, retro-transcribed into cDNA and expression was analysed by RT-qPCR. A: 
miR-132, B: TNFα, C: IL-1β, and D: IL-6. Expression values were then normalized 
to the HPRT internal standard values. Data from 2 separate experiments with 2 









































































































































Figure 4.8: Effect of TLR4-agonist adjuvants on WT or miR-132-/- cultured 
FRCs gene expression.  
LNs from the mice were digested and plated. The cells were treated with OVA/MPL-
A+TDM and OVA/GLA-SE for 5hrs, cells were lysed, total RNA was isolated, 
retro-transcribed into cDNA and analysed by qPCR. A: TNFα, and B: IL1β. 
Expression values were then normalized to the HPRT internal standard values. Data 
is shown as relative values. From 3 separate experiments. Two-Way ANOVA 
followed by multiple comparison Tukey’s test: *P ≤ 0.05, **P ≤ 0.01, *** P≤0.001, 





































































4.4.  Loss of miR-132 modulates LN structure 
To better understand the role of miR-132, untreated miR-132-/- mice were analysed and 
compared to WT mice (Figure 4.9). Frozen sections of pLNs were stained with B220 
and CD3 to stain for B cells and T cells respectively. From these histology results, it can 
be observed that the miR-132-/- pLNs are bigger and less organized than the WT pLNs. 
The B cell follicles are bigger and the separation between B and T cell zones is no 
longer distinct. The differences observed between WT and miR-132-/- LNs indicate a 
potential role for miR-132 in B cell follicle function and remodelling. 
4.5.  Adjuvant induced hypertrophy in miR-132-/- mice 
4.5.1.   Treatment induces an increase in immune cells 
Long-term experiments (prime + boost at day 21) were performed to quantify LN cell 
populations directly comparing GLA-SE with Alum. Immunizations with both 
adjuvants lead to increased total cellularity that is significantly higher in OVA/GLA-SE 
treated mice. There is a significant difference in the number of B cells in miR-132-/- 
mice. There is no difference between total T cells or CD4 T cells between WT and miR-
132-/- mice, but there are significantly less CD8 T cells in miR-132-/- mice upon 
treatment(Figure 4.10). There is no difference in the increase of DCs upon treatment in 
either WT or miR-132-/- mice. NK cells were increased upon treatment but there were 
significantly more NK cells in miR-132-/- mice upon treatment both with Alum and 
GLA-SE (Figure 4.11). 
4.5.2.   miR-132 regulates B cell follicle remodelling 
Immunization with both OVA/Alum and OVA/GLA-SE leads to an enlargement of 
pLNs in miR-132-/- and WT mice (Figure 4.12). The difference that can be observed is 
that treatment of miR-132-/- mice doesn’t induce remodelling as in WT mice. LNs got 
bigger with larger B cell follicles, which resembles more a treatment with Alum than 
with GLA-SE. Mice lacking miR-132 are not able to remodel in the same way.  
The images obtained in Figure 4.12 were quantified by using Cell Profiler image 
analysis software (www.cellprofiler.org). When treated with OVA/Alum, both miR-132-
/- and WT mice have bigger LNs but the difference between the two isn’t significant. 
However, treatment with OVA/GLA-SE leads to significantly bigger WT LNs than 
miR-132-/-. Treatment with OVA/GLA-SE in WT mice leads to an increase in the 
number of follicles that is bigger than in miR-132-/- mice, but the follicle area is 
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significantly bigger in miR-132-/- mice. Treatment induced a significant increase in 
follicle area in miR-132-/- mice but the number of follicles didn’t increase as much as 
WT mice (Figure 4.13).  
B cell subsets were quantified by flow cytometry. There is a significant increase in the 
number of follicular B cells and in activated B cells in miR-132-/- mice. 
4.5.3.   Role of miR-132 in stromal remodelling 
The stromal network mirrors the B and T cell distribution and follows the organization 
observed in Figure 4.12. Treatment induced an invasion of the LNs by lymphatic and 
blood vasculature growth in both WT and miR-132-/- mice (Figure 4.14). 
Treatment with OVA/GLA-SE led to an increase in all stromal cell types quantified 
(Figure 4.15). This increase in cellularity is significantly larger in miR-132-/- mice for 
FRCs and BECs. These results lead to the conclusion that miR-132 deficient mice are 
able to induce LN swelling mirrored by stromal cell expansion. However, miR-132 is 







Figure 4.9: Comparison of WT and miR-132-/- naïve LNs.  
LNs from 3 independent WT and 3 miR-132-/- mice were removed; a pLN from each 
mouse was used for histology. Frozen sections of the pLNs from WT and miR-132-/- 
mice were stained with antibodies against CD3 (T cells) and B220 (B cells). Scale 














Figure 4.10: Effect of adjuvants on adaptive cell populations in WT and 
miR-132-/- mice at day 24.  
Mice were immunized with PBS, OVA/Alum or OVA/GLA-SE and the popliteal 
LNs were removed and analysed via flow cytometry. A: Total cells, B: B cells 
(CD19+), C: T cells (CD3+), D: CD4 T cells (CD4+), and E: CD8 T cells (CD8+). 
AccuCheck counting beads from Invitrogen were used to get an accurate cell count. 
N=5. 3 separate experiments. Two-Way ANOVA followed by multiple comparison 








































































































































Figure 4.11: Effect of adjuvants on innate cell populations in WT and miR-
132-/- mice at day 24.  
Mice were immunized with PBS, OVA/Alum or OVA/GLA-SE and the pLNs were 
removed and analysed via flow cytometry. A: Dendritic cells (CD11c+MHCII+), 
and B: NK cells (NK1.1+). AccuCheck counting beads from Invitrogen were used to 
get an accurate cell count. N=5. 3 separate experiments. Two-Way ANOVA 
followed by multiple comparison Tukey’s test: *P ≤ 0.05, **P ≤ 0.01, *** P≤0.001, 
****P ≤ 0.0001. 
 
  

























































Figure 4.12: B and T cell zones in WT vs. miR-132-/- mouse LN. 
Frozen sections of the popliteal LN from PBS, OVA/Alum or OVA/GLA-SE 
immunized WT or miR-132-/- mice were stained with antibodies against CD3 (T 
cells), and B220 (B cells). N=20 mice, 5 separate experiments, 2 slides/LN, 













Figure 4.13: Quantification of histology results with Cell Profiler.  
A-C: Frozen sections of the pLN from PBS, OVA/Alum or OVA/GLA-SE 
immunized mice were stained with antibodies against CD3 (T cells) and B220 (B 
cells). Images obtained were then run through a Cell Profiler pipeline to get the A: 
Lymph node area, B: Number of follicles, and C: Follicle area.  
D-E: Mice were immunized with PBS, OVA/Alum or OVA/GLA-SE and the 
popliteal LNs were removed and analysed by flow cytometry. D: Follicular B cells 
(CD19+IgD+CD95-), and E: Activated B cells (CD19+IgD-CD95+GL7+).  
Data from multiple experiments. N=8, N=15 or N=5. Two-Way ANOVA followed 













































































































































Figure 4.14: Architecture of the stromal network in WT vs. miR-132-/- 
mouse LNs.  
Frozen sections of the popliteal LN from PBS, OVA/Alum or OVA/GLA-SE 
immunized WT or miR-132-/- mice were stained with antibodies against CD21/CD35 
(FDCs), ER-TR7 (reticular network), Lyve-1 (lymphatic vessels) and Meca-79 
(HEVs). N=20 mice, 5 separate experiments, 2 slides/LN, representative image was 

























Figure 4.15: Effect of adjuvants on stromal cell populations in WT and miR-
132-/- mice at day 24.  
Mice were immunized with PBS, OVA/Alum or OVA/GLA-SE and the popliteal 
LNs were removed and analysed by flow cytometry. A: Non-haematopoietic cells 
(CD45-), B: FRCs (CD45-CD31-GP38+), C: LECs (CD45-CD31+GP38+), and D: 
BECs (CD45-CD31+GP38-). AccuCheck counting beads from Invitrogen were used 
to get an accurate cell count. N=5. 3 separate experiments. Two-Way ANOVA 
followed by multiple comparison Tukey’s test: *P ≤ 0.05, **P ≤ 0.01, *** P≤0.001, 
****P ≤ 0.0001. 
 
  





































































































4.6.  Remodelling kinetics in miR-132-/- mice 
4.6.1.   Dissolution of LN architecture 
Short immunizations of three or seven days with OVA/GLA-SE were administered to 
WT or miR-132-/- mice. Cell types were analysed by flow cytometry (Figure 4.16). 
Treatment with OVA/GLA-SE led to a significant increase in total cellularity in miR-
132-/- mice. Immunization led to the same increase in T cells and in TFR cells. However, 
there were significantly more B cells and TFH cells in miR-132-/- mice by seven days 
post immunization.  
Analysis of WT mice showed that key steps in the remodelling process occurred during 
the first 72hrs. To further understand the mechanisms behind follicular remodelling, 
early time points of the immune response to OVA/GLA-SE were analysed using 
immunohistochemistry (Figure 4.17). By seven days of response to the adjuvant, WT 
LNs are remodelled and there are B cell follicles found in the paracortex, whereas miR-
132-/- mice still possess distinct B cell follicles found only in the cortex. This phenotype 
resembles that observed after a long-term treatment. 
The images obtained were analysed using Cell Profiler (Figure 4.18). When treated with 
OVA/GLA-SE for three and seven days, both miR-132-/- and WT mice have bigger 
LNs. At three days, treatment induced significantly larger LNs in miR-132-/- mice but by 
seven days the LNs are the same size between WT and miR-132-/- mice. Treatment with 
OVA/GLA-SE at seven days in WT mice leads to an increase in the number of follicles 
that is bigger than in miR-132-/- mice, but the follicle area is significantly bigger in miR-
132-/- mice at three days. 
4.6.2.   Normal stromal networks in miR-132-/- mice 
Based on the failure of B cell follicle remodelling in miR-132-/- mice the FDC network, 
lymphatic and HEV networks were compared during OVA/GLA-SE mediated 
remodelling. In WT mice GLA-SE induces rapid increase in LN size and leads to the 
dissolution of organized follicular structures resulting in the loss of organized FDC 
network (see FDCM2 staining at 72hrs). Immunohistochemistry results indicate that 
follicular structures are maintained in the miR-132 deficient mice at 72hrs (Figure 
4.19). Stromal cell types were analysed by flow cytometry (Figure 4.20). Treatment led 
to the same increase in stromal cell populations. Stromal remodelling is normal and the 






Figure 4.16: Effect of adjuvants on immune cell populations in WT and 
miR-132-/- mice at days 3 and 7.  
Mice were immunized with PBS, or OVA/GLA-SE for 3 or 7 days and the popliteal 
LNs were removed and analysed by flow cytometry. A: Total cells, B: B cells 
(CD19+), C: T cells (CD3+), D: T Follicular Regulatory Cells (CD4+PD1+CXCR5+ 
Foxp3+CD44+), and E: T Follicular Helper Cells (CD4+PD1+CXCR5+Foxp3-
CD44+). AccuCheck counting beads from Invitrogen were used to get an accurate 
cell count. N=10 or N=15 from 3 separate experiments. Two-Way ANOVA followed 
by multiple comparison Tukey’s test: *P ≤ 0.05, **P ≤ 0.01, *** P≤0.001, ****P ≤ 
0.0001. 
  
























































































** *** ** ***















































































Figure 4.17: LN architecture when treated with antigen/adjuvant complex at 
days 3 and 7.  
Immunizations with OVA in combination with GLA-SE in WT or miR-132
-/- 
mice for 
3 or 7 days. Frozen sections of the popliteal LN from PBS, or OVA/GLA-SE 
immunized mice were stained with antibodies against CD3 (T cells), and B220 (B 
cells). N=5 mice, from 3 separate experiments. Representative image was chosen. 














Figure 4.18: Quantification of histology results with Cell Profiler.  
Immunizations with OVA in combination with GLA-SE in WT or miR-132
-/- 
mice 
for 3 or 7 days. Frozen sections of the popliteal LN from PBS, or OVA+GLA-SE 
immunized mice were stained with antibodies against CD3 (T cells), B220 (B cells). 
Images obtained were then run through a Cell Profiler pipeline to get the A: Lymph 
node area, B: B cell Follicle Area, and C: B cell Follicle number. Data from 3 
separate experiments. N=18. Two-Way ANOVA followed by multiple comparison 








































































































Figure 4.19: LN stroma network when treated with antigen/adjuvant 
complex at days 3 and 7.  
Immunizations with OVA in combination with GLA-SE in WT or miR-132
-/- 
mice 
for 3 or 7 days. Frozen sections of the popliteal LN from PBS, or OVA/GLA-SE 
immunized mice were stained with antibodies against A: FDCM2 (FDCs), and B: 
RANK-L (MRCs), Lyve-1 (lymphatic vessels) and Meca-79 (HEVs). N=5 mice, 

























Figure 4.20: Effect of adjuvants on stromal cell populations in WT and miR-
132-/- mice at days 3 and 7.  
Mice were immunized with PBS, or OVA/GLA-SE for 3 or 7 days and the popliteal 
LNs were removed and analysed by flow cytometry. A: FRCs (CD45- gp38+CD31-
), and B: LECs (CD45-gp38+CD31+). AccuCheck counting beads from Invitrogen 
were used to get an accurate cell count. N=10 from 3 separate experiments. Two-
Way ANOVA followed by multiple comparison Tukey’s test: *P ≤ 0.05, **P ≤ 0.01, 
*** P≤0.001, ****P ≤ 0.0001. 
 
  






























































4.7.   Immunization effect on macrophages 
Antigen/Adjuvant immunization led to changes in macrophages localization (Figure 
4.21A). Treatment with OVA/Alum led to an increase in SSMs into the LN where they 
interact with DCs both in WT and miR-132-/- mice. OVA/GLA-SE treatment seems to 
lead to a reduction in SSM numbers, there are almost no more SSMs found and they are 
not interacting with dendritic cells.  
Macrophages were quantified by flow cytometry (Figure 4.21B-C). There was an 
increase in macrophages upon treatment with both OVA/Alum and OVA/GLA-SE but 
the increase in cellularity is significantly lessened in miR-132-/- mice treated with 
OVA/GLA-SE than with OVA/Alum. There is no difference in SSM numbers but there 
are more MSMs in the miR-132-/- mice when treated with OVA/Alum (Figure 4.21D). 
miR-132 does not appear to modulate macrophage migration or function. 
4.8.  Marginal reticular cell network remodelling 
MRCs are a specialised stromal cell population that have a lineage relationship with 
FDCs. MRCs were sorted three days post PBS or OVA/GLA-SE immunization. 
OVA/GLA-SE treatment led to a 2-fold increase in miR-132 expression in WT mice 
(Figure 4.22A).  
Immunizations with both adjuvants lead to increased MRCs cellularity that is 
significantly higher in OVA/GLA-SE treated mice after prime and boost (at day 24). 
This increase in cellularity is significantly larger in miR-132-/- mice for MRCs (Figure 
4.22B). 
Immunohistochemistry analysis of MRC localisation was done at day 24 (prime and 
boost) post immunization. At a resting state MRCs are found under the floor of the 
SCS. Treatment led to changes in the location of MRCs. MRCs in both treatments are 
found inside the LN and not just around it. miR-132-/- mice treated with OVA/GLA-SE 
have more MRCs and enter the LN more (Figure 4.23). MRCs migrate upon adjuvant 







Figure 4.21: Close up of the architecture in mouse LNs when treated with 
antigen/adjuvant at day 24.  
A: Immunizations with OVA/Alum or OVA/GLA-SE in WT or miR-132
-/- 
mice. 
Frozen sections of the popliteal LN from PBS, OVA/Alum or OVA/GLA-SE 
immunized mice were stained with antibodies, CD169 (Macrophages), CD11b 
(DCs). N=5 mice, representative image was chosen. 
B-D: Mice were immunized with PBS, OVA/Alum or OVA/GLA-SE and the pLNs 
were removed and analysed by flow cytometry. B: Macrophages (CD169+), C: SCS 
Macrophages (CD169+SIGNR1-), and D: Medullary Macrophages 
(CD169+SIGNR1+). AccuCheck counting beads from Invitrogen were used to get an 
accurate cell count. N=5. 3 separate experiments. Two-Way ANOVA followed by 































































































Figure 4.22: Effect of adjuvants on miR-132 expression in MRCs and on 
MRC expansion in WT and miR-132-/- mice.  
A: Mice were immunized with PBS, or OVA/GLA-SE for 3 days and the popliteal 
LNs were removed and MRCs were sorted by MOFLO. Cells were lysed, total RNA 
was isolated, retro-transcribed into cDNA and miR-132 expression analysed by RT-
qPCR. Expression values were then normalized to the RNU6 internal standard 
values. Data is shown as relative values. B: MRCs (CD45-CD31-GP38+MAdCAM-
1+) were quantified by flow cytometry at day 24 post immunization. AccuCheck 
counting beads from Invitrogen were used to get an accurate cell count. N=5. 3 
separate experiments. Two-Way ANOVA followed by multiple comparison Tukey’s 



























































Figure 4.23: Close up of the architecture in mouse LNs when treated with 
antigen/adjuvant at day 24.  
Immunizations with OVA/Alum or OVA/GLA-SE in WT or miR-132
-/- 
mice. Frozen 
sections of the popliteal LN from PBS, OVA/Alum or OVA/GLA-SE immunized 
mice were stained with antibodies, RANK-L (MRCs), Lyve-1 (lymphatic vessels) 













4.9.  MRC differentiation into FDCs 
MRCs during immune responses can differentiate into FDCs through down-regulation 
of RANK-L and MAdCAM-1, followed by an up-regulation of CD21/CD35 and 
CXCL13. The kinetics and gene expression of MRCs was quantified. At three and 
seven days post immunization, cell populations were quantified by flow cytometry 
(Figure 4.24). MRCs, MRCs expressing CD21/35 and FDCs are increased in numbers 
upon OVA/GLA-SE immunization. There are significantly more of these cell types at 
three days post immunization in miR-132-/- mice compared to WT mice. This number 
decreases by seven days.  
A hypothesis to explain the ring-like structure that appears in WT mice at three days 
post treatment was that there was a drop in CXCL13 production. To test this, CXCL13 
and CXC12 expression was analysed in total LNs (Figure 4.25A-B). There is an 
increase upon OVA/GLA-SE treatment in CXCL13 expression in both WT and miR-
132-/- mice. This increase is mirrored by a significant decrease in CXCL12 expression in 
total LN. CXCL12 and CXCL13 expression was then analysed in sorted MRCs after 
three days of OVA/GLA-SE immunization (Figure 4.25C-D). Treatment led to an 8-
fold increase in CXCL12 and a 15-fold increase in CXCL13 expression in WT mice. In 
miR-132-/- mice, treatment led to a 2-fold increase in both CXCL12 and CXCL13 
expression.  
CXCR5 expression was then analysed by flow cytometry (Figure 4.26). Interestingly 
treatment led to no increase in CXCR5 MFI in WT mice but to a significant increase in 





Figure 4.24: Quantification of MRC kinetics. 
Mice were immunized with PBS, or OVA/GLA-SE for 3 or 7 days and analysed by 
flow cytometry. A: Schematic showing the MRC differentiation into FDCs. B: 
MRCs (CD45-gp38+MAdCAM1+CD21/35-), C: MRCs CD21/35+ (CD45-
gp38+MAdCAM1+CD21/35+), and D: FDCs (CD45-gp38+MAdCAM1-
CD21/35+). N=4. Two-Way ANOVA followed by multiple comparison Tukey’s 

















































































































Figure 4.25: Investigating CXCL12 and CXCL13 expression in total LNs  
and in MRCs. 
Mice were immunized with PBS, or OVA/GLA-SE for 3 days and total RNA was 
isolated or MRCs were sorted on the MOFLO. Cells were then lysed, total RNA was 
isolated, retro-transcribed into cDNA and expression was analysed by qPCR. A-B: 
A: CXCL13 in total LN, and B: CXCL12 in total LN. Expression values were then 
normalized to the HPRT internal standard values. Two-Way ANOVA followed by 
multiple comparison Tukey’s test: *P ≤ 0.05, **P ≤ 0.01, *** P≤0.001, ****P ≤ 
0.0001. N=4 or 5. C-D: C: CXCL12 in sorted MRCs, and D: CXCL13 in sorted 













































































































Figure 4.26: Investigating CXCR5 expression in B cells by flow cytometry. 
Mice were immunized with PBS, or OVA/GLA-SE for 3 or 7 days and analysed by 
flow cytometry. CXCR5 MFI. N=4. Two-Way ANOVA followed by multiple 
comparison Tukey’s test: *P ≤ 0.05, **P ≤ 0.01, *** P≤0.001, ****P ≤ 0.0001. 
 
  

























4.10.   Role of TNFα in follicle structure 
B cell distribution in WT mice at three days treatment closely resembles that found in 
TNFα/TNFR deficiency and that found in the neonatal LN prior to B cell follicle 
formation. To test this hypothesis, TNFα was inhibited in mice and after three days, 
LNs were analysed. No changes in structure were observed in these mice (Figure 
4.27A). However, these results are inconclusive as there was no control done to make 
sure that TNFα was efficiently inhibited in the mice during the course of treatment. 
TNFα expression was analysed in BMDCs post TLR4 stimulation, no difference was 
observed between WT and miR-132-/- mice (Figure 4.27B). TNFα expression after three 
days of treatment with OVA/GLA-SE is identical to untreated mice (Figure 4.27C). 
This indicates that although TNFα production by B cell is required for initial follicle 
formation it is not required for the maintenance of existing B cell follicles, indicating 
that TNFα is involved in the differentiation of FDCs and CXCL13 up-regulation but not 
the maintenance of CXCL13 expression, thus TNFα is unlikely to have a key role in the 
observed phenotype. 
4.11.   Analysis of miR-132 mediated transcription 
4.11.1.  Dendritic cell regulation by miR-132 
Bone Marrow Derived Cells (BMDCs) from WT and miR-132-/- mice were cultured and 
treated with LPS, OVA/MPL-A+TDM or OVA/GLA-SE for 1.5hrs and RNA 
expression was then analysed by RT-qPCR (Figure 4.28). When treated with TLR4 
agonists, MMP-9 is over-expressed in both WT and miR-132KO mice. However, this 
expression is lower in miR-132 deficient BMDCs. HTRA1 is a serine protease which 
has the potential to cleave immobilized chemokine fields, anchored to glycoproteins, 
that helps guide and shape DC’s migration [238]. Up-regulation of HTRA1 by FRCs 
along with T cells and DCs is expected since this protease could be capable of 
modulating LN microenvironment through potential cleavage of extracellular matrix 
and bound chemokine that are secreted by FRCs and enable T cells and DCs to migrate. 
Treatment induced an up-regulation of HTRA1 in both WT and miR-132-/- BMDCs. Il-
22 is an inflammatory cytokine of the IL-10 family that helps initiate innate immune 
responses. Previous work showed that mice lacking IL-22 share a similar phenotype to 
miR-132 deficient mice. IL-22 Binding Protein (IL-22BP) regulates IL-22 by binding to 
the cytokine, this inhibits the effects of IL-22 and helps control inflammation. No 
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changes were observed in IL-22BP expression upon treatment.  
4.11.2.  Treatment effect on gene expression in total LNs  
To analyse the changes in gene expression after treatment, mice were treated long-term 
with PBS or OVA/GLA-SE in WT or miR-132-/- mice. pLNs were digested and FRCs, 
LECs, BECs, B cells, T cells and DCs were sorted on the MoFlo (Beckman Coulter). 
The differences in IL-22BP expression are not significant, but treatment induces a 
down-regulation of the protein, and when untreated IL-22BP is expressed at a higher 
level in miR-132-/- mice than in WT mice. The increase in HTRA1 is significantly larger 
in miR-132-/- mice in B cells and T cells (Figure 4.29).  
4.12.   Remodelling at 6 months post boost 
4.12.1.  LN structure 6 months post boost 
To determine the dynamic remodelling process, mice were immunized (prime and 
boost) and LNs were analysed six months later (Figure 4.30). Immunohistochemistry 
analysis was done followed by quantification with Cell Profiler. Six months post 
immunization; LNs have not yet reverted back to the untreated state but are the same 
size as controls. This showed that B cell remodelling is not permanent but LNs do not 
revert back to their original unprimed state even after six months, indicating that aspects 
of the remodelling process are permanent or take longer to resorb.  
4.12.2.  LN structure 3 day boost post 6 months post boost 
To further determine the effect of time on the remodelling process, mice were 
immunised (prime and boost) and six months later mice were immunised for a further 
three days (Figure 4.31). LNs are bigger but there is no follicle remodelling, there is no 






Figure 4.27: Role of TNFα in regulating the remodelling process. 
A: Mice were treated with an anti-TNFα antibody for 3 days. LNs were removed and 
frozen sections of the popliteal LN were stained for CD3 (T cells), B220 (B cells) 
and FDCM2 (FDCs). Scale bar = 200μm, N=5, 2 slides/LN, representative image 
was chosen. B: BM was flushed from WT and miR-132-/- mice and seeded in the 
presence of GM-CSF. After 12 days and after obtaining a pure population of 
BMDCs, the cells were treated for 1.5 hours with PBS as a control and with a series 
of TLR4 agonist adjuvants. Cells were lysed, total RNA was isolated, retro-
transcribed into cDNA and TNFα expression was analysed by RT-qPCR. C: Effect 
of 3 days of OVA/GLA-SE treatment on TNFα expression. Total LN cells were 
isolated from mice, cells were then lysed, total RNA was isolated, retro-transcribed 
into cDNA and TNFα and CXCL13 expression was analysed by RT-qPCR. 
Expression values were then normalized to the HPRT internal standard values. 





























































Figure 4.28: Role of miR-132 in Bone Marrow DCs response to adjuvants.  
BM was flushed from WT and miR-132-/- mice and seeded in the presence of GM-
CSF. After 12 days and after obtaining a pure population of BMDCs, the cells were 
treated for 1.5 hours with PBS as a control and with a series of TLR4 agonist 
adjuvants. Cells were lysed, total RNA was isolated, retro-transcribed into cDNA 
and expression was analysed by RT-qPCR. A: IL22-BP B: HTRA1 and C: MMP-9. 
Expression values were then normalized to the HPRT internal standard values. Data 
is shown as relative values. Data from 3 separate experiments. One-Way ANOVA 
followed by multiple comparison Tukey’s test: *P ≤ 0.05, **P ≤ 0.01, *** P≤0.001, 











































































































Figure 4.29: Role of miR-132 in stromal and immune cells’ response to 
adjuvants.  
Mice were immunized with PBS, or OVA/GLA-SE following the long-term model and 
cells were isolated from mice using the MOFLO sorter. Cells were then lysed, total 
RNA was isolated, retro-transcribed into cDNA and expression was analysed by RT-
qPCR. N=1. A: HTRA1, C: MMP-9, and C: IL-22BP. Expression values were then 









































































































































































































































































































































































































Figure 4.30: Analysis of LNs 6 months post immunization. 
WT and miR-132-/- mice were immunized and boosted 21 days later. After which 
LNs were removed 6 months later. The popliteal LNs were removed and analysed by 
immunohistochemistry. A: Frozen sections of the popliteal LN from PBS, or 
OVA/GLA-SE immunized mice were stained with antibodies against CD3 (T cells), 
B220 (B cells), ER-TR7 (Reticular network), Lyve-1 (lymphatic vessels), and Meca-
79 (HEVs). Images were then quantified by Cell Profiler. B: Lymph Node area, C: 
Follicle Area, and D: Follicle number. N=4 mice, 2 slides/LN, representative image 






























































































Figure 4.31: Analysis of LNs boosted for 3 days 6 months post immunization. 
WT and miR-132-/- mice were immunized and boosted 21 days later. After which LNs 
were boosted again 6 months later for a further 3 days. The popliteal LNs were removed 
and analysed by immunohistochemistry. A: Frozen sections of the popliteal LN from 
PBS, or OVA/GLA-SE immunized mice were stained with antibodies against CD3 (T 
cells), B220 (B cells), ER-TR7 (Reticular network), Lyve-1 (lymphatic vessels), and 
Meca-79 (HEVs). Images were then quantified by Cell Profiler. B: Lymph Node area, 
C: Follicle Area, and D: Follicle number. N=4 mice, 2 slides/LN, representative image 





































































4.13.   Haematopoietic and stromal contribution to remodelling 
To understand the stromal and haematopoietic contribution of miR-132, reciprocal BM 
chimeras were set up. Irradiated miR-132-/- mice reconstituted with WT BM, possess 
stromal cells that are miR-132 deficient but the haematopoietic cells are WT. This 
would enable the analysis of the stromal contribution. In contrast, irradiated WT mice 
were reconstituted with miR-132-/- BM, which would mean that stromal cells are WT 
but the haematopoietic cells are deficient for miR-132. This would enable the analysis 
of the haematopoietic contribution. There is no difference in the increase in cellularity 
in either stromal cells or B and T cells upon treatment between the two different 
conditions (Figure 4.32). 
Histology from the two reciprocal chimera experiments were done and no clear pattern 
came out of it. The phenotype is intermediate between WT and miR-132-/- mice. The 
phenotype between the two chimeras is very similar whether PBS or OVA/GLA-SE 
treated (Figure 4.33). Images were then quantified by Cell Profiler, in both chimeras 
treatment induced an increase in LN size and in follicle number. Treatment induced a 
smaller follicle area in WT mice reconstituted with miR-132-/- BM. This would mean 
that miR-132 is necessary in haematopoietic cells to have an increase in follicle area 
that we observe in miR-132-/- mice.  The controls for this experiment, that is WT 
reconstituted with WT and miR-132-/- reconstituted with miR-132-/- were not done. 
These results must therefore be considered as preliminary and the experiment repeated 






Figure 4.32: Flow cytometry on reciprocal Bone Marrow Chimeras to study 
the stromal vs. haematopoietic contribution of miR-132.  
Mice were irradiated and then reconstituted with bone marrow. miR-132-/- mice were 
reconstituted with WT BM and WT mice with miR-132-/- BM. After 8 weeks, mice 
were immunized with PBS, or OVA/GLA-SE following the long-term model and the 
popliteal LNs were removed and analysed by flow cytometry. A: Total cells, B: 
Non-haematopoietic cells (CD45-), C: FRCs (CD45-CD31-gp38+), D: LECs 
(CD45-CD31+gp38+), E: B cells (CD19+), and F: T cells (CD3+). AccuCheck 
counting beads from Invitrogen were used to get an accurate cell count. N=5 from 2 
separate experiments. Two-Way ANOVA followed by multiple comparison Tukey’s 



























































































































Figure 4.33: Histology on reciprocal Bone Marrow Chimeras to study the 
stromal vs. haematopoietic contribution of miR-132.  
Mice were irradiated and then reconstituted with bone marrow. miR-132-/- mice were 
reconstituted with WT BM and WT mice with miR-132-/- BM. After 8 weeks, mice 
were immunized with PBS, or OVA/GLA-SE following the long-term model and the 
popliteal LNs were removed and analysed by immunohistochemistry. A: Frozen 
sections of the popliteal LN from PBS, or OVA+GLA-SE immunized mice were 
stained with antibodies against CD3 (T cells), and B220 (B cells). Images were then 
quantified by Cell Profiler. B: Lymph Node area, C: Follicle Area, and D: Follicle 
number. N=7 mice, 2 separate experiments, 2 slides/LN, representative image was 
chosen. Scale bar = 500µm. 
  













































































4.14.   Summary of findings 
•   Stromal cells respond to TLR agonists in vitro and in vivo. 
•   Induction of TLR4 signalling regulates cytokines and miR-132 expression. 
•   miR-132 deficiency leads to an altered LN structure in naïve mice but also 
following TLR4 adjuvant immunization. This remodelling is not dependent on 
blood and lymphatic vasculature. 
•   miR-132-/- mice do not have the same remodelling kinetics as WT mice. There is 
no ring-like structure forming around the LN or new follicular structures 
appearing in the paracortex. 
•   Immunization of WT and miR-132-/- mice showed that miR-132 does not 
regulate macrophage migration and localization. 
•   MRCs migrate upon immunization and this is modulated in miR-132-/- mice. 
•   miR-132-/- mice have a deficiency in CXCL12 and CXCL13 production which is 
mirrored by an up-regulation of CXCR5 in B cells. 
•   LN remodelling is not a TNFα-dependent process. 
•   The remodelling process is not permanent but LNs do not revert back to naïve 
resting state after 6 months.  
•   BM chimeras illustrated that the remodelling process is dependent both on 
stromal and haematopoietic cells. 
4.15.   Discussion 
4.15.1.  Stromal cells respond to TLR stimulation 
Traditionally PRRs including TLRs are thought to be expressed by innate immune cells 
and barrier epithelium. Analysis of TLR4 mediated remodelling in Rag deficient mice 
in Chapter 3 indicated a key role for stromal cells in the remodelling process. The role 
of stromal cells in this process is still poorly understood. Data from the pre-existing 
gene expression database Immgen showed that FRCs, LECs and BECs express multiple 
TLRs, and the associated adapter molecule MyD88. In vitro cultured FRCs were treated 
with specific TLR agonists leading to the production of pro-inflammatory cytokines in 
response to stimulation. Treatment of FRC cultures with the TLR4 ligand LPS regulates 
TLR4 expression. By using FRCs from WT, TLR4-/- or Myd88-/-, it was possible to 
demonstrate that FRC stimulation is TLR mediated as response was dampened in the 
knockout mice. Our results obtained here demonstrate that stromal cells, namely FRCs 
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respond to TLR4 ligands. These results are key, as it has been believed that TLR4 
signalling was critical in immune cells. Here we showed that TLR4 signalling occurs in 
vitro in FRCs further indicating that stromal cells have a key role in LN remodelling.  
4.15.2.  miR-132 is up-regulated in LNs upon stimulation  
It has been shown that miR-132 has a key role in immune and stromal cells in 
regulating inflammation. miR-132 is also one of the microRNAs to have been linked to 
the TLR4 signalling pathway. To identify a pathway that regulates stromal cell 
activation, miR-132 expression was analysed. Adjuvant treatment of mice led to an 
increase in TNFα and IL-1β expression, this increased expression is mirrored by the 
increase in miR-132. This illustrates that as there is an immune response linked to 
TLR4 signalling leading to production of inflammatory factors, there is also an up-
regulation of miR-132. This is expected as miR-132 serves as a brake to over-
inflammation by inhibiting the TLR4 signalling pathway and TLR4 induced genes. 
Stimulation of FRCs from WT and miR-132-/- mice showed that TLR4 stimulation 
drives inflammatory factor production but this production is lessened in the case of IL-
1β. These results are surprising as miR-132 is expected to dampen inflammation, so 
absence of this microRNA would lead to a higher expression of these inflammatory 
molecules. This indicates that miR-132 may have a differential role in FRCs than that of 
inhibiting inflammation such as regulating the production of certain molecules or their 
ability to respond to TLR4 stimulation. A similar experiment was done with isolated B 
cells and their response to TLR4 stimulation. No clear difference in cytokine production 
was observed between WT and miR-132-/- B cells. miR-132 deficiency in B cells does 
not alter these cells’ ability to respond to TLR4 stimulation. Even though miR-132 
expression is regulated in cells both in vitro and in vivo and the expression correlates 
with cytokine production, deficiency does not alter cytokine production. miR-132’s 
effect on architecture was then analysed to investigate the role it might have in LN 
structure. 
4.15.3.  miR-132 deficiency leads to changes in LN structure 
To determine the role of miR-132 in LN development and function, which is currently 
unknown, LN structure was analysed. Analysis of miR-132 deficient mice showed 
distinct differences to littermate controls. This might in part be due to a failure to fully 
down-regulate immune responses to the endogenous bacterial flora in mice. LNs from 
miR-132 deficient mice are increased in size, with larger B cell follicles and a less 
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distinct separation between B and T cell zones. This could be due to differences in B 
and T cell gene expression or changes to the LN microenvironment. The difference 
observed between miR-132 deficient mice and WT mice indicates a role for miR-132 in 
B cell follicle function and remodelling. miR-132 is one of the many microRNAs to 
have been linked to B cell maturation and function. Here we observed a clear phenotype 
in untreated mice. Therefore further studies were done to try and elucidate the role of 
miR-132 in the changes in architecture.  
To investigate if miR-132 affects the LN hypertrophy and remodelling process, immune 
cells, both innate and adaptive, were quantified. Treatment led to increase in all cell 
types observed; therefore miR-132 does not alter recruitment of cells to the LN. 
However, there was more B cells and CD8 T cells in miR-132-/- mice illustrating that 
miR-132 does have a role in regulating B cells during hypertrophy. How these changes 
alter LN remodelling was then investigated to determine if miR-132 regulates B cell 
follicle remodelling. Differential remodelling was observed in miR-132-/- mice 
compared to WT mice. In vivo experiments showed LN expansion but a decrease in 
tissue remodelling. LNs from miR132-/- mice were not as large upon stimulation as LNs 
from WT mice, but possessed larger B cell follicles restricted to the LN cortex rather 
than smaller ones found in the paracortex. Although miR-132 does not appear to 
regulate B cell response to TLR4 stimulation, it does have a role in LN remodelling and 
hypertrophy, as mice lacking miR-132 do not remodel as WT mice. miR-132 regulates 
LN remodelling. How B cell remodelling affects other stromal cell populations was then 
investigated. Stromal cell networks, both FRC and FDC mirror the changes in LN 
architecture in B and T cell zones. Vasculature remodelling is the same between both 
miR-132-/- and WT mice illustrating that the changes in architecture observed are not 
dependent on changes in vasculature.  
Previous work in Chapter 3 illustrated that in WT mice the key steps in the remodelling 
process occurred during the first 72hrs. Therefore, the kinetics of remodelling was 
compared between WT and miR-132-/- mice. The ring-like structure that was observed 
in WT mice was absent in miR-132 mice. By seven days of treatment, the phenotype 
resembled that after a long-term treatment. WT LN had small B cell follicles in the 
paracortex while miR-132-/- mice had big B cell follicles limited to the cortex. This 
illustrates that B cell follicles fail to dissociate in the absence of miR-132, which leads 
to bigger follicles that stay in their compartment rather than migrating into the 
paracortex. Absence of miR-132 does not alter inflammatory molecule production but 
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does alter LN architecture and leads to differential structure.  
Based on the failure of B cell follicles to dissociate, the effect on stromal cell networks 
was investigated. There were no changes in stromal cell number increase upon 
treatment for short period and the stromal cell networks mirrored the B and T cell 
architecture and there were no changes in vasculature. The differences observed in LN 
architecture between WT and miR-132-/- mice are not due to changes in stromal cells 
but appear to be in B cells from early on in the immune response.  
There is a clear phenotype in miR-132-/- mice. The LN remodelling process that we 
observed in WT mice is altered in miR-132-/- mice. miR-132 appears to be regulating B 
cell follicle formation by having a role in the dissociation of these rigid compartments 
in response to immunization. How this affects the immune response to immunization 
still needs to be investigated. 
4.15.4.  Macrophage and MRC migration in miR-132-/- mice 
The SCS is a region of the LN that is critical in the initiation of the immune response. 
SSMs have been shown to migrate down towards B cell follicles during an immune 
response to present antigen. SSMs dynamics have a key role in regulating immune 
responses, thus they were analysed in the miR-132 deficient mice. SSMs were analysed 
by histology, to study their positioning in the LN. Treatment with OVA/GLA-SE led to 
there being less macrophages on the SCS and they appeared to have migrated into the 
LN in both WT and miR-132-/- mice. Treatment with Alum led to more total 
macrophages and MSMs in mice deficient in miR-132. However, treatment with the 
TLR4 agonist, GLA-SE led to no change in macrophage numbers. miR-132 does not 
modulate macrophage migration or numbers upon immunization. Macrophages are 
important in the initiation of the immune response namely in activating B cells by 
presenting antigen. However the changes observed in the different LN architecture in 
mice lacking miR-132 is not due to changes in macrophage numbers or their 
localization. Another element that needs investigating is the interaction between 
macrophages and B cells to analyse if miR-132 could be regulating antigen presentation 
and interactions between these cells. 
MRCs are a specialised stromal cell population that have a lineage relationship with 
FDCs. Therefore, the distribution and number of MRCs was quantified. miR-132 is up-
regulated in MRCs upon GLA-SE treatment and after 24 days of treatment there are 
more MRCs in miR-132-/- mice than WT mice. To further investigate this, MRCs were 
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analysed by histology and it was shown that in WT mice there are more MRCs upon 
adjuvant treatment than in untreated mice. However, in miR-132 deficient mice there 
appear to be more MRCs still in the SCS but also more that have entered the LN. MRCs 
migrate in response to adjuvants and this is modulated in miR-132 deficient mice. 
MRCs express CXCL13 and adhesion markers promoting B cell migration in B cell 
follicles and their interaction with macrophages. As there are more MRCs in mice 
lacking miR-132, this microRNA could modulate MRC numbers in order to alter 
interactions with the increased number of B cells leading to the dissolution of B cell 
follicles that we observed by 3 days.  
4.15.5.  MRC differentiation and potential mechanisms of remodelling 
MRCs have been shown to be precursor cells for FDCs during an immune response 
[62]. MRCs differentiate into FDCs through loss of RANK-L, up-regulation of 
CD21/CD35 and CXCL13. The kinetics and gene expression of MRCs was therefore 
quantified. At three days of OVA/GLA-SE treatment in miR-132-/- mice there are more 
MRCs, MRCs expressing CD21/35 and FDCs. CXCL12 and CXCL13 expression in 
total LNs were quantified. An increase in CXCL13 and a decrease in CXCL12 were 
observed that was the same between WT and miR-132-/- mice. However, the increase in 
CXCL12 and CXCL13 was dampened in miR-132-/- mice compared to WT mice. 
Deficiency in miR-132 leads to more MRCs but they express less chemokines that 
regulate B cell positioning. To further analyse this change, CXCR5 expression on B 
cells was investigated. miR-132-/- mice had less CXCR5 than WT mice in untreated 
mice, CXCR5 expression increased upon treatment in miR-132-/- mice to levels similar 
to that of WT mice. This shows that in miR-132-/- mice there is an increase in CXCR5 
that is not observed in WT mice. miR-132 plays a role in CXCR5 expression in B cells 
either in the expression on the surface or in the internalization and degradation process 
of this receptor. Absence of miR-132 leads to a deficiency in chemokine production by 
MRCs even though there are more MRCs. The phenotype observed of B cell dissolution 
could also be affected by changes in CXCR5 expression on B cells.  
miR-132 has multiple targets that might also regulate the remodelling process. Thus 
several potential targets of miR-132 were analysed. The targets analysed showed no 
difference upon treatment between WT and miR-132-/- BMDCs. However there was an 
increase in miR-132-/- B and T cells of HTRA1, which might be a key regulator of 
chemokine gradients crucial for T cells and DCs [14, 238]. Transcriptional control of 
 
151 
HTRA1 appears to occur through miR-132 control, which might modulate chemokine 
gradients controlling the localised microenvironment.  
4.15.6.  TNFα is critical in B cell follicle formation but not remodelling 
TNFα has been shown to be critical in B cell follicle formation in the LN anlagen. 
Therefore, we investigated if TNFα has a role in the remodelling process. Blocking 
TNFα does not induce changes in B cell follicle structure. This indicates that even 
though it is crucial in the development of B cell follicles it is not required for new 
follicle formation. Treatment of BMDCs with TLR4 led to the same increase in TNFα 
in WT and miR-132-/- mice. Three days treatment with GLA-SE led to no changes in 
TNFα in total LN of WT mice. These results indicate that the remodelling process is 
unlikely to be driven by TNFα. However, deficiency in TNFα might alter the 
remodelling process. To investigate this WT mice would have to be treated with anti-
TNFα during treatment with GLA-SE and LN architecture observed. 
4.15.7.  LN structure 6 months after immunization 
To determine the stability of the remodelling process mice were treated and LN 
architecture was analysed six months later with or without a boost. Restimulation of 
WT and miR-132-/- mice after 6 months for a further 3 days led to a rapid increase in LN 
size but no difference in the remodelling process between them. The LNs appeared to be 
more reactive to restimulation. LNs analysed after 6 months of immunization were 
small but had not returned to the naive resting state. This illustrates that changes in LN 
structure and remodelling are not permanent even though after 6 months LNs have not 
reverted back to resting state. This could mean either that LNs never go back to their 
naïve state or that it takes longer to go back to resting state. It is possible that for a time 
LNs stay in a slightly activated state ready for a secondary infection. 
4.15.8.  Stromal and haematopoietic contribution of miR-132 
In our model miR-132 appears to be crucial in both stromal and immune cell regulation. 
Chimeras were set up to determine which component was necessary for the changes in 
phenotype observed in miR-132 deficient mice. Quantification of stromal cells and 
immune cells showed no difference between WT and miR-132-/- mice. Imaging showed 
that in both types of chimeras there was an intermediate phenotype between WT and 
miR-132-/- mice. The only change observed was that in WT mice reconstituted with 
miR-132-/- haematopoietic cells there is a lessened follicle area. The increase in follicle 
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area that was observed in miR-132-/- mice appears to be dependent on miR-132 
expression in stromal cells. From these results it appears that the phenotype observed of 
LN architecture is mediated by both haematopoietic and stromal cells which is 
consistent with the changes observed both in MRCs and CXCR5 expression in B cells. 
4.15.9.  Conclusion 
miR-123 has shown to be a key regulator in the LN hypertrophy and remodelling 
process. There is a clear difference in LN architecture between WT and miR-132-/- mice 
illustrating that there might be an altered immune response. These changes in LN 
architecture upon TLR4 stimulation are dependent on miR-132 expression both in 
stromal and haematopoietic cells. miR-132 is crucial in LN remodelling but the 
mechanism behind these changes in architecture are due to various different factors and 
cell types that are regulated by miR-132. Through analysis of GC formation and 
activated B cells but also of antibody production, the functionality of these changes in 




Chapter 5:   Consequence of TLR4 mediated remodelling 
on the immune response 
5.1.   Introduction 
5.1.1.   Effect of LN hypertrophy on B cell follicles 
LNs are indispensable organs for the generation of an adaptive immune response to 
antigen encounter in peripheral tissues. LNs are highly organized structures with 
distinct B and T cell zones. There are two types of stromal cells described in the cortex, 
FDCs and MRCs [5]. FDCs express CD21/35 and FDCM2 and are capable of 
displaying opsonized antigen to B cells. FDCs also secrete CXCL13 and BAFF, which 
are critical in the recruitment and survival of B cells, respectively [52]. CXCL13 is an 
important chemokine in the generation of GCs [50]. LN expansion during an immune 
response is due to an increase in adaptive and innate immune cells and the underlying 
stromal cell networks. LN remodelling serves as a scaffold for the increased entry of 
lymphocytes and DCs into the organ [3, 5]. In inflamed LNs, the follicles grow and start 
to migrate into the T cell zone. Stromal cells that are in this zone are then converted into 
CXCL13 expressing cells through a LTβ pathway. These cells were dubbed versatile 
stromal cells as they lose CXCL13 expression after resolution of inflammation and 
follicle withdrawal as B and T cell zones return to their original limits [74]. GCs are 
structures that appear in follicles during an immune response when B cells encounter 
antigen and are subsequently activated and then driven to proliferate. GCs likely result 
from the expansion and differentiation of FDCs. Activated B cells drive the formation 
of the light zone and proliferating B cells drive dark zone formation, in addition to 
attracting more naïve B cells, thus increasing chances of a cell being capable of 
recognizing antigen.  
5.1.2.   GC formation 
GCs are composed of a light zone that is orientated to antigen entry points close to the 
SCS and a dark zone that is close to the T cell zone [239]. The dark zone contains a 
multitude of large proliferating B cells with low expression of surface immunoglobin 
called centroblasts. Due to the presence of FDCs the light zone contains less B cells that 
express surface immunoglobulin called centrocytes [240]. B cells in GCs have similar 
migration patterns as naïve B cells but possess dendrite like structures enabling them to 
probe for antigen with a greater surface [241, 242]. In GCs, B cells go through clonal 
 
154 
expansion, class switch recombination, somatic hypermutation, and affinity maturation 
[49]. These GC structures are critical in the production of B cell effector and memory 
cells. The classic GC model is that B cells in the dark zone undergo quick cellular 
division, class switch recombination, and somatic hypermutation. B cells then migrate 
into the light zone where with the help of TFH cells they go through antigen selection 
[240]. Since this model was developed, studies using in vivo tracking of B cells have 
shown that B cells migrate dynamically in both directions between the light zone and 
the dark zone [33, 241, 242]. Somatic hypermutation is the process of random point 
mutations appearing in the V regions of the immunoglobin genes of B cells. Class 
switching is the process whereby the type of immunoglobin converts through 
recombinations in the constant region of the antibody heavy chain while the variable 
region stays the same. This process doesn’t affect the affinity of antibodies but leads to 
changes the functional properties of immunoglobulin [243]. AICDA encodes for a 
DNA-editing deaminase (AID) involved in somatic hypermutaion and class-switching 
of immunoglobulin genes [244, 245]. AICDA expression gives an idea of antibody 
specificity. B cells undergo cellular proliferation and antigen selection in both these 
zones. Upon antigen encounter, B cells up-regulate CCR7 expression enabling the 
migration to the T cell zone boundary following CCL19 and CCL21 gradients. In this 
zone, B cells interact with CD4 TH cells [246]. B cells entering the follicle seed the GC 
reaction and rapidly divide forming the two zones. In the dark zone, B cells express the 
chemokine receptor CXCR4 and migrate to this area through CXCL12 signalling by 
stromal cells. CXCR4 down-regulation in dark zone B cells leads to migration towards 
the light zone following the CXCL13 gradient binding to CXCR5 on B cells [74, 247]. 
After class switch recombination, and somatic hypermutation, B cells are selected for 
antigen reactivity [248]. B cells are selected for antigen recognition by the BCR and 
also TFH presentation in the light zone.  
TFH cells are characterised as being CXCR5 high enabling them to migrate to the T cell 
zone/B cell follicle border following CXCL13 gradients [249]. TFH differentiation 
happens after T cell and DC interactions with the production of IL-6, IL-12 and the co-
stimulatory molecule inducible co-stimulator (ICOS). These signals are indispensable 
for the transcription of B-cell lymphoma 6 (Bcl6), which is critical for the 
differentiation into TFH cells [250, 251]. Transcription factor achaete-scute complex 
homolog 2 (Ascl-1) expression induces expression of CXCR5 on TFH cells. Full 
differentiation into GC TFH cells is mediated by interaction of precursor TFH cells with B 
 
155 
cells mediated by ligation of CD84 and Ly108 and supported by SLAM-Associated 
Protein (SAP), an intracellular adaptor molecule [252]. GC B cells compete for 
interaction with TFH cells. TFH cells in turn provide survival and differentiation signals to 
high affinity B cells through CD40/CD40L interaction and production of cytokines such 
as IL-21 and IL-4 [253]. B cells pick up antigen presented by FDCs on their mutated 
BCR and present it in turn to MHCII found on TFH cells. Only high affinity B cells are 
able to interact with TFH cells leading to high affinity plasma cells and memory cells 
[254]. B cells that do not obtain a signal through their BCR and through CD40 undergo 
apoptosis [33].  
TFR cells are also found in GCs. These cells are very similar to TFH cells but do not 
express molecules to help B cells such as IL-21 and CD40 ligand. TFR cells appear 
during an immune response and the peak numbers are between days 11 and 17, 
compared to 7 and 11 for TFH cells. Studies suggest that TFR cells limit the size of 





Figure 5.1: The Germinal Centre reaction. 
Representation of B cell maturation in germinal centres. At the border between 
follicle and T cell zone, B cells receive stimulatory signals by presenting antigen to T 
helper cells. Cells then enter the dark zone where they undergo somatic 
hypermutation and cell proliferation. Cells then migrate into the light zone where the 
mutated BCR is selected by exposure to antigen by FDCs. If there is high affinity, B 
cells receive survival signals and receive further signals from TFH cells and go 
through class switching. B cells then either re-enter the dark zone, exit as memory 






5.1.3.   Plasma cells and antibody production 
A population of differentiated B cells called plasma cells produces antibodies [257]. 
There are two types of antibody producing cells, plasmablasts that are short lived and 
produce low affinity antibodies and plasma cells that are produced from T-cell 
dependent GC reactions that can produce high affinity antibodies for weeks. 
Plasmablasts can be found three days after the start of the immune response, whereas 
plasma cells appear later at about six days [258]. Plasma cells are distinguished by 
expression of syndecan-1 on their surface and a rough endoplasmic reticulum [259]. 
Plasma cell differentiate through the transcriptional repressor Blimp-1, which inhibits 
most B cell pathways, and the GC specific genes AICDA and Bcl6. The transcription 
factor XBP1 is essential in the survival of plasma cells from the stress put on the 
endoplasmic reticulum due to high antibody production [257, 260]. The medulla is the 
part of the LN that contains the least immune cells in resting conditions. However, 
during an immune response, the medulla is colonized by the plasma cells generated. 
During an immune response, LN medulla is remodelled in a B-cell and LTβR 
dependent way [86]. This migration from the GCs to the medulla is chemokine 
dependent, namely CXCL12 that binds to CXCR4 on plasma cells [261]. Plasma cells 
there produce antigen specific antibodies that are sent into the circulation in large 
quantities helping to clear the pathogen [262, 263]. It is suggested that cells in the 
medulla, either myeloid or stromal, under inflammatory conditions, produce IL-6 and A 
Proliferation-Inducing Ligand (APRIL) that promote plasma cell recruitment and 
survival [264]. This plasma niche is created upon inflammatory conditions in the 
medulla following LN expansion. Egress from the medulla of long-lived plasma cells is 
critical for their survival and is dependent on S1P expression [21, 265]. 
Antibodies are fundamental components of the adaptive immune system, they protect 
against infection through binding of pathogens participating in their inactivation. This 
binding also recruits different immune cells and the complement [266]. Antibodies can 
either be produced as cell-surface bound or secreted. Antibodies possess a Y structure 
with two identical binding sites at the arms of the structure. They are composed of a 
light chain and a heavy chain held together by non-covalent and covalent bonds. In the 
mammalian immune system, there are 5 classes of antibodies, IgA, IgD, IgE, IgG and 
IgM that have their own type of heavy chain. The class of antibody produced is 
determined by class switching that occurs in the GC. IgM is the first type of antibody 
made by immature B cells; mature B cells possess both IgM and IgD. IgG is the major 
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type of antibody found in the blood. IgA is the most common antibody found in 
secretions such as saliva and respiratory and intestinal secretions as well as mucosal 
surfaces. IgE is critical for the secretion of histamine by eosinophils [267-269].  
5.1.4.   Summary 
GCs are key structures required for the clearance of pathogens by the adaptive immune 
system. GCs develop during an immune response and lead to the production of high 
affinity memory B cells and plasma cells. This is done through migration between the 
light zone and the dark zone where the B cells undergo proliferation, class-switching 
and somatic hypermutation. B cells recognize antigen on FDCs and present it to TFH 
cells, triggering their differentiation into high affinity effector cells. Plasma cells then 
migrate to the medulla in a CXCL12-dependent way. There they produce antibodies and 
secrete them into circulation. Cell egress from there happens where they enter the 
circulation or go to the bone marrow following S1P gradients. Antibody production is 
one of the key ways used here to measure the effect of LN structure changes on the 
immune response, namely the measure of TH1 versus TH2 antibodies. 
We hypothesize that since miR-132 deficiency during TLR4 agonist adjuvant 
immunization results in changes in cell numbers and in LN structure, the phenotype 
observed leads to functional changes. These functional changes in the adjuvant efficacy 
were measured by analysing key cell types in GC development and antibody production 
and affinity.  
5.1.5.   Aims 
•   Determine the effect of miR-132 deficiency on GC formation and the associated 
cell types. 
•   Investigate effect of miR-132 deficiency in antibody production both at long-
term treatments and short term. 





5.2.  Adjuvant effect on AICDA expression in total LNs  
Treatment with OVA/GLA-SE leads to an increase in AICDA in both mouse strains. 
This over-expression is significantly greater in miR-132-/- mice, potentially driving 
higher affinity immune responses and promoting the class switching of antibodies 
during the response (Figure 5.2). 
5.3.   Immune cell analysis 
Follicular and activated B cells were quantified by flow cytometry at day 24 (Figure 
5.3). Treatment induces a significant increase in both WT and miR-132-/- mice 
compared to the PBS control. There is a significant difference in the total number of B 
cells, follicular B cells and activated B cells in the miR-132-/- mice. 
B cells, TFR cells and TFH cells were analysed by flow cytometry at three days and seven 
days post treatment (Figure 5.4). Treatment with OVA/GLA-SE led to a significant 
increase in B cells in miR-132-/- mice at seven days compared to WT mice. Treatment 
led to the same increase in TFR cells in both WT and miR-132-/- mice. However, there 
were significantly more TFH cells in miR-132-/- mice which is interesting as they are 
critical for the creation and maintenance of GCs [29]. This is even more noteworthy as 
immunohistochemistry results indicate that germinal centres are formed by seven days 








Figure 5.2: Effect of TLR4-agonist adjuvant on AICDA expression in WT 
and miR-132-/- mice.  
Thirty 10µm sections were taken from LN imaged earlier from the long-term 
treatment study after taking care to remove as much OCT as possible. Total RNA 
was then isolated from the sections, retro-transcribed into cDNA and AICDA 
expression was analysed by qPCR. Expression values were then normalized to the 
HPRT internal standard values. Data is shown as relative values. N=4. Two-Way 
ANOVA followed by multiple comparison Tukey’s test: *P ≤ 0.05, **P ≤ 0.01, *** 
P≤0.001, ****P ≤ 0.0001. 
 
  































Figure 5.3: Effect of adjuvants on B cell populations in WT and miR-132-/- 
mice at day 24.  
Mice were immunized with PBS, OVA/Alum or OVA/GLA-SE and the popliteal 
LNs were removed and analysed by flow cytometry. A: B cells (CD19+), B: 
Follicular B cells (CD19+IgD+CD95-), and C: Activated B cells (CD19+IgD-
CD95+GL7+). AccuCheck counting beads from Invitrogen were used to get an 
accurate cell count. N=10. 2 separate experiments. Two-Way ANOVA followed by 
























































































Figure 5.4: Effect of adjuvants on cell populations in WT and miR-132-/- 
mice at days 3 and 7.  
Mice were immunized with PBS, or OVA/GLA-SE for 3 or 7 days and the popliteal 
LNs were removed and analysed by flow cytometry. A: B cells (CD19+), 
B: Follicular Regulatory T Cells (CD4+PD1+CXCR5+ Foxp3+CD44+), and 
C: Follicular Helper T Cells (CD4+PD1+CXCR5+Foxp3-CD44+). AccuCheck 
counting beads from Invitrogen were used to get an accurate cell count. N=10 or 
N=15 from 3 separate experiments. Two-Way ANOVA followed by multiple 
comparison Tukey’s test: *P ≤ 0.05, **P ≤ 0.01, *** P≤0.001, ****P ≤ 0.0001. 
 
  





























































































Figure 5.5: Germinal centre formation post immunization in WT and miR-132-
/- mice.  
Immunizations with OVA in combination with GLA-SE in WT or miR-132
-/- 
mice for 3 
or 7 days. Frozen sections of the popliteal LN from PBS, or OVA/GLA-SE immunized 
mice were stained with antibodies against IgD (naïve B cells) and PNA (GCs). N=5 














5.4.  OVA specific antibody production 
5.4.1.   Antibody titration at day 24 
Adjuvants are used in order to induce high titre, high affinity antibody responses. 
Therefore, antibody production was compared between WT and miR-132 deficient mice 
when primed and boosted with either OVA/Alum or OVA/GLA-SE. Antibody titration 
and avidity was determined (Figure 5.6). These results indicate a profound role for both 
TLR4 agonists and miR-132 in regulating the type and avidity of the response. In 
comparison to Alum, GLA-SE produces both a strong IgG2c (TH1) response and higher 
avidity response in both WT and miR-132-/- mice. miR-132 deficiency leads to a loss in 
IgG1 (TH2) and a corresponding polarization to an IgG2c (TH1) response. Despite the 
LN remodelling that occurred in Alum treated miR-132-/- mice, a near total inhibition of 
IgG1 antibody response occurred. To further pursue these results, different antibodies 
were analysed in the serum, IgA and IgE. There was no difference in these 
immunoglobulins between WT and miR-132-/- mice upon treatment either with 
OVA/Alum or OVA/GLA-SE.  
5.4.2.   Rapid antibody production post treatment 
Antibody production was compared between WT and miR-132-/- mice when primed 
with OVA/GLA-SE for three or seven days. Antibody titration was determined (Figure 
5.7). In miR-132-/- mice at seven days there are significantly more specific IgG, IgG1 
and IgG2c antibodies than in WT mice. This correlates with the fact that there were 
GCs at seven days in miR-132-/- mice as shown in the PNA staining in Figure 5.4 and an 
increased number of TFH cells. Inhibiting miR-132 could be a novel way of getting 
specific B cells. 
5.4.3.   Antibodies at 6 months, 3 days post boost 
To further understand the immune response dynamics, mice were primed and six 
months after boosted for three days and the OVA-specific antibodies were analysed 
(Figure 5.8). Due to the memory response, a quick production of OVA-specific 
antibodies was expected. Treatment led to an increase in total IgG in both WT and 
significantly in miR-132-/- mice. There is significantly less IgG1 in miR-132-/- mice post 





5.4.4.   Antibody production in chimeras 
Irradiated miR-132-/- mice reconstituted with WT BM, possess stromal cells that are 
miR-132 deficient but the haematopoietic cells are WT. This would enable the analysis 
of the stromal contribution. In contrast, irradiated WT mice were reconstituted with 
miR-132-/- BM, which would mean that stromal cells are WT but the haematopoietic 
cells are deficient for miR-132. This would enable the analysis of the haematopoietic 
contribution. To further determine the immune response, antibody titres were 
determined (Figure 5.9). There is no difference in antibody titres between the chimeras 






Figure 5.6: Antibody titration and avidity in WT and miR-132-/- mice.  
Mice were immunized with PBS, OVA/Alum, or OVA/GLA-SE and the serum was 
analysed for OVA-specific antibodies. A-E: IgG, IgG1, IgG2c, IgA and IgE 
antibody titration, and F-H: IgG, IgG1 and IgG2c antibody avidity. N=5. 
Representative graphs from 2 separate experiments. Two-Way ANOVA followed by 
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Figure 5.7: Antibody production in WT and miR-132-/- mice after 3 or 7 days 
of OVA/GLA-SE treatment.  
Mice were immunized with PBS, or OVA/GLA-SE and the serum was analysed for 
OVA-specific antibodies. A: IgG, B: IgG1, and C: IgG2c antibody titration. N=9 
from 2 separate experiments. Two-Way ANOVA followed by multiple comparison 
Tukey’s test: *P ≤ 0.05, **P ≤ 0.01, *** P≤0.001, ****P ≤ 0.0001. 
 
  





































































































Figure 5.8: Antibody production in 6 month prime and boost mice.  
Mice were injected with PBS or OVA/GLA-SE for 3 weeks then boosted and left for 
6 months after which the mice were boosted again for a further 3 days. The serum 
was analysed for OVA-specific antibodies. A: IgG, B: IgG1, and C: IgG2c antibody 
titration. N=5. Two-Way ANOVA followed by multiple comparison Tukey’s test: *P 





































































Figure 5.9: Antibody production in reciprocal bone marrow chimeras.  
Mice were irradiated and then reconstituted with BM. miR-132-/- mice were 
reconstituted with WT BM and WT mice with miR-132-/- BM. After 8 weeks, mice 
were immunized with PBS, or OVA/GLA-SE following the long-term model and the 
serum was analysed for OVA-specific antibodies. A: IgG, B: IgG1, and C: IgG2c 
antibody titration. N=5. Two-Way ANOVA followed by multiple comparison 

















































































5.5.   Summary of findings 
•   Treatment with OVA/GLA-SE leads to an increase in AICDA expression that is 
greater in miR-132-/- mice than WT mice. 
•   There were more activated B cells and TFH cells in miR-132-/- mice compared to 
WT mice upon OVA/GLA-SE treatment. 
•   At seven days post-treatment there are GCs in miR-132-/- mice that are absent in 
WT mice. 
•   There is a rapid increase in antibody production upon treatment in miR-132-/- 
mice. After a long-term OVA/GLA-SE treatment there is a polarization of the 
response towards TH1 in miR-132-/- mice. 
•   After six months of immunization and a further three days of OVA/GLA-SE 
treatment, there is a rapid production of antibodies, but no difference between 
WT and miR-132-/- mice. 
•   Chimeras showed that presence of miR-132 is necessary in both stromal and 
haematopoietic cells for the polarization towards a TH1 immune response 
5.6.  Discussion 
5.6.1.   GLA-SE treatment leads to an increase in AICDA and specific cell 
types 
Previous results (Chapter 3 and 4) have shown that miR-132 has a crucial role in the 
remodelling process. LN structure after GLA-SE treatment was altered in miR-132-/- 
mice. Thus the role of architectural remodelling on functional changes in the type of 
immune response generated following antigen/adjuvant administration was investigated. 
AICDA is an enzyme that controls the process of somatic hypermutation and class 
switching and it is a surrogate marker for antibody responses as it regulates the affinity 
and isotype during the immune response. There was a significantly higher AICDA 
expression in miR-132-/- mice compared to control mice after a long-term OVA/GLA-
SE treatment. The next steps were to investigate antibody production and avidity to 
address the question of whether this increase in AICDA translates into differences in the 
antibody response in miR-132-/- mice. 
To understand the dynamics of immune responses to the defined antigen OVA; B cell 
subsets were analysed by flow cytometry. miR-132-/- mice had increased numbers of all 
subsets including follicular B cells and activated B cells after OVA/GLA-SE treatment 
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compared to WT mice. This indicates that miR-132 is either directly, by acting on B cell 
function, or indirectly through modulating LN structure, regulating B cell responses in 
the LN. To further investigate the effect of miR-132 and TLR4 treatment, cell types 
were analysed after short-term treatments during which time OVA/GLA/SE treatment 
induces follicular remodelling. Though there was no difference in the increase of TFR 
cells upon treatment between WT and miR-132-/- mice, there were more B cells and TFH 
cells by seven days of OVA/GLA-SE treatment in miR-132-/- mice in addition to 
differences in the remodelling process quantified in Chapter 4. TFH cells are 
indispensable for the proper generation of GCs. Therefore if there are more TFH cells 
and B cells as well as activated B cells in miR-132-/- mice, the early formation of larger 
GCs might be a compound effect. The function of TFH cells in the miR-132 deficient 
mice remains to be investigated. This could be done through investigating their markers 
and the cytokines they produce to determine if miR-132 could be regulating their 
function directly and potentiating the GC reaction.  
The mechanism driving these changes in TFH and B cell activation is unclear but might 
involve changes in cytokine and chemokine expression patterns in the LN. The cell type 
responsible for this is unknown. To further investigate the effect of different cell types 
and miR-132 in antibody production, chimeras were set up and serum collected. Results 
obtained demonstrated that miR-132 is necessary in both haematopoietic and stromal 
cells to regulate OVA-specific antibody production. miR-132 in stromal cells alone or 
haematopoietic cells was not enough to polarize the response towards TH1 as observed 
in miR-132-/- mice indicating that it is a combination of both structural changes and B 
and TFH dynamics that lead to this faster TH1 response. 
5.6.2.   miR-132 deficiency leads to a rapid formation of GCs and 
production of antibodies 
miR-132-/- and WT mice were treated for three and seven days and histology was 
analysed for GCs. At three days, there is no ring-like structure of B cells in the 
paracortex in miR-132-/- mice compared to WT mice. By seven days, miR-132-/- mice 
had LNs that were significantly larger, but no B cell follicular remodelling had 
occurred. At seven days post OVA/GLA-SE treatment, there were more GCs found in 
miR-132-/- mice and none were found in control mice, miR-132-/- mice also had higher 
titres of both IgG1 and IgG2c and total IgG. miR-132-/- draining LNs had accelerated 
GC formation but also contained increased numbers of B cells and TFH cells than WT 
mice. Inhibiting miR-132 leads to a rapid formation of GCs, more B cells and TFH cells 
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and faster production of OVA-specific antibodies. Inhibiting miR-132 in conjunction 
with vaccination could drive the response to a quicker production of specific antibodies 
to the antigen. Thus driving faster higher affinity antibody responses to diseases where 
resolution is essential to pathogen/toxin clearance. 
5.6.3.   Absence of miR-132 leads to a polarization of the immune response 
Antibody titration and avidity was investigated comparing WT and miR-132-/- mice. 
These results indicate a profound role for both TLR4 agonists and miR-132 in 
regulating the production of specific antibodies and avidity of the response; however, 
using a simple antigen the full effects were not possible to measure. In comparison to 
Alum, GLA-SE produces both a strong IgG2c (TH1) response and higher avidity 
response in both WT and miR-132-/- mice. miR-132 deficiency leads to a decrease in 
IgG1 (TH2) and a corresponding polarization to an IgG2c (TH1) response. Alum is 
known to induce a strong TH2 response; however, despite the changes in LN structure in 
Alum treated miR-132 deficient mice, a near total lack of IgG1 antibody response 
occurred. This indicates that the mechanism controlling the TH1 switch is not in itself a 
miR-132 driven process. Thus miR-132 inhibition in conventional Alum based vaccines 
is not a useful method to modulate the type of response. However, inhibiting miR-132 
could be a novel way to further polarize the immune response towards TH1 responses 
during vaccination with TLR4 adjuvants. A preliminary experiment using miR-132 
LNA inhibitor was performed, but the inhibitor-dosing regimen in mice still needs to be 
optimized, as no difference was observed to the control (data not shown). This is likely 
to be pharmacodynamics problem that requires optimisation to replicate the miR-132-/- 
mouse phenotype. 
5.6.4.   miR-132 has no role on the memory response 
To investigate the effect of miR-132 on long-term memory response to repeated 
immunization, mice were immunized, left for six months and boosted for a further three 
days. There is a rapid production of antibodies after treatment with OVA/GLA-SE in 
both WT mice and miR-132-/- mice. There is no difference in changes in total IgG or 
IgG2c but less IgG1 in miR-132-/- mice compared to WT mice. miR-132 does seem to 
have an effect on the memory response, although there is an increase in antibody 
production as in WT mice, there is less IgG1. This has interesting implications to the 
potency of miR-132 inhibition in skewing the memory response, thus miR-132 
inhibition has the potential to have long-term effects on the immune response. The 
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molecular and cellular mechanisms of this process are not known, it is possible that 
miR-132 modulates the memory cell niche biasing the response, or modifies memory T 
cells. 
5.6.5.   Conclusion 
These results indicate that miR-132 regulates the kinetics of GC formation and the type 
of antibodies produced. Inhibition of miR-132 may be a way to super-potentiate TH1 
immune responses that provide protection against intracellular pathogens. miR-132 is 
critical in the proper development of LN structure changes in response to TLR4 agonist 
adjuvant immunization and inhibiting it could be a way of manipulating the immune 
response to get early antibody secretion but also to push the immune response towards 
TH1 responses. Likewise transient overexpression of miR-132 might induce additional 





Chapter 6:   General Discussion 
6.1.   Summary of findings and relevance 
6.1.1.   TLR4 adjuvants induce rapid LN remodelling 
Historically, mechanisms driving adjuvant efficacy have been thought to be driven by 
APC maturation and function. However, unlike Alum that works in a NLRP3 
inflammasome dependent process, TLR stimulation has the potential to drive the 
activation of many different cell types at both the site of vaccine delivery and in the 
draining LN. This project was based on the previous finding that repeated CFA delivery 
that possesses potent TLR stimulatory capacity, drives large scale LN remodelling 
although the molecular and cellular mechanisms driving this process are unknown 
(summarised in Figure 1.6). Due to the toxicity and excessive inflammation that 
prevents CFA use in humans and multiple administrations into mice an alternative 
model was developed using GLA-SE, a potent TLR4 agonist. This also enabled the 
investigation of LN remodelling using an adjuvant that has been proven in clinical trials 
to have significant potency without uncontrolled toxic inflammation. The remodelling 
induced by GLA-SE involved a rapid increase in all cell types including innate and 
adaptive immune cells and the underlying stromal cell networks. This increase was 
mirrored by an increase in the production of different cytokines, chemokines and 
extracellular matrix as well as the induction of miR-132 expression. Signalling induced 
by this adjuvant drove rapid new B cell follicle formation involving B cell follicle 
dissolution and formation of large numbers of new follicles in the LN cortex.  
6.1.2.   MiR-132 is a regulator of the immune response to adjuvants 
An increase in miR-132 expression was observed post treatment in LNs. miR-132 is 
known to be up-regulated upon TLR4 stimulation and regulate genes driving 
inflammation. miR-132-/- mice were found to have an altered architecture in naïve LN 
with an intermingling of B and T cell zones. Immunization with TLR4 adjuvants led to 
a different LN architecture compared to WT. Dissolution of B cell follicles was not 
observed in miR-132-/- mice and there were no new B cell follicles in the paracortex. 
Instead, B cell follicles increased in size but remained in the cortex. The mechanisms 
behind this process were investigated but no clear mechanism could be identified as 
miR-132 regulates a plethora of genes from cytokines to proteases. It was shown that 
there are more MRCs and MRCs differentiating into FDCs in miR-132-/- mice. These 
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MRCs express less chemokines in miR-132-/- mice compared to WT mice. A differential 
expression of CXCR5 was also observed in miR-132-/- mice. This altered chemokine 
and chemokine receptor expression could explain why no B cell follicle dissolution 
occurs in the absence of miR-132 as B cells are guided differently. This could also 
explain why bone marrow chimeras indicate that both radiation sensitive (B and T cells, 
DCs) and insensitive cells (stromal cells, endothelium, macrophages, innate lymphoid 
cells, memory T cells) are involved in process of LN reorganisation. 
6.1.3.   Consequence of LN remodelling on the immune response 
As the process of LN remodelling upon TLR4 adjuvant immunization was altered in 
miR-132-/- mice, the potential function effect was investigated. To elucidate the role of 
remodelling antibody production and cell types required for GC reactions were 
characterised. Both B cells and TFH cells were increased in miR-132-/- mice after 
treatment compared to controls and large GCs appeared after only seven days of 
treatment, prior to formation in WT mice. Correlating with accelerated GC formation 
rapid production of antibodies was also observed in miR-132-/- mice concurrent with 
polarization of the immune response towards TH1 and additional AICDA expression. 
This indicates that inhibiting miR-132 could lead to more efficient vaccines and aids in 
identifying targets that might improve the function of adjuvants by targeting selective 
pathways using small molecules or agonistic proteins.  
6.2.  Conclusion and schematic of miR-132 role in remodelling 
We have shown that TLR4 agonist adjuvants are potent in inducing LN remodelling. 
These adjuvants have also been shown to be very efficient in generating an immune 
response to vaccination and are currently in clinical vaccine trials. Through 
investigating the cellular and molecular mechanisms behind LN remodelling we showed 
that it involved an increase in both immune and stromal cell types, cytokines and miR-
132. In WT mice by three days post-delivery, B cell follicle dissolution was observed 
and by seven days complete remodelling was observed with new follicle formation in 
the LN paracortex surrounded by T cell stroma (illustrated in Figure 6.1). Using miR-
132-/- mice it was possible to show this microRNA had an essential role in regulating 
changes in LN structure following OVA/GLA-SE immunization. There were increased 
numbers of MRCs, B cells and TFH cells in mice lacking miR-132 compared to WT 
mice as well as changes in chemokine expression. By three days of treatment of miR-
132-/- mice, the B cell follicles did not dissolve, rather B cell follicles got bigger and 
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were restricted to the marginal zone in the cortex. By seven days of OVA/GLA-SE 
treatment there were significantly increased B cell follicles that possessed large GCs. 
These changes in architecture observed led to an accelerated production of antibodies in 
miR-132-/- mice and to polarisation towards a TH1 immune response. This is illustrated 
in Figure 6.2. Inhibiting miR-132 could be a novel way of regulating the immune 
response during vaccination to get a rapid induction and polarization towards TH1 




Figure 6.1: Schematic of changes to LN structure in WT mice upon 
OVA/GLA-SE treatment. 
The structure of a naïve LN is tightly regulated by stromal cells; however, during 
immunization with TLR4 agonists there is an increase in cytokine and miR-132 
production and a rapid increase in LN size with a ring-like structure of B cells 
forming in the cortex. After 7 days of treatment, LNs are remodelled with B cell 


















Figure 6.2: Schematic of changes to LN structure in WT mice upon 
OVA/GLA-SE treatment. 
In WT mice, remodelling of LNs starts with a dissolution of B cell follicles leading to 
at 7 days post immunization new follicles forming in the paracortex. However, in the 
absence of miR-132 there are more MRCs migrating into the LN but they produce less 
CXCL13 and CXCL12 while B cells up-regulate CXCR5. At 3 days the LNs do not 
have dissolution of B cell follicles but they get bigger. By 7 days there are big B cell 




































6.3.  Outstanding questions and future work 
6.3.1.   Role of MRCs 
The results obtained showed a clear role of MRCs in the LN remodelling process. A 
rapid increase in MRC numbers was observed that correlated with histology results 
where there were increased number of MRCs in the SCS and entering the LN in miR-
132-/- mice compared to WT mice. These histological results still need to be quantified 
in order to be certain that what was observed does in fact coincide with there being 
more MRCs entering the cortex of the LN. An automated pipeline in Cell Profiler to 
quantify the observations is currently being developed.  
6.3.2.   MiR-132 effect on the breadth of the immune response 
An aspect that still needs investigation is the effect of miR-132 deficiency on the 
breadth of the immune response. An experiment has been completed in vivo and serum 
is in the process of being analysed using influenza epitope protein arrays. Control and 
miR-132 deficient mice were treated with OVA/adjuvant then with influenza, or with 
influenza/adjuvant to examine the diversity of response. This should enable the 
determination of whether miR-132 inhibition could lead to a more diverse lower affinity 
immune response.  
6.3.3.   Effect of miR-132 inhibition on other microRNAs 
miR-132 has a profound effect on LN remodelling upon immunization. However, there 
are many different miRNAs that collectively regulate cellular function, multiple 
different miRNAs are regulated through TLR signalling and most miRNAs have 
multiple targets. Therefore, why does the absence of a single microRNA lead to such a 
distinct phenotype when there is strong evidence for redundancy in miRNA-mediated 
regulation of transcription? Although miR-132 has multiple direct targets, most of the 
key changes observed are not direct target genes of miRNA-132 and lack target 
sequences. Therefore, the more likely interpretation is that miR-132 acts mostly 
indirectly through regulation of master regulatory proteins that control transcription of 
genes that regulate tissue remodelling. Strong evidence shows that miR-132 can 
negatively regulate EP300 in endothelial cells, a core protein involved in the 
transcription of many genes [184]. Recently, miR-132 has been shown to regulate 
expression of the RISC Component Ago 2 (AGO2) a regulator of the miRNA-mediated 
gene silencing and miRNA biogenesis machinery [270]. miR-132’s unique role in the 
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remodelling process likely arises from its capacity to act as a master regulator of 
mechanisms driving the inflammatory cascade. We speculate that the processes that 
occur in early inflammation induce a “stop and wait” signal preventing tissue 
remodelling. Subsequent induction of miR-132 turns off this signal permitting cell 
migration and remodelling to occur (Figure 6.3A). In miR-132-/- mice this “stop and 
wait” signal is not appropriately turned off delaying the tissue remodelling process due 
to a failure of miR-132 to shut down inflammation in stromal cells (Figure 6.3B). This 
delay in shut down results in a failure of MRC migration and B cell follicle dissolution 
driving large and faster GCs with increased number of B cells and TFH cells leading to 
the early antibody formation observed in miR-132-/- mice. We speculate that MRCs and 
DCs differentially migrate due to the high levels of TLR4 agonist in the SCS of the LNs 
driving high levels of miR-132 up-regulation. Interestingly the inflammatory “stop and 
wait” phenotype is found in number of tissues including the skin where initial 
inflammation inhibits wound closure, likely benefitting the host by allowing time for 
macrophages and DCs to sense and respond to pathogen infection. Data from the Coles 
laboratory indicates that this process has a key role in the inflammatory pathology 
observed in non-healing chronic wounds in humans, where inflammation appears not to 







Figure 6.3: The “stop and wait” model.  
TLR stimulation leads to an initial inflammation that activates cytokine and chemokine 
production by stromal fibroblasts (Marginal Reticular Cells) inhibiting cell migration. 
miR-132 is rapidly upregulated down modulating inflammation and permitting 
migration to predominate over inflammation. In the absence of miR-132, inflammation 
predominates over migration driving enhanced B cell recruitment and retention within 
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6.3.4.   TLR4 as a target 
The specificity of this phenotype to TLR4 over other PRR stimulation is unknown. That 
is if the phenotype observed in LN remodelling is a general principle of all TLRs or 
intracellular detection by Stimulator of Interferon Genes (STING). Different TLR and 
STING agonists are being developed for use as next generation adjuvants for the 
efficient induction of TH1 antibody responses, and efficient CTL induction to 
therapeutically treat chronic viral infection and cancer. LN architecture and the 
molecular mechanisms following immunization needs to be characterised in response to 
a range of TLR adjuvants. This would determine if the mechanism behind miR-132 is a 
generalised phenomenon or specific to TLR4 and provide new insights into novel 
agonist and antagonist approaches for adjuvant formation.  
6.3.5.   Determining which cell types are indispensable in LN remodelling 
Using TLR4-/- and MyD88-/- mice and developing chimeras it would be possible to 
determine whether the expression of TLR4 on radiation sensitive or on resistant 
components drives LN remodelling. This would provide new insights into the different 
cell types required for LN architecture formation and remodelling. Radiation chimeras 
are inherently difficult to interpret as radiation sensitivity depends on the capacity of a 
cell to repair cell damage, this process is deficient in lymphocytes, and other sensitive 
cells like dendritic cells are short lived when they are activated. Radiation is inherently 
inflammatory and depletes existing pools of host DCs. In contrast macrophages are 
long-lived cells and are radiation resistant. Recent evidence shows that Innate 
Lymphoid Cells are also radiation resistant. Therefore, development of tissue and cell 
specific knock outs of miR-132, TLR4, MyD88 and other signalling components will 
provide more precise information for their individual roles in the inflammatory 
processes. 
To further determine which cell types are involved and determine miR-132’s role in 
different cell types, Rag-/- mice were injected with WT LN cells, miR-132-/- LN cells, 
WT B cells and miR-132-/- T cells or miR-132-/- B cells and WT T cells. This experiment 
was repeated twice and both times the there were very few cells found in the LNs with 
no follicular structures. It has previously been observed in the Coles’ laboratory that 
HEVs are deficient in Rag-/- mice leading to poor trafficking into the host LNs by the 
donor cells. This is likely very inefficient in the pLNs. It has been shown that transfer of 
cells into neonatal mice leads to efficient LN reconstitution even in mice deficient in the 
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common gamma chain providing an alternative model to understand stromal cell 
function without using radiation chimeras [43].  
6.3.6.   How do changes in LN help develop better adjuvants? 
It has already been shown that TLR4 adjuvants are potent adjuvants, which has led to 
the use of different formulations of MPL-A by GSK: AS04 in Fendrix and Cervarix, 
and AS01 in Mosquirix. We have demonstrated that one of the outcomes of vaccines is 
massive LN remodelling driving changes to stroma networks, and vasculature within 
the LNs. It was possible to identify methods to modulate LN remodelling by 
determining the molecular mechanism driving this process. This would enable the 
modulation of the timing and type of immune response and provide potential insights 
into how the diversity of the immune response might be modulated. The effect observed 
in LNs following TLR treatment could explain how the “shock and kill” approach 
works in the eradication of HIV. Survival of HIV-infected individuals has increased 
through the use of anti-retroviral therapy but it does not lead to a full eradication of the 
virus that will remain in the body. The “shock and kill” approach involves reactivating 
latent HIV transcription in memory CD4+ T cells, which would lead to immune 
clearance and infected cell death.  A study using a TLR9 agonist stimulated strong 
antiviral responses to HIV as well as enhanced HIV transcription [271]. The increase in 
LN size and drastic remodelling observed in the case of treatment with the TLR4 
agonist GLA-SE could explain how these TLR agonists are working in the “shock and 







Ago2 Argonaute 2 
AICD Antigen Induced Cell Death 
AICDA Activation-Induced Cytidine Deaminase 
AID DNA-editing deaminase 
Alum Aluminium 
AP Alkaline phosphatase 
APC Antigen Presenting Cell 
APRIL A Proliferation-Inducing Ligand 
ASC Apoptosis-associated Speck-like protein containing CARD 
Ascl-1 Achaete-scute complex homolog 2 
BAFF B cell Activating Factor 
Bcl6 B-cell lymphoma 6 
BCR B Cell Receptor 
BEC Blood Endothelial Cell 
BM Bone marrow 
BMDC Bone Marrow Derived Cell 
BSA Bovine Serum Albumin 
BSF Biological Services Facility 
CFA Complete Freund’s Adjuvant 
CLEC-2 C-type Lectin receptor 
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CR1/CR2 Complement Receptor 1 and 2 
CREB cAMP-Response Element Binding protein 
CSF-1 Colony Stimulating Factor-1 
Ct Threshold cycles 
CTL Cytotoxic T Lymphocyte 
DAMP Damage Associated Molecular Patterns  
DAPI 4’,6’-diamidino-2-phenylindole  
DC Dendritic Cell 
dsRNA Double-stranded RNA 
DTR Diphtheria Toxin Receptor 
DTx Diphteria toxin 
EDTA Ethylenediaminetetraacetic Acid 
ELISA Enzyme-Linked Immunosorbent Assay 
ER-TR7 Reticular Fibroblasts and Reticular Fibres 
FACS Fluorescence-Activated Cell Sorting 
FCS Foetal Calf Serum 
FDC Follicular Dendritic Cell 
FRC Fibroblastic Reticular Cell 
FSC Forward scatter 
GC Germinal Centre 
GLA-SE Glucopyranosyl Lipid Adjuvant-Stable oil in water Emulsion 




GSK Glasko Smith Kline 
HB-EGF Heparin-Binding Epidermal-like Growth Factor 
HBV Hepatitis B Virus 
HCMV Human Cytomegalovirus 
HEV High Endothelial Venule 
Hprt Hypoxanthine phosphoribosyltransferase  
ICAM Intercellular Adhesion Molecule 
ICOS Co-stimulatory molecule inducible co-stimulator 
IDRI Infectious Disease Research Institute 
IFA Incomplete Freund’s Adjuvant 
IFN Interferon 
IL-7 Interleukin-7 
iLN Inguinal LN 
Immgen Immunological Genome Project 
IRF3 Interferon Regulatory Factor 3 
ISCOM Immune Stimulating Complexes 
LCMV Lymphocytic Choriomeningitis Virus 
LEC Lymphatic Endothelial Cell 
LFA-1 Lymphocyte Function-associated Antigen-1 
LN Lymph Node 




LRR Leucine-Rich Repeat 
LTi Lymphoid Tissue inducer cell 
LTo Lymphoid Tissue organizer 
LTα1β2 Lymphotoxin α1β2 
LTβR Lymphotoxin β Receptor 
MAdCAM-1 Mucosal Vascular Addressin Cell Adhesion Molecule-1 
MARCO Macrophage Receptor with Collagenous Structure 
MHCII Major Histocompatibility Complex II 
miRNA MicroRNA 
MMP-9 Matrix metallopeptidase 9 
MPL-A Monophosphoryl Lipid-A 
MR Mannose Receptor 
MRC Marginal Reticular Cell 
MSM Medullary Sinus Macrophage 
MyD88 Myeloid Differentiation Factor 88 
NK Natural killer cell 
NLRP3 NLR family, Pyrin Domain containing 3 
OVA Ovalbumin 
PACT Protein Activator of PKR 
PAMP Pathogen-Associated Molecular Pattern 
PAZ Piwi Argonaut and Zwille 
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PBS Phosphate Buffered Saline 
PBS/T PBS/0,05%Tween 
PFA Paraformaldehyde 
pLN popliteal LN 
PMA Phorbol 12-myristate 13-acetate 
PNAd Peripheral Node Addressin 
PRR Pattern Recognition Receptor  
qPCR quantitative PCR 
RANK-L Receptor Activator of Nuclear Factor kappa-B ligand 
REST Repressor Element 1 Silencing Transcription factor 
RISC RNA-Induced Silencing Complex 
Rnu6 U6 small nuclear RNA 
rRNA Ribosomal RNA 
RT Reverse Transcriptase 
S1P Sphingosine-1-Phosphate 
S1PR1 Sphingosine-1-Phosphate Receptor 1 
SAP SLAM-associated protein 
SCS Subcapsular Sinus 
SEM Standard Error of the Mean 
siRNA Small interfering RNA  
SLA-SE Second generation lipid adjuvant – stable oil in water emulsion 
SLO Secondary Lymphoid Organ 
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snRNA Small nuclear RNA 
SSC Side scatter  
SSM Subcapsular Sinus Macrophage 
STAT4 Signal Transducer and Activator of Transcription 4 
STING Stimulator of Interferon Genes 
TCM Central Memory T cell 
TCR T Cell Receptor 
TDM Trehalose Dicorynomycolate 
TEM Effector Memory T cell 
TFH Follicular Helper T cell 
TFR Follicular Regulatory T cell 
TH T Helper cell 
TIR Toll/Interleukin-1 Receptor-like 
TIV Inactivated Influenza Vaccine 
TLR Toll-Like Receptor 
TNFα Tumor Necrosis Factor α 
TRAM TRIF-Related Adapter Molecule 
TRBP Tar RNA Binding Protein 
Treg Regulatory T cell 
TRIF TIR-domain-containing adapter inducing interferon-β 
tRNA Transfer RNA 
VCAM Vascular Cell Adhesion Molecule 
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VEGF Vascular Endothelial Growth Factor 
VSV Systemic Vesicular Stomatitis Virus 
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